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10 | Chapter 1
Dr. X is a well respected psychiatrist who is 60 years old and works in a large psychiatric out-
patient clinic. Every day, he sees many patients with a wide range of psychopathology. Often, 
younger colleagues refer complex patients to him because of his extensive experience. During 
his career, he has witnessed many developments in psychiatry: new types of medication, the 
anti-psychiatry movement, empowerment of patients, the diminishing popularity of psycho-
analytic therapy, the upcoming of protocollized therapies, and the progress of molecular and 
genetic insights in psychiatric disorders. In his outpatient clinic, like in many others, the national 
guidelines for the treatment of psychiatric disorders have been embraced and implemented. Like 
many of his colleagues, dr. X was interested, yet sceptical, and worried that guidelines would 
make all creativity in his profession disappear. Nevertheless, dr. X committed to the treatment 
algorithms used in his institution. He kept up with the scientific publications on medication 
and psychotherapy, especially on major depressive disorder (MDD), since most of his patients 
suffered from depression. He read the promising results of randomized clinical trials (RCTs) on 
different drugs and new methods of psychotherapy. Meanwhile, in his clinical practice, the 
results of medication or psychotherapy were often disappointing and patients kept struggling 
with their depression. Dr. X got the impression that treatment for MDD in RCTs is a lot more 
successful than in “real life”. He started to wonder: do my patients even look like those in RCTs? 
How should I interpret the results from RCTs? Do RCTs tell us anything about “real life”? Is it right 
to base treatment guidelines for daily practice on results from RCTs that might be so far away 
from daily practice? 
This thesis is about Dr. X’s questions.
Not so long ago, the treatment of psychiatric disorders was based on the personal expertise 
and interests of individual psychiatrists. Nowadays, evidence based medicine has become 
the ‘gold standard’ for clinical practice. In this respect, modern psychiatry does not differ 
from other medical specialties. Treatments proven to be effective in randomized clinical 
trials (RCTs) are transformed into clinical practice guidelines, which are implemented in 
routine clinical practice. Treatments (yet) without evidence are left aside. But how “golden” 
is this modern medical standard? Are therapies that have been proven effective in the strict 
research setting of RCTs as effective in routine clinical care? Clinical practice guidelines 
are based on results from RCTs. But are results from clinical trials generalizable to daily 
psychiatric practice? 
 In this thesis, we aim to establish to what extent results from RCTs are applicable to 
daily practice for patients suffering from major depressive disorder (MDD), one of the 
most common psychiatric disorders. Next, we explore factors that may influence the 
generalizability of results from clinical trials in MDD to daily practice.
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How are results from randomized clinical trials used in daily practice?
Like dr. X, most psychiatrists in the Western world now follow evidence based guidelines 
on the treatment of MDD. Often, guidelines are presented as or implemented in treatment 
algorithms that are used in daily practice. In Western psychiatry, the guidelines of the 
American Psychiatric Association (APA) and the National Institute of Clinical Excellence 
(NICE) guidelines in the UK are well known. Most other countries have developed similar 
guidelines for the treatment of MDD based on scientific evidence. In the Netherlands, the 
guidelines are developed by a national task-force for guideline development: Landelijke 
Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ and are published by the 
Netherlands Institute on Mental Health and Addiction (Trimbos Instituut).
 In every guideline a clear description of the way it was constructed is given. They all 
rely heavily on evidence from RCTs, and in most guidelines, the reliability of evidence from 
scientific research has been ranked (weighted). Below are the descriptions that two well-
known professional organisations give of their methodology. We also describe the methods 
used to weigh the evidence for the multidisciplinary guidelines for depression in the 
Netherlands.
Guideline of the American Psychiatric Association 
(APA, United States of America, http://www.psych.org) 
“This guideline strives to be as free as possible of bias toward any theoretical posture, and 
it aims to represent a practical approach to treatment. Studies were identified through 
an extensive review of the literature by using MEDLARS for the period 1971–1999. Major 
review articles and standard psychiatric texts were consulted. The Agency for Healthcare 
Policy Research Evidence Report on Treatment of MDD-Newer Pharmacotherapies [14] was 
reviewed in its entirety. Review articles and relevant clinical trials were reviewed in their 
entirety; other studies were selected for review on the basis of their relevance to the particular 
issues discussed in this guideline. Definitive standards are difficult to achieve, except in 
narrow circumstances in which multiple replicated studies and wide clinical opinion dictate 
certain forms of treatment. In other areas, the specific choice among two or more treatment 
options is left to the clinical judgment of the clinician. The recommendations are based on 
the best available data and clinical consensus with regard to the particular clinical decision. 
The summary of treatment recommendations is keyed according to the level of confidence 
with which each recommendation is made.”
Guideline of the national institute of clinical excellence 
(NICE, United Kingdom, http://www.nice.org.uk) 
“The systematic identification of evidence is an essential step in clinical guideline 
development. Systematic literature searches undertaken to identify evidence of clinical and 
cost effectiveness should be thorough, transparent and reproducible. These searches will 
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also minimize ‘dissemination biases’ [15], such as publication bias and database bias, that 
may affect the results of reviews.”
Guideline from the netherlands institute of mental Health and Addiction 
(Trimbos Institute, the Netherlands, http://www.ggzrichtlijnen.nl) 
“A guideline is based on results from scientific research and additional opinions by 
professionals and patients, and aims to specifically describe good medical practice. In 
this partial revision of the guideline, the EBRO method of evidence based guideline 
development is used and the assumptions of the Landelijke Stuurgroep Multidisciplinaire 
Richtlijnontwikkeling in de GGZ are followed. Subsequently the Appraisal of Guidelines for 
Research & Evaluation (AGREE) instrument has been used. AGREE is a European instrument 
to assess the quality of guidelines. Finally, the Health Technology Assessment was used in 
the substantiating of the recommendations.” (translated from Dutch). Scientific evidence is 
evaluated as follows in the Dutch Guidelines (in order of methodological rigour):
A1. Systematic review of at least two independent research projects of A2 level.
A2. Randomized, double-blind, clinical trials of good quality and large enough sample size.
 Research comparing a method to a reference test (gold standard) with beforehand 
defined outcome and independently judged results in a large enough sample size of 
patients who had both the investigated method and the reference test.
 Prospective cohort study with large enough sample size, controlled for confounding and 
selective follow-up.
B. Clinical trials, without the methodological rigour mentioned in A2.
 Research comparing a method to a reference test (gold standard) without the metho-
dological rigour mentioned in A2.
 Prospective cohort study without the methodological rigour mentioned in A2 
C. Non-comparative research.
D. Expert opinion.
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What is major Depressive Disorder?
Major depressive disorder (MDD) is one of the most common psychiatric disorders. Patients with 
MDD suffer from a depressed mood and/or loss of interest or pleasure, often accompanied by 
loss of weight, disturbed sleep, psychomotor agitation or retardation, loss of energy, feeling of 
worthlessness, loss of concentration and recurrent thoughts of death [2]. According to the World 
Health Organisation (https://www.who.int/en), MDD is the leading cause of disability as measured 
by Years Lived with Disability (YLDs), and the fourth leading contributor to the global burden 
of disease (Disability Adjusted Life Years, DALY). DALY measures the total number of days lived 
with disability of a population. By the year 2020, MDD is projected to reach second place of the 
ranking of DALYs regardless of age and gender. Today, MDD is already the second cause of DALYs 
in the age category 15–44 years for both sexes combined. MDD occurs in persons of both genders, 
all ages, and regardless of ethnic and social backgrounds and affects about 121 million people 
worldwide. In the Netherlands, the lifetime prevalence for MDD is 10.9% for men and 20.1% for 
women. The 12-month prevalences are 4.1% and 7.5%, respectively [9]. The number of DALY’s in 
the Netherlands for MDD is 158.000 per year. Besides the unmistakable suffering of individual 
patients and their loved ones, MDD has substantial economic consequences for society: patients 
suffering from MDD use more health care and social security, and MDD causes a loss in production 
due to absence. The costs of treatment for MDD in the Netherlands amount to 660 million euros 
per year. Besides these costs, 953 million euros are lost due to absence from employment. In total, 
the costs for MDD are 1.1% of the total healthcare costs in the Netherlands [11] (https://www.
trimbos.nl).
First step-treatments for mDD according to the guidelines
In the guidelines mentioned above, the use of either pharmacotherapy or psychotherapy is 
recommended as first treatment step for moderate MDD in psychiatric outpatient practice 
[16,17]. Both therapies have been proven to be effective for patients who are suffering 
from MDD for longer than three months. Pharmacotherapy and psychotherapy are equally 
effective in patients suffering from moderate-to-severe MDD [18]. For patients suffering from 
(very) severe MDD, the guidelines recommend antidepressant medication as first treatment 
step. In the past, different types of antidepressants, selective serotonin reuptake inhibitors 
(SSRIs), tricyclic antidepressants (TCAs), venlafaxine and mirtazapine have been shown to 
be equally effective. However recent studies indicate differences in efficacy and tolerability 
[19]. Regarding psychotherapeutic treatment for MDD, cognitive behavioral therapy (CBT), 
behavioral therapy (BT) and interpersonal therapy (IPT) are recommended. All have been 
proven to be effective, and so far, few differences have been found in the efficacy of CBT, BT 
and IPT [20]. Currently, studies on CBT do outnumber IPT trials though.
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For dr. X, the guidelines provide a clear algorithm of the subsequent evidence based steps that he 
has to take when treating patients suffering from MDD. He is however still puzzled by questions 
on the generalizability of the results from RCTs, which are conducted in a strict research setting, 
to his daily practice. In the next paragraph, we describe several methodological aspects of 
RCTs that are related to the generalizability of RCT results.
What clinicians always wanted to know about the methodology of Rcts, but were 
afraid to ask...
In order to answer the question: “Are results from RCTs generalizable to daily practice?” we 
first have to know how RCTs are designed. RCTs are also called efficacy-trials: their results 
describe the impact of treatment on the disease (e.g. MDD) in a defined population (e.g. 
patients suffering from MDD without co morbid disorders within a certain age-range). To 
obtain the most reliable results in efficacy trials, much effort is put in optimization of the 
internal validity of the trial: the extent to which a result reflects the real causal relationship 
between a compound (investigated treatment) and change in disease status. Results from 
efficacy trials need to be replicable and solely contributable to the investigated treatment. 
For example, when in an RCT, CBT in MDD has proven to be effective, this means that for a 
group of patients usually between 18–55 years old, suffering from MDD without co morbid 
disorders, CBT applied according to the protocol has been proven to be more effective than 
a placebo treatment or treatment as usual within a defined period of time. But dr. X does not 
treat groups of patients, does not apply patient selection, and does not treat patients with a 
placebo treatment. He simply treats individual patients, each with their own specific features, 
and he merely wants to know: “what do I tell my patients about the chances of recovery 
when I apply a treatment that is in my guidelines?” efficacy might be a useful way to describe 
the influence of a specific treatment on disease status, but for daily practice, the concept of 
effectiveness is more appropriate. Effectiveness is a broader concept than efficacy. It may 
comprise a number of outcomes (e.g. efficacy, tolerability, costs of treatment, outcome in 
social functioning or quality of life). It can be defined as the impact of the treatment on 
the disease in a general population. For MDD and most other psychiatric disorders, it is still 
unknown how efficacy and effectiveness relate to one another. Is outcome the same in a 
trial setting and daily practice, when the same treatments are applied? Both researchers and 
clinicians would intuitively state: “Probably not!”. But how large is the difference between 
efficacy and effectiveness? 
 Whereas internal validity is essential for the evidence of efficacy of treatments, external 
validity is equally important or even more important for the evidence for effectiveness of a 
treatment in a daily practice. External validity is defined as the extent to which a result can 
be generalized to a larger (real world) population with more heterogeneous characteristics. 
External validity is equivalent to generalizability. Internal and external validity are sometimes 
the two ends of the same balance: if one improves the internal validity, one decreases the 
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external validity. Internal and external validity might seem methodological concepts that 
are important for researchers and methodologists, but not for clinicians like dr. X. However, 
in order to judge whether results from RCTs can be generalized to daily practice, it is also of 
clinical relevance to understand the relationship between these two concepts. 
 The following methods are used in efficacy trials to optimize internal validity: 
randomization, blinding, sample size calculation (power estimation), and the strict use 
of eligibility criteria. Some of these methods might jeopardize the generalizability of the 
outcome of the trial to routine clinical practice, while others do not. In the frames below we 
will give an overview of the methods used to improve the internal validity of RCTs and their 
influence on external validity [21]. Furthermore, we will describe the effect of these methods 
on the difference between efficacy and effectiveness [7,22-30]. 
methods in Rcts to improve internal validity that do not jeopardize external validity
Randomization is used to ensure that unknown factors that could influence the result (e.g. age, 
gender, baseline severity of the disease, co morbid disorders) will be equally distributed in both 
the treatment and the control group. By randomization possible confounding (confounders are 
factors that influence treatment outcome if they are unequally distributed between treatment 
and control group) is neutralized. Randomization does not influence external validity.
Blinding is an attempt to prevent investigators and/or participants from influencing the 
identification of relevant events during a trial. In other words, if the participant and/or the 
researcher do not know whether the participant receives the active drug or placebo, they are not 
biased by this knowledge in observing the effect. Blinding is used to optimize internal validity by 
ruling out placebo-effect as much as possible. It is often difficult to guarantee complete blinding 
in antidepressant-trials, since antidepressants cause specific side-effects that are impossible to 
mimic in placebo-pills. For psychotherapy, blinding is even more difficult and requires creative 
procedures [3-5]. As an alternative to complete double-blinding, independent (blind) outcome-
rating personnel is often used in trials. Blinding does not influence external validity.
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Sample size calculation: the sample size defines the robustness of the result of the efficacy trial. A 
larger sample size provides more accurate findings (and narrower confidence intervals and smaller 
p-values). Sample size calculations (power estimation) are performed in advance of the start of the 
efficacy trials. Sample size calculation does not influence external validity and has no effect on 
the difference between efficacy and effectiveness. Nevertheless, it is important for clinicians to 
take into account that, while interpreting results from efficacy-trials for daily practice, p-values 
and confidence intervals are influenced by two factors: by the magnitude of the found difference 
between an investigated treatment and control-condition and by the sample size. For example, a 
difference in proportion of remitters of 5% between investigated treatment and control-condition 
can be highly significant if the sample size is large, but does not tell you what the clinical relevance 
of the found difference is. It is up to the clinician to judge the clinical relevance of efficacy results 
for daily practice. Statistical analysis is no more and no less than an estimation of the magnitude 
of a result and an estimation of the probability of finding these results. Clinicians who are not very 
familiar with statistical analysis might easily be impressed by very small p-values when reading 
reports on clinical trials.
Randomization and Blinding can contribute to possible differences between efficacy and 
effectiveness: in daily practice the clinician judges whether a certain treatment is more 
appropriate, or more likely to be successful for his individual patient based on several features of 
this patient (e.g. age, gender, co morbid disorders). Also, the patient can express his preference 
for a certain treatment. In a (double) blind trial, the patient’s preference for a specific treatment 
is not taken into account. Some patients might refuse participation in RCTs if the treatment of 
their choice is not investigated in the trial. Furthermore, the possibility by itself of clinicians and 
patients to choose a treatment might be associated with a better treatment outcome [12,13]. 
Thus, if randomization and blinding were the only differences between a trial setting and daily 
practice, one would probably expect to find better results in daily practice.
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methods in Rcts to improve internal validity that might jeopardize external validity
The use of eligibility criteria: in efficacy trials stringent in- and exclusion criteria are used. The use 
of these criteria is vital for methodological reasons: only in a homogenous (e.g. without co morbid 
disorders, with sufficient severity etc.) patient population the difference found in outcome can be 
solely attributed to the investigated treatment. Furthermore, the use of exclusion criteria might 
be inevitable for ethical reasons: e.g. risk of suicide, risk of teratogenic effects of the investigated 
drug in pregnancy; risk of dangerous or intolerable side effects of certain drugs to specific patient 
groups etc. The use of strict eligibility criteria facilitates analysis and detection of differences in 
treatment outcome between groups. Therefore, the use of strict eligibility criteria in efficacy trials 
is essential during the development of a new compound. However, the generalizability of the 
results to routine care is usually poor, since the results are only applicable to a small, selected 
part of the patient population in clinical practice. It is not clear to what extent clinical practice 
may benefit from results of RCTs when the generalizability of these results is poor [7]. This topic 
will be addressed in detail in the paragraph “The influence of (un) intended patients selection on 
treatment outcome in RCTs” in the Introduction Chapter of this thesis.
other aspects of Rcts that may hamper the external validity
The trial setting: the circumstances under which the trial takes place might differ in many aspects 
from the routine clinical practice of the clinician who wants to find evidence for a treatment. The 
trial can be conducted in another country than that of the clinician, where they use other methods 
of diagnosis and management, where the susceptibility to the disease in the population is 
different, or where the health care at the location of the trial is organised in a different way (length 
of waiting lists, access to health care, financial limits). Furthermore, trials are often conducted in 
very specialized centres and by highly trained and motivated clinicians with ample time for the 
protocollized treatment of every individual trial participant without the daily time pressure so 
common in routine clinical practice.
The selection of patients before or beyond consideration of eligibility criteria: due to recruitment 
procedures, unintended patient selection might occur. This topic is addressed in detail in the 
paragraph “The influence of (un)intended patient selection on treatment outcome in RCTs” in the 
Introduction Chapter of this thesis.
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other aspects of Rcts that may hamper the external validity (Continued)
The use of run-in periods and/or enrichment strategies: run-in periods of medication are used to 
exclude patients who are poorly compliant or who suffer from unacceptable side effects. Exclusion 
of these patients does probably jeopardize external validity. Likewise, the use of enrichment-
strategies in which patients who are likely to respond well are actively recruited might jeopardize 
external validity.
Pre-trial treatment or non-trial management: patients who need medication for other medical 
conditions (non-trial management) are often excluded from participation in efficacy trials. 
Exclusion of these patients might jeopardize the generalizability of  the results. Furthermore, in 
some RCTs, specific preparation of participants for the trial is conducted (pre-trial treatment), 
which probably influences treatment outcome in RCTs and therefore might contribute to the 
efficacy-effectiveness difference.
Treatment in the control group of efficacy trials: the control condition in the trial sometimes differs 
very much from daily practice, which hampers generalizability.
The definition of outcome and duration of follow-up period: sometimes in trials, outcome measures 
that are not clinically relevant are used and the follow-up period is usually short. Therefore the 
generalizability to daily practice might be poor.
How is successful treatment outcome in mDD defined in Rcts? 
In RCTs, results of treatment of MDD have been defined in many different ways. Different 
instruments have been used to assess treatment progression and final results. The most 
common method to evaluate treatment is the use of questionnaires. These questionnaires 
can be generic, which means that they measure improvement in general terms of “well 
being”, or “quality of life”. They can also measure the severity of symptoms of a specific 
disorder. For MDD, outcome can be rated on symptoms like anhedonia, loss of sleep, and 
depressed mood. Furthermore, questionnaires can either be self report instruments, which 
means that the patients fill in the questionnaires by themselves, or observer rated, which 
means that the severity of symptoms is assessed by an observer, usually a clinically trained 
person. In antidepressant efficacy trials (AETs), the most commonly used instruments to 
define primary treatment outcome are the Hamilton Rating Scale for Depression (HAMD), 
17-item or 21-item version [31] or the Montgomery-Asberg Depression Rating Scale 
(MADRS) [32]. These instruments are both symptom-specific, observer rated instruments. In 
psychotherapy efficacy trials (PETs), the most commonly used instrument to define primary 
treatment outcome is the Beck Depression Inventory (BDI) [33], a symptom-specific self 
report questionnaire. Often other instruments are used in efficacy trials to assess secondary 
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outcome (quality of life, social functioning, additional disease specific instruments, 
instruments that measure tolerance for medication or treatment adherence, etc.). AETs and 
PETs typically use different definitions of treatment outcome:
In general, AETs use response and remission percentages to define outcome.
Response percentage: proportion of MDD patients who reach a reduction of symptoms 
of 50% or more.
Remission percentage: proportion of MDD patients who reach a symptom level below 
a defined cut-off score.
PETS generally use effect size, written in abbreviated form as Δ, [34] as the definition of 
outcome.
Effect size Δ: difference in symptom level pre-and post treatment, controlled for sample 
size
Δ = (μpre –μpost) / σ
μpre = mean pre-treatment
μpost = mean post-treatment
σ = standard deviation pre-treatment
During the last decade, several researchers have introduced other definitions for treatment 
outcome in research and in daily practice, e.g. clinical significant change. These recent 
definitions of treatment success might have more clinical relevance [35-38]. However, they 
have not been used in RCTs, yet. So to compare the available body of RCTs and daily practice, 
we have to use the same definitions as used in RCTs.
treatment outcome for mDD in daily practice: how can we assess success?
In daily practice, systematic evaluation of treatment progress is needed to provide 
insight in the course of individual therapies, or of groups of patients suffering from the 
same psychiatric disorder such as MDD. Routine Outcome Monitoring (ROM) comprises 
the systematic assessment of patients in daily practice. ROM provides data on treatment 
effects in daily practice that allows clinicians to evaluate treatment progress. It also allows 
researchers to explore treatment success in routine clinical practice in general, and factors 
associated with success. Through ROM, many clinical research questions can be addressed 
scientifically. The data on routine clinical practice used in this thesis are derived from the 
ROM system of Rivierduinen, which is described in detail in the frame below.
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In spring 2002, the Regional Mental Health Provider (RMHP) ‘Rivierduinen’ (an institute serving 
a region with more than 1 million inhabitants) and the Department of Psychiatry of the Leiden 
University Medical Center (LUMC) started collaboration for routine assessment of the DSM-
IV diagnosis as well as the symptom severity, well-being and health status at time of the first 
interview of outpatients referred to the RMHP Rivierduinen.
At the start, ROM was restricted to patients referred for treatment of mood, anxiety, and somatoform 
(MAS) disorders. These patients form a relatively homogenous group with substantial mutual co 
morbidity [1] and they mainly receive outpatient care. To be eligible, patients had to have sufficient 
mastery of the Dutch language and had to be able to complete self report instruments. Patients 
who are considered (by their clinician) to be too ill to complete questionnaires or who refuse to be 
assessed are excluded from ROM assessment.
All patients are assessed by an independent psychiatric research nurse at the start, and during 
follow up at intervals of three to four months, at the beginning of a new treatment step and at the 
end of the treatment. 
During the first session, a standardized diagnostic interview is administered and observer- and 
self reported ratings are determined. At baseline the Axis-I diagnosis according to the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) is established using the Mini-International 
Neuropsychiatric Interview-plus [6]. The interviews are performed by psychiatric research nurses 
who have been extensively trained and supervised. The Dimensional Assessment of Personality 
Pathology (DAPP-SF) is administered to assess maladaptive personality traits [8].
Subsequently, a number of symptom severity rating scales is administered at baseline, and is also 
completed at each re-assessment to allow for the evaluation of treatment outcome. Together, these 
instruments cover change in three areas of functioning: symptom reduction, increased wellbeing, 
and improvement in general life functioning [10]. They are commonly used in treatment outcome 
research and have good psychometric properties as evidenced by national and international 
publications (an overview of instruments used is available at http://www.lumc.nl/psychiatry/ROM-
instruments). Outcome is assessed by patients’ self report and by an independent assessor, and 
includes both generic and disorder-specific measures. Clinicians receive a report on the results 
of the baseline assessments as well as follow-up reporting on treatment outcome in the above 
mentioned domains. Results of the assessments are provided in detail by the research nurses as 
well as in a summarized form. The summaries facilitate clinicians to discuss the results with their 
patients and use them as a tool to evaluate the treatment. Results are also used, in an anonymous 
form, for scientific purposes. Since ROM-data are primarily being used by clinicians and patients 
to monitor treatment progress, no specific informed consent is needed. The use of anonymized 
data for research purposes has been approved by the Medical Ethical Committee of the LUMC.
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the influence of (un) intended patient selection on treatment outcome
As mentioned above, results from efficacy trials in MDD might not be applicable to daily 
practice because of the use of stringent in- and exclusion criteria for patient selection in 
these trials. A fairly recent solution to this problem is the so called “pragmatic trial”. Pragmatic 
trials are designed to optimize the generalizability of the results, and therefore use broader 
inclusion criteria. For instance, for participation in pragmatic trials some co morbid Axis I and 
II disorders [39] are allowed. Pragmatic trials provide more information for daily practice, but 
the certainty of a causal relationship between investigated treatments and outcome and the 
reproducibility is less clear. As mentioned before, the efficacy of first step MDD treatments 
(antidepressants, cognitive behavioral therapy and interpersonal therapy) is investigated 
in AETs and PETs. In this thesis we aim to explore the differences between efficacy and 
effectiveness of antidepressant treatment as well as individual psychotherapy for MDD. 
Both AETs and PETs use exclusion criteria for their selection of patients. The consistency 
of exclusion criteria across AETs has been explored in previous research and a set of 
consistently used exclusion criteria was identified (see below) [40,41]. Remarkably, which 
eligibility criteria are consistently used in psychotherapy efficacy trials (PETs) for MDD was 
not studied in previous research. In this thesis we explore for the first time the consistency 
of eligibility criteria across PETs. 
 It has been demonstrated that the use of exclusion criteria in AETs leads to exclusion of 
many MDD patients [30,42,43]. The use of exclusion criteria might also influence the outcome 
of AETs, i.e. patients not meeting an exclusion criterion might do better. Limited data on the 
influence of eligibility criteria on outcome in AETs are available. A study found that patients 
who would be eligible for AETs had a more favorable outcome in clinical practice, but this 
has not been explored further [44]. As mentioned above, previous research identified a 
set of consistently used exclusion criteria across AETs. The following criteria were found to 
be consistently used in AETs: history of DSMIV manic or hypomanic episodes; presence of 
psychotic features in current depression; significant risk of suicide, alcohol/drug abuse or 
dependency; mild MDD (not meeting a baseline severity of 18 on the Hamilton Rating Scale 
for Depression, 17 item version, HAMD17 [31]); presence of underlying dysthymic disorder; 
presence of non-depressive, non-substance use co morbid Axis I disorders; presence of 
borderline personality disorder. 
 Clearly, the use of these exclusion criteria might hamper the generalizability of the results 
of AETs. Exclusion of patients suffering from bipolar depression or from MDD with psychotic 
features, which is very often done in AETs, will limit the generalizability of results from MDD 
trials to bipolar patients and patients suffering from MDD with psychotic features. However, 
as bipolar disorder and MDD with psychotic features are considered to be separate entities 
of MDD that are covered in trials especially designed for those target populations, the use 
of these exclusion criteria does not hamper clinicians in their evaluation of the usefulness 
of RCTs for their patients. Exclusion of suicidal patients, patients with co morbid substance 
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abuse disorders, patients with other Axis I or Axis II disorders and patients suffering from 
milder MDD, however, will hinder the generalizability of results from RCTs to daily practice. 
This is because many “real world” MDD patients suffer from suicidal ideations, substance 
abuse or other co morbid disorders and/or personality pathology. In addition, while in RCTs 
a minimum depression severity is required, in daily practice many more patients suffer from 
mild-to-moderate MDD than from severe MDD. These exclusion criteria might also influence 
the outcome in clinical practice. Substance abuse disorders are associated with poorer 
treatment outcome [45], presence of other Axis I disorders also seem to be associated with 
poorer treatment outcome, although results are not unambiguous [45-48]. Suicidality seems 
to be associated with treatment resistance [47] and the presence of personality pathology 
seems to be associated with poorer or different treatment outcome, but also in this field the 
results are not unambiguous [47,49-51]. Milder MDD is sometimes associated with better 
treatment outcome [47], but is also associated with poorer response due to a larger effect 
of regression to the mean in more severe MDD. Outcome research in MDD with co morbid 
disorders as well as in mild-to-moderate MDD is scarce and the results are contradictory. 
 In brief, the following exclusion criteria that are consistently used in AETs are relevant 
for the generalizability of the results of AETs: co morbid Axis I and II disorders, suicidality 
and mild MDD. In this thesis, we explore the occurrence of these criteria in daily practice 
and subsequently investigate the eligibility of daily practice patients for MDD trials and the 
influence of the mentioned features on treatment outcome.
 The use of inclusion and exclusion criteria leads to explicit selection, but selection bias in 
the research population might also occur beforehand as the sample from which participants 
will be selected may differ from clinician to clinician. For instance, they may already differ 
with respect to age, sex, race, severity of disease, educational status, social class, and place 
of residence [21]. Other aspects of recruitment may also contribute to unintended selection 
bias in sociodemographic and socioeconomic features. For instance, participation in RCTs 
is usually without costs for the participants. In countries where there is no extensive social 
security system and patients have to pay themselves for mental healthcare, participation in 
trials might be the only way to obtain treatment for patients with limited financial means. As 
a result recruited patients might have lower socioeconomic status than the average patient 
in daily practice when this is not controlled for. The area in which patients are recruited, 
and the recruitment strategy (ads in newspapers, certain magazines, internet, through 
clinicians), may also contribute to unintended selection bias. Finally, as participants will 
have to agree with the possibility of receiving placebo treatment, this might also introduce 
selection bias. Together with the use of exclusion criteria, unintended selection bias amounts 
to an exclusion rate of 73% of the initial patient population available for RCTs. Most of the 
selection takes place before or beyond consideration of the exclusion criteria [52]. 
 In this thesis, we explore sociodemographic and socioeconomic differences between 
RCT participants and “real life” MDD patients. Subsequently, we explore the influence of 
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sociodemographic and socioeconomic features on treatment outcome for MDD in clinical 
practice. 
Aims AnD ReseARcH questions
Until recently the choice of therapies for psychiatric disorders was based on personal 
experience, knowledge and preferences (experience based medicine). Nowadays, it 
has become common practice to gain evidence for the efficacy of treatments in RCTs, 
incorporate treatments that are proven to be effective in RCTs in guidelines, and implement 
these guidelines in routine psychiatric care. However, important questions about the 
generalizability of results from RCTs to daily psychiatric practice have not been addressed:
1. To what extent does outcome of treatments for MDD in trial settings (efficacy) and in 
routine clinical practice (effectiveness) differ?
2. Which proportion of “real life” patients would be eligible for participation in MDD trials 
and what is the influence of exclusion criteria on treatment outcome for MDD in daily 
practice?
3. Do participants of RCTs on MDD differ from daily practice patients in sociodemographic 
and socioeconomic features and do sociodemographic and socioeconomic features 
influence treatment outcome in MDD in daily practice?
contents oF tHe tHesis
In chapter 2, we addressed the first research question: To what extent does outcome of 
treatments for MDD in trial settings (efficacy) and in routine clinical practice (effectiveness) 
differ? We examined treatment outcome of antidepressant treatment; individual 
psychotherapy; and a combination of both. We derived the efficacy results from a large sample 
of selected meta-analyses. These meta-analyses all provided an aggregated estimate of the 
within group efficacy of antidepressants, individual psychotherapy and/or combination 
treatment. We also compared the outcome results from ROM to a large so-called “pragmatic” 
trial, STAR*D [39], which was designed to be as comparable to daily practice as possible. 
Outcome of treatments for MDD in routine clinical practice was explored in data derived 
from ROM. We compared effectiveness results from ROM with the efficacy results of these 
therapies when investigated in RCTs. We hypothesized that outcome in daily practice would 
be less favorable than efficacy results from RCTs and closer to the results from STAR*D.
 In chapter 3, we addressed the second research question: Which proportion of “real life” 
patients would be eligible for participation in MDD trials and what is the influence of these 
eligibility criteria on treatment outcome for MDD in daily practice for AETs? For this purpose, 
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we used the model of Zimmerman and colleagues [30] on consistency in the use of exclusion 
criteria in antidepressant trials. Furthermore, we investigated the influence of eligibility, 
both for the individual exclusion criteria as well as “being eligible” in general, on treatment 
outcome. We explored how many patients of a large group of ROM patients suffering from 
MDD would be eligible for AETs. In line with previous research, we hypothesized that only a 
minority of patients in daily practice will be eligible for participation in AETs. In line with a 
previous report on the STAR*D trial [44], we also expected patients who are eligible for AETs 
to have better treatment outcome than patients who are not. If the generalizability of results 
from AETs would turn out to be hindered by the use of eligibility criteria, this might be an 
explanation for differences between efficacy and effectiveness.
 In chapter 4, we addressed the second research question, but now for PETs. We explored 
the consistency of exclusion criteria in trials on CBT and IPT. We aimed to create a set of 
consistently used exclusion criteria, in line with the model of Zimmerman and colleagues 
[40]. Furthermore, we estimated the influence of commonly used exclusion criteria in PETs 
on treatment outcome in our ROM population. We hypothesized that patients who meet 
the exclusion criteria would have better treatment results than patients who do not. If 
generalizability of results from PETs would turn out to be hindered by the use of exclusion 
criteria, this might be an explanation for differences between efficacy and effectiveness.
 In chapter 5 and 6 we addressed the third research question: Do participants in RCTs 
on MDD differ from daily practice patients in terms of sociodemographic features and 
socioeconomic status and do these sociodemographic and socioeconomic features 
influence MDD treatment outcome in daily practice? In chapter 5, we explored the reporting 
of several sociodemographic and socioeconomic features of participants in a large number 
of AETs and PETs. We summarized the sociodemographic and socioeconomic features of 
RCT participants. In this way, clinicians will be able to judge whether the results of RCTs 
are generalizable to their own patient population or individual patients. In chapter 6, 
we used the results of this study to compare the sociodemographic and socioeconomic 
characteristics (age, gender, marital status, ethnicity and employment status) of participants 
in AETs and PETs with those of ROM patients. We subsequently assessed the influence of 
sociodemographic and socioeconomic status as seen in AETs and PETs on treatment 
outcome in ROM. We hypothesized that daily practice patients differ from trial participants 
and expected that sociodemographic/economic differences between RCT participants 
and daily practice would influence treatment outcome. If generalizability of results from 
AETs and PETs would turn out to be hindered by this form of selection bias, it might be an 
explanation for differences between efficacy and effectiveness.
 In chapter 7, we summarized and critically reviewed the main findings of our studies. 
We addressed the difficulties and pitfalls in comparing treatment outcome in daily practice 
to efficacy estimates from RCTs. We discussed the limitations of scientific research on data 
from Routine Outcome Monitoring. Finally, we discussed the implications of our findings for 
clinical practice as well as several suggestions for future research.
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ABstRAct
Background: results from RCTs are considered to give the most reliable information on 
treatment outcome (efficacy). Yet, the generalizability of efficacy results to daily practice 
(effectiveness) might be diminished by the design of RCTs. The STAR*D trial approached 
daily practice as much as possible, but still has some properties of an RCT. In this study, 
we compare results from treatment of major depressive disorder (MDD) in routine clinical 
practice to those of RCTs and STAR*D.
methods: Effectiveness in routine clinical practice was compared with efficacy results from 
15 meta-analyses on antidepressant, psychotherapeutic and combination treatment and 
results from STAR*D. Data on daily practice patients and treatments was derived from a 
Routine Outcome Monitoring (ROM) system. Treatment outcome was defined as proportion 
of remitters (MADRS≤10) and within group effect size. 
Results: From ROM, 598 patients suffering from a MDD according to the MINIplus were 
included. Remission percentages were lower in routine practice than in meta-analyses for 
all treatment modalities (32% vs.40–74%). Differences were less explicit for antidepressants 
(21% vs. 34-47%) than for individual psychotherapy (27% vs. 34–58%; effect size of 0.85 
vs. 1.71) and combination therapy (21% vs. 45–63%), since only 60% of the meta-analyses 
for antidepressants showed significant differences with ROM, while for psychotherapy 
and combination treatment almost all meta-analyses showed significant differences. No 
differences in effectiveness were found between routine practice and STAR*D 
conclusions: effectiveness of treatment for mild to moderate MDD in daily practice is similar 
to STAR*D and significantly lower than efficacy results from RCTs. 
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intRoDuction
During the past decades, the selection of treatments for major depressive disorder 
(MDD) has shifted from an approach based on clinical expertise towards evidence based 
medicine. Evidence based treatment guidelines are based on the results of randomized 
controlled trials (RCTs) [1]. Adherence to these treatment guidelines is expected to improve 
effectiveness of treatment in daily practice [2]. However, the effects in clinical practice may 
not be comparable to those found in RCTs. RCTs are designed to maximise the internal 
validity of the investigated trial i.e. their aim is to look for effects that are replicable and 
solely attributable to the investigated treatment. Therefore, RCTs usually include patients 
following stringent selection criteria. Unlike clinical practice, in RCTs patients with co 
morbidity or risk of suicide are excluded, and a minimum symptom severity is required for 
inclusion. Also, much more effort is put in maximizing treatment adherence than is usual in 
clinical practice. Furthermore, RCTs are frequently carried out in specialised settings [3-5]. 
While clearly increasing the internal validity, these features limit the external validity, i.e. 
the generalizability, of RCTs [6,7]. Hence, it is important for clinicians to know what may be 
expected from evidence based treatments of MDD in routine clinical practice. Unfortunately, 
publications on effectiveness are very scarce. The Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) was one of the first studies designed to resemble the routine 
clinical practice of the treatment of MDD. However, in STAR*D prior non-responders to the 
study drugs, patients with a preference for non-pharmacological treatment before the first 
treatment step, and patients with a baseline severity of less than 14 on the 17-item Hamilton 
Rating Scale for Depression (HAMD) were excluded [8]. Furthermore, in STAR*D much effort 
has been put in maximizing adherence to the treatment protocol, both for participating 
patients and therapists. Therefore, the STAR*D-design has elements of both RCTs and routine 
clinical practice. Success rates in STAR*D were modest, and in daily practice treatment 
results for might be even worse, as many of the STAR*D strategies to enhance treatment 
adherence may not be feasible. However, some other factors in routine mental health care 
might contribute to a better treatment outcome, such as the possibility to allow for patient 
preferences [9]. To our knowledge, no studies on the effects of evidence based depression 
treatments in routine clinical practice have been published yet.
 Since 2002, the Dutch Regional Mental Health Provider (RMHP) Rivierduinen assesses 
psychopathology and other characteristics with structured interviews and rating scales 
as a part of routine clinical practice. The assessments are done during the first visit and 
subsequently on every three to four months to monitor progress. This routine outcome 
monitoring (ROM) is integrated with stepped care protocols, based on evidence based 
treatment guidelines [10]. 
 The ROM data allow a comparison of the effects of treatment for MDD in RCTs, in STAR*D, 
and in routine daily outpatient practice. In the present study, we compared the effects of 
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treatments with antidepressants, with psychotherapy and with combination therapy 
between the three different settings. As in routine clinical practice a limited set of inclusion 
and exclusion criteria is used and no extra effort is put to enhance treatment adherence, 
we expected to find the smallest effect sizes in routine clinical practice, with effect sizes in 
STAR*D in-between those of routine clinical practice and RCTs.
metHoDs
Rcts: selection of meta-analyses
As there are many RCTs of treatments for MDD, we used the results of meta-analyses. As 
the topic of this study is the outcome of treatments in different settings and not the effects 
relative to a control group, we selected meta-analyses providing within-group results. 
 First, we searched PubMED and PsycInfo for meta-analyses of depression treatment in 
adult psychiatric outpatients. We also screened the reference lists of selected meta-analyses 
for other meta-analyses, searched an extensive database on psychotherapy-RCTs (http://
www.psychotherapyrcts.org) and contacted two experts in psychotherapy of depression for 
other references of meta-analyses of psychotherapy. We finally identified 431 meta-analyses. 
 Inclusion criteria for meta-analyses in the present study were: 1) provide data on within-
group efficacy on depression severity, total number of patients per treatment arm and 
number of responders or remitters or within-group effect size. 2) select secondary care 
outpatients with unipolar, non-psychotic MDD without co morbidity. 3) outcome defined 
with the Hamilton Depression Rating Scale (HAMD)[8], the Montgomery Asberg Depression 
Rating Scale (MADRS) [11] or the Beck Depression Inventory (BDI-II) [12]. Exclusion criteria 
were: 1) rate of relapse, drop-out rate or response rapidity as only efficacy measure, or 
focus on specific symptoms like physical complaints. 2) focus not the effect of treatment, 
but another like the placebo-effect. 3) focus on antidepressant drugs unavailable in the 
Netherlands or very infrequently used in RMHP Rivierduinen during the investigated 
period (2002-2006): duloxetine, escitalopram, desvenlafaxine, reboxetine, moclobemide, 
milnacipran, trazodone, and nefazodone. 
 After application of these in- and exclusion criteria, 17 of the 431 meta-analyses were 
included. Most meta-analyses were excluded because they did not provide within-group 
data. Another two meta-analyses were excluded because they overlapped with other meta-
analyses [13,14]. In six of the finally 15 selected meta-analyses, outcome was defined as the 
proportion of responders [15-20]; in four as proportion of remitters [21-24] and in four as 
both [25-28]. Only one meta-analysis [29] (on psychotherapy) defined outcome as effect size 
on the BDI [30]. Pre-and post-treatment data within each individual trial were aggregated to 
estimate the individual effect size of that trial. In addition, the individual effect sizes of the 
trials were aggregated to estimate an overall effect size [30]. Although effect size is generally 
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used as an estimate of between-group efficacy, in the meta-analysis of Minami et al. on 
psychotherapy a within-group effect size was generated as a benchmark for future research 
and clinical practice. 
 Response was defined as a 50% reduction of severity on a depression scale. Four meta-
analyses used the 17-items HAMD [20,25-27] to assess response, one meta-analysis used the 
21-items HAMD [28] and five used either one or both versions of the HAMD (17 or 21 items) 
and/or the MADRS [15-19]. With respect to remission, cut-off scores on the post-treatment 
assessment of a depression severity scale were used. In two meta-analyses the cut-off was 
a score of ≤7 on the 17-item HAMD [26,27], in one meta-analysis the cut-off was ≤7 on the 
first 17 items of the 21-item version HAMD [28], another used <7 as cut-off on the 17-item 
HAMD [23]and yet another a score of ≤ 8 on the 17-item HAMD [25]. Two meta-analyses 
included trials with different definitions of remission on different scales (17 item HAMD, 21 
item HAMD, MADRS, and BDI) [21,22]. 
 
stAR*D
Two publications from the STAR*D trial provided within-group results of antidepressant 
therapy, cognitive behavioral therapy and combination therapy [31,32]. Only remission was 
assessed and the cut-off was defined as a score of ≤7 on the 17-item HAMD.
Routine clinical practice: the Dutch mental health care system and treatment 
steps for mDD 
In the Netherlands, health insurance is obligatory for all citizens, and mental health care is 
not (yet) restricted by the financial means of patients. The Dutch mental health care system 
is organized in a stepped-care-manner and uses evidence based treatment guidelines. 
Patients with mood complaints visit their general practitioner (GP) first. The treatment 
guidelines recommend that patients with mild to moderate depression be treated with 
psychotherapy or pharmacotherapy, based on the patient’s preferences [33]. Patients with 
severe depression should preferably start a pharmacotherapy. Rating of severity is based on 
clinical judgment. Reasons to refer patients to a RMHP are a preference for psychotherapy, 
more severe, recurrent or refractory depression or the presence of co morbid psychiatric or 
somatic disorders. After baseline assessment and a clinical interview at our RMHP, patients 
were offered treatment steps as recommended by the guidelines. Patients suffering from 
moderate to severe MDD could choose between psychotherapy and antidepressants. 
For severe depression antidepressants were the first choice. When patients are already 
on antidepressants the dose is optimized or patients are offered to switch to another 
antidepressant or start psychotherapy. 
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Routine outcome monitoring
ROM at the RMHP Rivierduinen is described in detail elsewhere [10]. The assessments 
are carried out by specially trained research nurses with the help of dedicated software. 
The outcomes are fed back to the therapist, and discussed with the patient. The 
baseline assessment comprises a standardized diagnostic interview (Mini-International 
Neuropsychiatric Interview Plus MINIplus [34]), collection of sociodemographic and 
socioeconomic data, administration of observer rated scales (including the MADRS) and self 
report questionnaires (including the BDI-II), and general measures of health and quality of 
life. Only patients with insufficient mastery of the Dutch language are not eligible for ROM. 
 In this study anonymized ROM data were used, in agreement with the Psychiatric 
Academic Registration Leiden (PAREL), which has been approved by the Medical Ethical 
Committee of the University Medical Hospital Leiden.
 From 2002 through 2006, 1653 of the patients with ROM suffered from a MDD according 
to the MINI plus at intake. Of these, 879 had only one ROM assessment: 190 did not start 
treatment after the baseline assessment, 350 remained in treatment but had no follow-
up assessments, and for 339 no information on treatment continuation after baseline 
assessment was available. Of 774 patients two or more assessments were available. Of these 
patients, 169 were excluded for the following reasons: time between baseline and follow-
up too short (<4 weeks) or too long (>52 weeks) for a single treatment (n=47), inpatient 
treatment in the period before the second assessment (n=43), psychotic features or bipolar 
disorder (n=42), no treatment information available (n=28), a MADRS ≤10 at baseline (n=15), 
and over 65 years of age (n=1). There remained 598 patients for further analysis. Of them, 82 
were treated with antidepressants only, 170 with individual psychotherapy only, 167 with 
the combination of both, 90 with antidepressants and supportive therapy and 89 with other 
treatments. 
statistical analysis
For comparison of the ROM results with the RCT and STAR*D data, the response and 
remission rate, and the within group effect size Δ were computed. For ROM, we defined 
response as a 50% symptom reduction on the MADRS. For remission, the most commonly 
used threshold in RCTs is a score of 7 or less on the HAMD17. Several methods to compute an 
equivalent MADRS score has been described, either by equations [35-37] (a score of 7 on the 
HAMD17 corresponds to a MADRS score between 8–10) or with the Item Response Theory 
([38] (a score of 7 of the HAMD17 corresponds with a MADRS score of 8–9). In other research 
several definitions of remission on the MADRS were described: a threshold of 10, 11 or 12, 
corresponding with “borderline mentally ill” or no symptoms of illness on the CGI-S (clinical 
global impression-severity of illness) [39,40]. We defined research remission as MADRS score 
of ≤10 [39]. Recently, a cut-off of ≤5 on the MADRS has been suggested as more appropriate 
to define remission [40]. Therefore, we also computed proportions of remission defined as 
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MADRS ≤5. However, these proportions were not used in the comparison with the meta-
analyses, since RCTs used a higher cut-off to define remission. Proportions of response 
and remission were computed for antidepressant treatment, individual psychotherapy, 
the combination of both and the combination of antidepressants and supportive therapy. 
Within-group effectsize for individual psychotherapy was defined as Δ = (μpre –μpost) / σ in 
which μpre = mean pre-treatment, μpost =mean post-treatment and σ = standard deviation 
pre-treatment on the BDI-II [30].
 The results of the meta-analyses, of STAR*D and of ROM were compared using two 
independent proportions in the following statistical formulas [41,42]:1) 95% Confidence 
interval: se(p1-p 2) = √ p1(1- p1) / n1 + p2 (1- p2) / n2, p1-p2 – 1,96 x se(p1-p 2) to p1-p2 + 1,96 x se(p1-p 
2), in which se= standard error, p1= proportion of responders/remitters in meta-analyses, 
p2=proportion of responders/remitters in ROM population, n1= number of patients in meta-
analyses within the treatment modality, n2= number of patients in ROM population within 
the treatment modality. and 2) Hypothesis test (with continuity correction): P = (r1 + r2) / 
(n1 + n2) , se(p1-p 2) = √ p1(1- p1) / n1 + p2 (1- p2) / n2, zc = | p1-p 2 | - 0,5 (1/n1 + 1/n2 ) / se(p1-p 2), 
in which P= probability given H0 is true (no difference between p1 and p2), r1= number of 
responders/remitters in meta-analyses, r2= number of responders/remitters in ROM sample, 
zc = z-score in normal distribution-two tailed areas (z -> p-value).
ResuLts
Rom patients
Characteristics of the included ROM patients. We included 598 patients with a current 
MDD with at least one follow-up ROM assessment. Table 1 shows the sociodemographic 
features of this group. Table 2 shows clinical characteristics at baseline assessment (severity 
of the MDD, co morbid Axis I disorders, primary clinical diagnosis) and the timeframe of 
assessments.
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Comparison with lost-to-follow-up group. To assess a possible selection bias, we compared 
the 598 included patients to the 879 patients who were not included. We classified the 
879 patients who were lost to follow-up in three categories: patients who dropped out of 
treatment after baseline assessment (n=190), patients who remained in treatment but had 
no follow-up assessments (n=350), and patients on whom no information on treatment 
continuation after baseline assessment was available (n=339). We compared these groups 
and the included sample on the following variables: age, gender, ethnicity, marital status, 
employment status, educational level, baseline severity of the depression (MADRS, BDI-II), 
recurrence of the depressive disorder, co morbid Axis I disorders and suspected personality 
pathology as assesses with DAPP-SF. On the majority of these variables, no differences were 
found. The included patients differed from those who dropped out of treatment immediately 
after baseline assessment with respect to co morbidity and socioeconomic status. The latter 
were younger (mean age 36 vs. 39, difference 3 years, 95% CI 1.0–4.7, p=0.002), more often 
single (46% vs. 31%, p=0.003) and there was a trend towards a lower educational level (56% 
vs. 44 % had less than secondary school diploma, p=0.05). They also had a higher score on 
the BDI-II (33.2 vs. 30.6, difference 2.6, 95% CI -4.2– -0.6, p=0.003) and higher scores on the 
DAPP-SF (52% vs. 38%, p=0.006). Finally, they suffered more often from posttraumatic stress 
disorder (21% vs. 15%, p=0.05) and alcohol/drug abuse (16% vs. 9%, p=0.003). 
Effectiveness in the ROM sample. Response percentages for the different modalities in ROM 
varied between 29% and 32%, remission percentages between 17% and 27%. Response 
percentages in the ROM sample were very close to the remission percentages due to the 
low baseline severity. The mean baseline severity of the different treatment modalities 
varied between 23.3 and 27.9 on the MADRS, which means that a response (50% reduction 
of symptoms) had to be a MADRS score ≤11.7-14.0; while remission was defined as a MADRS 
≤10. When remission was defined as MADRS ≤5, remission percentages in the ROM sample 
were between 7% and 10%. The within group effect sizes of the treatment modalities varied 
between 0.68 and 0.97. 
comparison of outcomes
We compared proportions of remitters in the ROM sample and in meta-analyses or STAR*D. 
We also compared proportions of responders, but these results were similar, as most patients 
in ROM suffered from mild to moderate depression (data not shown). 
 Comparison of the remission percentages in ROM and meta-analyses showed that 
effectiveness (27%) was lower than efficacy (34–47%). Differences in remission between 
meta-analyses and daily practice were less explicit for pharmacotherapy than for individual 
psychotherapy or combination therapy, since for only three of the five meta-analyses 
on antidepressants the differences were significant (table 2). However, for individual 
psychotherapy and combination therapy, daily practice did significantly worse than RCTs: 
two out of three meta-analyses of individual psychotherapy showed significantly better 
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results on remission (34–58% versus 27%) and all three meta-analyses of combination 
therapy also showed significantly better results for combination therapy than in daily 
practice (45–63% versus 21%). We found no differences between the proportion of remitters 
in routine clinical practice and the proportions of remitters on the different treatment steps 
in STAR*D.
 Within-group effect sizes in ROM could be compared with the results of one meta-
analysis on psychotherapy and this showed that the outcome of individual psychotherapy 
was significantly less favorable in ROM (effect size 0.85) than in RCTs (effect size 1.71, CI 
1.60–1.82). This difference was statistically significant, since the ROM effect size is smaller 
than the 95% confidence interval in the meta-analysis (p<0.05). 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































41Efficacy versus effectiveness | 
2
Discussion
We compared the outcome of evidence based treatments for MDD in a Dutch daily 
practice sample with the outcomes reported in meta-analyses of RCTs and in the STAR*D 
trial. As expected, effectiveness results were less favorable than efficacy results reported 
in RCTs for antidepressants, individual psychotherapy and combination treatment, and 
more comparable to those of the STAR*D trial [31,32]. The differences were smaller for 
pharmacotherapy than for individual psychotherapy and combination treatment.
 Our findings support a frequently heard criticism of clinicians who claim that achieving 
success with “real world” patients is more difficult than RCT-results suggest. 
 Several explanations for the observed differences may be considered. First, there may 
be differences in patient characteristics, as RCTs use stringent exclusion criteria, for obvious 
ethical and methodological reasons, which may jeopardize the generalizability of the results 
[43] [3-6]. The STAR*D group found that patients who were eligible for RCTs had better 
treatment outcome than non-eligible patients [44]. Contrary to this finding, in a previous 
study on our routine practice sample, the influence of eligibility for RCT on outcome was 
very small [45]. However, we did confirm that milder depression very frequently occurs 
in routine practice, and that exclusion of these patients from the analysis led to a more 
favorable treatment outcome. In RCTs, patients with less severe depression are usually 
excluded [46]. 
 Participants of RCTs probably also differ from daily-practice patients on other features 
potentially related to positive treatment outcome. Improvement of treatment outcome 
due to participation in a research setting, the Hawthorne effect, is well known [47]. Further, 
participants of RCTs may be highly motivated and hence have good adherence to treatment 
[2] [48]. Participants in RCTs typically accept randomization to different therapies, whereas 
in daily practice many patients specifically ask for a certain type of therapy. There might be 
an intrinsic difference between these groups of patients. The fact that in some trials patients 
are rewarded for participation might also influence outcome. Furthermore, the treatment 
provided in trials might be of higher quality than in daily practice as in trials special efforts 
are made to increase adherence and improve quality of treatment.
 It remains unclear why differences between effectiveness and efficacy are more profound 
for individual psychotherapy and combination therapy than for pharmacotherapy. The side-
effects of antidepressants that resemble symptoms of depression may contribute to a lower 
proportion of remission in antidepressant efficacy trials. Furthermore, there may be relevant 
differences between participants in antidepressant trials and in psychotherapy/combination 
therapy trials. Finally, there are some methodological differences between antidepressant 
trials and psychotherapy trials, for instance in the definition of the placebo treatment. 
 Besides the finding that treatment outcome for depression in RCTs is better than in 
daily practice, there are two other remarkable findings in our study. First, contrary to our 
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hypothesis, we found no differences between outcome in our ROM population and the 
results of the STAR*D trial. This is somewhat contradictory to previous reports that stated 
that STAR*D exaggerated the effectiveness of antidepressant treatment [9]. Second, there 
was a discrepancy between the low baseline severity on the MADRS and the relatively 
high score on the BDI in our population. One of the explanations is that in our population 
many patients might suffer from so-called “stress-related” depressions, rather than so called 
“somatic/biological” depression. In previous research, a discrepancy was found between 
observer rated (MADRS) and self reporting (BDI) scales in stress-related depression [49]. 
 We consider the generalizability to “real life” psychiatric outpatient populations and the 
large number of well-documented, routinely monitored patients to be major strengths of 
our study. To our knowledge, no previous research has reported on treatment outcome for 
MDD with data from daily routine clinical practice. 
 There are also limitations to consider. It should be noted that we relied on meta-analyses, 
which might have overestimated the efficacy of treatments for depression because of 
publication bias. We could only include a limited number of meta-analyses. Meta-analyses 
of psychotherapy that reported within-group results were scarce. 
 There was a considerable loss-to-follow up in our naturalistic sample. However, the 
loss-to follow-up-analysis showed that our patient selection was fairly representative for 
daily-practice-patients who receive treatment. Nevertheless, there was a small under-
representation of employed patients and patients with higher baseline severity of 
depression. 
 Due to the loss-to-follow-up, the subgroups for each treatment modality were rather 
small. To assess possible power problems, we computed the differences between efficacy 
and effectiveness for a situation in which the number of patients would have been ten times 
larger. In this scenario, we found that still all but one meta-analysis reported significantly 
better outcomes than our results. For STAR*D, the differences remained non-significant. We 
therefore conclude that the relatively small sample-size did not importantly influence our 
main findings. 
 Although we believe our sample to be representative of an out-patient population with 
MDD, this might not be completely the case for the setting. The fact that patients were 
monitored and patients and therapists received feedback may have influenced treatment 
outcome. Previous research has shown improvement of treatment outcome by monitoring 
[50,51]. Finally, to allow comparison with meta-analyses we had to use “classical” measures 
of outcome like percentages remission and response. The validity of these definitions of 
treatment outcome for daily practice has been questioned [52-55]. In previous research 
[40] a cutoff of a MADRS score ≤5 (equivalent to “completely recovered” on the CGI, in our 
ROM population only 9.5% of the patients) has been suggested as a more valid definition 
of remission. The use of lower thresholds for remission or other definitions of treatment 
outcome, together with more advanced techniques of statistical modelling, might yield 
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more useful information on outcome in daily practice, but may also diminish the possibilities 
for comparison with previous scientific literature. 
 In conclusion, our results indicate that the outcomes of treatments for MDD in routine 
clinical practice, which is predominantly of mild to moderate severity, are indeed less 
favorable than the outcomes reported in meta-analyses of RCTs of different treatments for 
MDD. Further research into factors that influence outcome in routine clinical care is needed 
to optimize treatment for patients with MDD.
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ABstRAct
Background: Generalizability of antidepressants efficacy trials (AETs) to daily practice is 
questioned because of their very stringent patient selection. This study aims to determine 
eligibility for AETs of outpatients suffering from major depression in a routine outpatient-
setting and investigates influence of eligibility on treatment outcome.
methods: Data collection (n=1653) through routine outcome monitoring by independent 
trained research nurses. MINIplus and DAPP-SF were used for diagnostic assessment and 
personality pathology screening. MADRS was used for assessment of baseline severity 
and treatment outcome. Eligibility was assessed by stepwise application of commonly 
used exclusion criteria. Influence of eligibility on treatment outcome was investigated in a 
subsample of the 1653 patients who had at least one follow up assessment (n=626). Eligible 
and non-eligible patients were compared on proportion of response (50% reduction) and 
remission on MADRS (MADRS≤10).
Results: 17–25% of the patients were eligible for AETs. The most common reasons for 
exclusion would be “not meeting minimum baseline severity” and “presence of co morbid 
Axis I disorder”. Eligible and non-eligible patients did not differ in treatment outcome. Only 
“meeting the minimum baseline severity” is associated with remission. 
conclusion: The majority of “real life” outpatients is not eligible for AETs. However, the 
influence of eligibility on treatment outcome seems to be small. This suggests that stringent 
patient selection by eligibility criteria is not the major reason for lack of generalizability 
of AETs. Exclusion of less severely depressed patients from the analyses resulted in better 
treatment outcome. Milder depression is highly prevalent in daily practice and more 
research into treatment effectiveness in milder depression is warranted.
Key words: major depression; routine outcome monitoring; generalizability; antidepressant 
efficacy trials; eligibility
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intRoDuction
During the past decades, depression treatment has shifted from an approach based on 
clinical expertise towards an evidence based approach using results from randomized 
clinical trials (RCTs) on antidepressants and/or psychotherapy [1,2]. However, for 
methodogical and ethical reasons, antidepressant efficacy trials (AETs) will always need 
strict, randomized and placebo-controlled conditions, and use stringent inclusion and 
exclusion criteria for patient selection. In this way, internal validity is optimized. However, 
by optimizing internal validity, external validity (generalizability) might be compromised. 
Hence, the generalizability of the results from AETs to clinical practice can be questioned 
[3-7]. Three studies in the United States examined the eligibility of depressive patients for 
inclusion in AETs [8-10]. These reported that only 12–34% of these patients were eligible for 
AETs. However, these investigations regarded only fee-for-service settings, which may not 
be generalizable to the European healthcare system. In a European study, the eligibility of 
volunteers for AETs was also found to be limited: 34% of the patients who volunteered for 
an AET finally entered the trial [11]. The majority of the volunteers was excluded because 
of co morbid disorders. Investigators of the STAR*D trial [12] used less stringent inclusion 
criteria in order to obtain more generalizable results. In their study 22% of the included 
patients would have been eligible for AETs and had better treatment outcome than non-
eligible patients [13]. However, the generalizability of STAR*D to routine clinical practice 
may still be limited, due to exclusion of prior non-responders to the study drugs, and the use 
of a minimum baseline severity. In addition, the generalizability of STAR*D to non-US health 
settings is unclear [14]. In the present study, we investigated in routine outpatient-care to 
what proportion of depressive patients the results of AETs would apply. We chose to limit 
the AETs to classical RCTs, since in national and international treatment guidelines [15-17], 
classical RCTs are considered the most robust evidence for efficacy. We do, however, expect 
that in the near future the results from more pragmatic trials like STAR*D and GENDEP [12,18] 
will influence guidelines. We applied the most frequently used inclusion and exclusion 
criteria for classical AETS to a large consecutive series of patients. Comprehensive data on 
patients’ characteristics were available through the extensive Routine Outcome Monitoring 
(ROM) system. In addition, we investigated whether eligible patients differ from non-eligible 
patients in treatment outcome.
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metHoDs
the Dutch mental health care system and treatment steps for major depression
In the Netherlands, health insurance is obligatory for all citizens and regulated by the 
government. Mental health care is easily accessible and not restricted by the financial means 
of individual patients. The Dutch mental health care system is organized in a stepped-care-
manner and uses evidence based treatment guidelines. Patients with mood complaints visit 
their general practitioner (GP) first. The treatment guidelines recommended that patients with 
mild to moderate depression should be treated with psychotherapy of pharmacotherapy, 
based on the patient’s preferences [17]. Patients with severe depression should preferably 
start a pharmacotherapy. Rating of severity is based on clinical judgment. Reasons to 
refer patients to a regional mental health provider (RMHP) are a preference of patients for 
psychotherapy (not provided by GPs), more severe, recurrent or refractory depression or 
the presence of co morbid psychiatric or somatic disorders. After baseline assessment and 
a clinical interview at our RMHP, patients were offered treatment steps as recommended by 
the guidelines. Patients suffering from moderate to severe major depression could choose 
between psychotherapy and antidepressants. For severe depression antidepressants were 
the first choice. When patients were already on antidepressants the dose was optimized or 
patients were offered to switch to another antidepressant or start psychotherapy. 
Routine outcome monitoring
In 2002, the RMHP Rivierduinen (service area with 1.1 million inhabitants), in collaboration 
with the University Medical Hospital Leiden, implemented ROM and evidence based, 
stepped care protocols. In ROM, all patients referred to the RMHP for treatment of a mood, 
anxiety or somatoform disorder have an extensive baseline assessment. Treatment progress 
is then assessed at three to four monthly intervals and before starting a new treatment 
step. The baseline assessment comprises a standardized diagnostic interview (Mini-
International Neuropsychiatric Interview Plus [19]), the collection of sociodemographic 
and socioeconomic data, the administration of disease specific severity-scales, and general 
measures of health. For a more extensive description of ROM we refer to the design paper 
[20]. 
Patients
To examine the eligibility of depressive outpatients for AETS, we included all outpatients 
with a DSM-IV diagnosis of a current major depressive disorder as established by the Mini-
International Neuropsychiatric Interview (MINIplus) [19], who sought treatment at the 
RMHP Rivierduinen from January 2002 until January 2007. The MINIplus does not yield a 
hierarchy in primary disorder and co morbid disorders. We included all patients with a major 
depressive disorder, regardless of the fact whether depression was the primary diagnosis 
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as determined by the treating clinician or a so-called co morbid disorder. We decided to do 
so since primary clinical diagnosis is a concept often used in clinical practice but not well 
defined in literature and is depending heavily on the personal expertise of the individual 
clinicians. Including patients based on primary clinical diagnosis of depressive disorder 
only would have led to selection bias and results in a less well defined sample. Since the 
presence of a primary clinical diagnosis of depression might influence treatment outcome, 
we controlled for it in the analyses on the influence of eligibility on treatment outcome.
 In order to examine the influence of eligibility to AETs on treatment outcome, we 
selected all patients in our sample with at least one follow up assessment in ROM (follow-up 
group). The treatment outcome of the first treatment step was explored in this project. We 
examined possible selection bias by comparing the patient characteristics of the follow-
up group and the lost-to-follow-up group. We conducted an extensive chart review in the 
follow-up group in order to obtain information on primary clinical diagnosis and treatment 
modality. In order to allow comparison with classical AETs, we defined treatment outcome 
in the same dichotomous variables used in AETs: 
1. Proportion of responders: 50% reduction of the baseline score on the Montgomery 
Asberg Depression Rating Scale (MADRS) [21].
2. Proportion of remitters: MADRS≤10. 
commonly used exclusion criteria for Antidepressant efficacy trials 
In an extensive review of the literature Zimmerman and co-workers identified exclusion 
criteria that where consistently used in AETs published between 1994 and 1999 in the top-
five Impact Ranking journals in the US [9,22]. We expanded this search by inclusion of AETs 
published between 1994 and 2007, not only in the aforementioned journals, but also in 
the remaining journals of the top-ten Impact Ranking psychiatric journals of 2005. With our 
expanded search, we obtained 17 additional articles on AETs [1,23-36,37,38]. No additional 
exclusion criteria for AETs were identified. The commonly used exclusion criteria, identified 
by Zimmerman and co-workers [9] are listed below, together with the operationalisations 
for our sample.
1. History of DSM-IV manic or hypomanic episodes
At least one (hypo) manic episode on the MINIplus.
2. Experiencing psychotic features during the current episode of depression
Diagnosis of a current depression with psychotic features on the MINIplus. 
3. Significant risk of suicide
In our sample, suicidality was assessed with the corresponding item on the MADRS item 
8. Patients with a score of 3 or higher were considered to meet this exclusion-criterion.
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The item is a Likert-scale from 0-6:
0 Enjoys life, takes it as it is.
2 Tired of life, only transient suicidal thoughts.
4 Probably better off dead. Suicidal thoughts often occur and suicide is considered to 
be a possible solution. No specific plans. 
6 Explicit plans to commit suicide. Active preparation of suicide. 
4. Alcohol or drug abuse or dependency within the last six months
 Diagnosis of current abuse or dependence on drugs or alcohol on the MINIplus. 
5. Mild depression, as determined by low baseline score on the Hamilton depression-scale 
The most commonly used threshold for inclusion in an efficacy trial is a minimum score of 
18 (HAMD 17 items) or a minimum score of 20 (HAMD 21 items) on the Hamilton depression 
scale [10,39]. Because in our setting the MADRS is used to asses depression severity, an 
equivalent of the HAMD score was computed using three previously developed regression 
equations based on three trials that compared the MADRS and the HAMD17 in outpatients 
Mittmann et al. [40] (A); Hawley et al., [41] (B) and Zimmerman et al. (C) [42]. Since the Item 
Response Theory (IRT) has recently been proven to be a probably more reliable method of 
conversion of the MADRS into the HAMD17 as well [43,44], we also used the IRT method to 
compute proportions of patients not meeting the criterion of minimum baseline severity. 
1. (A) MADRS = 1.23 x HAMD - 0.30 
(cutoff MADRS = 21.8)
2. (B) MADRS = 1.30 x HAMD + 0.7  
(cutoff MADRS = 24.1)
3. (C) MADRS = 1.43 x HAMD + 0.87  
(cutoff MADRS = 26.6)
6. Presence of underlying dysthymic disorder
Diagnosis of dysthymic disorder on the MINIplus. 
7. Illness duration of less than 4 weeks or more than 2 years
Duration of less than 4 weeks or more than 2 years of the current episode is an exclusion 
criterion for antidepressant efficacy trials. Unfortunately, in our sample no reliable 
information on the duration of the current episode of the major depression was available. 
Therefore, we could not use this exclusion criterion in our analysis. 
8. Presence of co morbid non-depressive, non-substance use Axis I disorders
Diagnosis of anxiety disorder, somatoform disorder, eating disorder, or attention deficit 
hyperactivity disorder on the MINIplus. 
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9. Presence of borderline personality disorder
In our setting, the Dimensional Assessment of Personality Pathology, short Dutch 
version DAPP-SF [45,46] was used as a screening instrument for personality-pathology. 
Stringent and less stringent cut-off scores were used to identify patients with a possible 
personality disorder within a population suffering from mood-, anxiety-, and somatoform 
disorders [46]. Quartiles (low score-intermediate low-intermediate high-high score) 
were computed for the patients in our sample on (weighted) scores for the dimensions 
Emotional Dysregulation, Dissocial Behavior and Inhibition. The scores were weighted 
by the factor loadings derived from research on psychometrics of the DAPP-SF [46]. 
In our sample, patients with a cut-off of 3.7 and a “high score” on all three dimensions 
were considered to meet the exclusion-criterion of borderline personality according to 
“stringent criteria”. Patients with a cut-off of 2.6 and a “high score” on all three dimensions 
were considered to meet the exclusion-criterion of borderline personality disorder 
according to “less stringent criteria”.
statistical analysis
For each exclusion criterion, we determined the percentage of patients that met the 
criterion. For the DAPP-SF quartiles were computed for (weighted) scores. The scores were 
weighted by the factor loadings derived from research on psychometrics of the DAPP-SF 
[20]. In our sample, there were missing values for the MADRS (n=103) and the DAPP-SF 
(n= 415). Comparison of complete cases and cases with missing data showed differences 
on many variables. Therefore it is likely that the missing data were not missing-completely-
at-random (MCAR). Complete case analysis is likely to yield biased estimates [47]. Therefore, 
the MICE (multivariate imputation by chained equations [48]) method was used to estimate 
missing values for MADRS. With these imputed data, we computed the percentage of 
patients meeting the exclusion criteria of Mild Depression and Significant Risk of Suicide. We 
did not impute missing values for the DAPP-SF, as this instrument consists of dimensional 
components that we considered too complex to predict. If the score for the DAPP-SF was 
missing for a patient, we considered the patient as not meeting the exclusion criterion of 
Presence of Borderline Personality Disorder. Comparison of proportion of responders and 
remitters in the eligible and non-eligible patient-groups were performed by Chi-square tests. 
The influence of the exclusion criteria and “eligibility for RCTs” on treatment outcome was 
computed by logistic regression after MICE. Odds-ratios (OR) and their confidence intervals 
were computed by using the robust standard error. Statistical analyses were performed with 
SPSS 16.0 and STATA10.0. 
54 | Chapter 3
ResuLts
Patients 
4157 outpatients were assessed at baseline between January 2002 and January 2007. Of 
these patients, 1653 suffered from a current major depressive disorder according to the 
MINIplus. The demographic features of the 1653 patients are described in table 1. 
table 1. Demographics.
n=1653 Percentage mean (+sD)
Age in years 38.19 (SD 11.68)
Gender 33.3% male; 66.7% female
Marital situation













Education 9.2% primary school or less
25.4% secondary school, lower level
29.5% secondary school intermediate/high level
12.1% academic or higher professional education
23.8% unknown
Ethnicity 64.5% born in the Netherlands
4.1 % born in Morocco/Turkey
2.1% born in Suriname/Antilles
5.6% born elsewhere
23.4% unknown
Ethnicity II 60.0% parent(s) born in the Netherlands
4.6% parent(s) born in Morocco/Turkey
2.3% parent(s) born in Suriname/Antilles
8.8% parent(s) born elsewhere
23.4% unknown
MADRS at baseline 26.76 (SD 7.52)
SD = standard deviation
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Application of commonly used exclusion criteria for Aets
Bipolarity and Psychotic Features
A total of 25 of the 1653 patients (1.5%) had at least one (hypo) manic episode (current or 
history). 31 patients suffered from a depression with psychotic features (1.9%). There was no 
overlap between these two groups. Following the approach by Zimmerman and colleagues 
[9,49], we excluded these 56 patients (3.4%) from further analysis. The other exclusion 
criteria were examined on the remaining 1597 patients.
Suicidality
Of the 1597 patients 241 patients (15.1%) would have been excluded from AETs because of 
suicide risk. 
Alcohol or drug abuse/dependence
142 of the 1597 patients (8.9%) met the exclusion-criterion of current abuse/dependence 
on drugs or alcohol. 
Severity of the depression at baseline
According to the first regression equation (A), 435 of the 1597 patients (27.2%) did not meet 
the cut-off score of 18 on the HAMD17. The second and the third regression (B, C) equations 
yielded identical scores, and 664 of the 1597 patients (41.6%) had a score lower than 18 
on the HAMD17. The IRT yielded almost identical proportions: 38.7 % (cut-off MADRS 24) – 
44.5% (cut-off MADRS 25) of the patients had a score lower than 18 on the HAMD17.
Co morbid Dysthymic Disorder
136 of the 1597 patients (8.5%) met the exclusion-criterion for a co morbid dysthymic 
disorder. 
Other co morbid Axis I disorders
1003 of the 1597 patients (62.8 %) had co morbid diagnoses on Axis I according to the 
MINIplus. 730 patients (45.7%) had at least one anxiety disorder.180 patients (11.3%) had at 
least one somatoform disorder. Another 32 patients (2.0%) had other co morbid disorders.
Personality Pathology
31.6–61.6% of the 1597 patients in our sample may have had some form of personality 
pathology according to the DAPP-SF. Within this group, the estimated percentage of patients 
suffering from a borderline personality disorder ranges from 3 patients (0.2%, stringent 
criteria) to 112 patients (7.0%, less stringent criteria).
Percentage of patients eligible for Antidepressant efficacy trials and comparison 
with previous research
Finally, the sample of 1653 depressed outpatients was filtered by stepwise application of 
the exclusion criteria. Only 17.0%–24.5% of our patients would have been eligible for AETs. 
Stepwise application of the exclusion criteria is described in figure 1. Comparison of the 
incidence of the individual exclusion criteria in our sample with previous research [9] is 
described in table 2.





858 (53.7%) 667 (41.7%)
406 (25.4%) 312 (19.5%)
405 (24,5%) 311 (18,8%)
376 (22,7%) 285 (17,2%)
Bipolarity/ Psychotic features
Alcohol/ drugs abuse  
Severity at Baseline*
Mittman Hawley / Zimmerman 
Suicidality





772 (48.3%) 600 (37.6%)
Figure 1. Stepwise Application of Commonly Used Exclusion Criteria and the Resulting Percentages 
of Patients Eligible for Antidepressant Efficacy Trials. 
* Severity at baseline was assessed with the Montgomery Asberg Rating Scale for Depression. Equivalent Hamilton rating 
Scale for Depression scores (17 items version)  were calculated using three previously developed regression equations. 
table 2. Comparison of incidences of exclusion criteria (%) between our sample and Zimmerman’s 
sample [9].
current research 
Percentages of  
excluded patients
Previous research
Percentages of  
excluded patients
Bipolarity/ psychotic features 3.4 15.3
Suicidality 15.2 19.8
Alcohol/drugs 8.6 7.8
Severity at baseline 27.2–41.6 54.3
Dysthymic disorder 8.5 8.9
Other Axis I disorders 62.8 68.3
Borderline personality pathology 0.2–7.0 11.9
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Follow-up group 
From the 1653 patients suffering from major depression, 46% (n=774) had a follow-up 
assessment. Extensive chart-review was done for those 774 patients. 148 patients had to 
be excluded from further follow-up analysis due to suspected bipolarity/psychotic features, 
admission to an inpatient-clinic during follow-up, remission on the MADRS at baseline or a 
time-span between baseline and follow-up assessment which we considered either to be 
too short or too long to provide reliable information. Finally, 626 patients were selected for 
follow-up analysis. In 4% of the 626 patients, information on primary clinical diagnosis for 
was missing. Patient selection is described in figure 2. 
patients with major 











psychotic features on MINIplus: n=7
bipolar disorder on MINIplus: n=12
Admission to clinic during follow-up: n=43
Clinical suspiscion bipolarity or 
psychotic features n=23
Older than 65: n=1
Time between baseline and  
follow-up assesment
 <4 weeks or >52 weeks: n=47
MADRS≤10 at baseline: n=15 
Figure 2. Selection of the follow-up group.
In chart review, we identified that 54% of the selected patients in the follow-up group 
received antidepressants, either as solo treatment or in combination with other treatment 
modalities. Five treatment modalities were identified: “antidepressants (AD)” (13%), 
“individual psychotherapy (IP)” (27%, mostly cognitive behavioral therapy or interpersonal 
therapy), “combination of antidepressants and individual psychotherapy (AD+IP)” (27%), 
“antidepressants and social supportive therapy (AD+SST)” (14%) and “other treatment/
insufficient information” (19%). The mean time-span between start of treatment and follow-
up assessment was as follows: AD 20.8 weeks (CI 18.7–22.9); IP 20.1 weeks (CI 18.5–21.6); 
AD+IP 21.5 weeks (CI 20.0–23.1); AD+SST 21.6 weeks (CI 19.9-23.3); other 19.1 weeks 
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(CI 17.1–21.1). In 113 patients treatment was primarily started for a clinical diagnosis other 
than major depression, of whom 88 patients received psychotherapeutic treatment focussed 
specifically on anxiety/somatoform disorders.
Lost to follow-up analysis
The follow-up group and the lost-to-follow-up group did not differ on most exclusion criteria. 
The follow-up group only differed from the lost-to-follow-up group in larger proportions 
of patients with a generalized anxiety disorder (7.3% vs. 4.6%, X²=5.08, df1, p=0.02) and 
depression with psychotic features (0.9% vs. 2.7%, X²=7.42, df1, p=0.01). Based on these 
results, selection bias was considered to be very small. 
influence of eligibility on treatment outcome
In the follow-up group, 28% of the patients met the criteria for response and 21% of the 
patients met the criteria for remission. There were no significant differences in response-
percentages between the patients who would have been eligible for AETs (25%) and those 
who were not (28%), X²=0.26, df1, p=0.61. Remission percentages did not differ either: 
16% (eligible patients) vs. 23 % (non-eligible patients), X²=1.80, df1, p=0.18. The influence 
of patient features commonly used as exclusion criteria on response and remission was 
examined in multivariate regression models. The following variables were entered as 
covariates in a multivariate regression model: risk of suicide; minimum baseline severity 
of depression; co morbid substance dependency/abuse; co morbid dysthymia, co morbid 
anxiety disorder, co morbid somatoform disorder, other co morbid Axis I disorders. 
“Primary clinical diagnosis” and “treatment modality” were entered in the model as possible 
confounders. Overall, the explained variance (R-square) was very low for remission (4.1%) 
and response (1.4%). Only “the criterion of minimum baseline severity” contributed to 
remission (OR 2.0, CI 1.3–3.1). None of the exclusion criteria contributed significantly to 
response. The influence of “eligibility for AETs”, which we defined as “not meeting any of the 
exclusion criteria”, was investigated in a separate model and did not contribute significantly 
to response (OR 0.90, CI 0.5–1.8) nor remission (OR 1.0, CI 0.5–2.0).
Discussion
We evaluated the eligibility for inclusion in AETs in 1653 outpatients with a major depressive 
disorder in a Dutch general psychiatric outpatient setting. We followed a model developed 
for the consistency of exclusion criteria used in AETs [9,22]. We found that the majority of 
patients in our sample (75%) did not meet the inclusion criteria. The most common criteria 
for inclusion that would not have been met were “minimum baseline severity of 18 on the 
Hamilton rating scale” and “no co morbid Axis I disorder”. In addition, we examined the 
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influence of eligibility on treatment outcome. The influence of exclusion criteria on response 
and remission appears to be small. Only the exclusion of mild depression contributed to 
improvement of treatment outcome in our sample. Exclusion of less severely depressed 
patients from the analyses resulted in better treatment outcome. Milder depression is 
highly prevalent in daily practice and more research into treatment effectiveness in milder 
depression is warranted.
comparison with previous research: eligibility for Aets
Our findings are in line with those of previous research [8,11,13,49]. The percentage of 
patients eligible for participation in AETs in our study was higher than in earlier research 
but similar to the latest report on eligibility in the STAR*D trial [13]. An explanation for the 
larger proportion of eligible patients in our sample might be the fact that the percentage of 
patients meeting the criterion of minimum baseline severity was larger in our sample. This 
might be due to the way in which the Dutch health care system is organized. First, there is 
no (financially) limited access to mental health care. Poor socioeconomic status has been 
shown to be associated with more severe pathology and co morbidity [50]. Therefore, we 
expected a higher percentage of patients with more severe depression in our sample. We 
also expected higher percentages of co morbid Axis I disorders, but the prevalence of co 
morbidity was similar to previous research. Another explanation for the higher percentage 
of patients that met the criteria for baseline severity is the role of the GP as ‘gate keeper’ 
in Dutch health care. Still, a considerable part of our patients did not meet the criteria for 
minimum baseline severity (27–42%).We found lower percentages of bipolarity / psychotic 
features and borderline personality disorders in our sample. In our RMHP those patients are 
often directly (preceding ROM baseline assessment) referred to specialized teams, which 
might explain the low prevalence in our sample. 
comparison with previous research: influence of eligibility on treatment outcome
In contrast to the recent STAR*D report [13], we found no differences in treatment outcome 
between eligible and non-eligible patients. Together with the marginal explained variance 
that we found in our model, this suggests that other patient features are more associated 
with treatment outcome than eligibility for AETs. Many patients, either eligible or not, would 
not be willing or able to participate in AETs. Participants might differ from non-participants 
in: sociodemographic/socioeconomic status, motivation/adherence to treatment and the 
interaction between clinician and patients. This might also partially explain the differences 
between our results and the ones found in the STAR*D report [13]. In the STAR*D trial, 
much effort has been undertaken to improve adherence to treatment and to motivate the 
participating patients and clinicians [12]. It is possible that by “controlling” for these aspects 
an association between eligibility and treatment outcome can be detected. Unfortunately, 
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the magnitude of the influence of eligibility on treatment outcome is not reported in the 
STAR*D report and therefore not available for comparison. 
Treatment outcome in our study was less favorable than the outcomes typically found in 
classical AETs and also less favorable than the outcome in STAR*D. A thorough comparison 
and exploration of differences between the outcomes in RCTs, in more pragmatic trials 
like STAR*D, and in our ROM project will be important for daily practice. We are currently 
performing such a comparison and exploration.
strengths
The use of Routine Outcome Monitoring in daily mental health care provided comprehensive 
data on a large number of patients As the only restriction for participation is sufficient 
language competence and ability to complete computerized or written questionnaires, the 
results of this type of data collection are very representative of and generalizable to ‘real-life’ 
psychiatric practice. Furthermore, we consider the fact that the Dutch health care system 
provides unrestricted access to mental health care as a strong quality of this research. It 
diminishes the possibility of selection bias even further. 
Limitations
There was a considerable loss to follow-up in our study. In 22% of the lost to follow-up, 
patients dropped out of treatment directly after baseline assessment and in 38% of the lost 
to follow-up, patients stayed in treatment, but we had no information on their treatment 
course. The major reasons for drop-out are unclear; patients might have recovered, 
were perhaps unsatisfied with the offered treatment or treatment results, or had poor 
compliance. As 38% of the lost-to-follow-up patients remained in treatment, loss to follow-
up may also have resulted from factors hampering the ROM follow-up assessments, such 
as administrative issues or a reduced adherence of clinicians to the ROM methodology. A 
large loss to follow up might be a problem in all studies with a more naturalistic design. For 
example, STAR*D had reached a loss-to-follow-up of 48% in step II of the study. Of the 4790 
patients who were screened at baseline, 12% was not willing to participate; 3% did not meet 
inclusion criteria; 8% had an HAMD <14 or no data on the HAMD; and 25% left the study 
[12]. Although we had a considerable loss to follow-up, the follow-up group was very similar 
to the lost-to-follow-up group with respect to criteria for eligibility. We therefore expect the 
influence of the loss to follow-up on our results to be small.
 The absence of information on illness duration is another limitation of this study. Although 
we expect not to have included patients with illness duration shorter than four weeks as 
most patients are seen several times by their GP before referral, it is however possible that 
patients were depressed for more than 2 years. This might have lead to an overestimation of 
the amount of eligible patients. Furthermore, a possible suboptimal diagnostic assessment 
of borderline personality disorder the fact that we had no information on physical health 
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problems (not included in Zimmerman’s model on exclusion criteria, but still often used as 
an exclusion criterion) might also have led to an overestimation of the amount of eligible 
patients. On the other hand, there might be some underestimation of the eligibility in our 
sample, due to the fact that no data were available on patients who were too ill to complete 
questionnaires. Not all the patients in our sample were treated with antidepressants. A 
considerable proportion received other treatment (i.e. psychotherapy) for their depression. 
However, the percentage of eligible patients turned out to be equal in the antidepressants-
group and the other-treatment-group. For comparability with former research, we used the 
model of Zimmerman et al. which does not take differences between AETs, like active versus 
placebo controlled, into account. Differences in AET architecture will probably influence 
eligibility, but were not investigated in the present study. Finally, to optimize comparability 
in treatment outcome with classical RCTs, we used the same definitions of outcome as RCTs: 
response and remission, determined by a cut-off score. This dichotomization of scales might 
lead to loss of information compared to continuous outcomes [18] .
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ABstRAct 
Background: treatment guidelines for major depressive disorder (MDD) are based on results 
from randomized clinical trials, among others in psychotherapy efficacy trials. However, 
patients in these trials differ from routine practice patients since trials use stringent criteria 
for patient selection. It is unknown whether the exclusion criteria used in psychotherapy 
efficacy trials (PETs) influence symptom outcome in clinical practice. We first explored which 
exclusion criteria are used in PETs. Second, we investigated the influence of commonly used 
exclusion criteria on symptom outcome in routine clinical practice.
methods: We performed an extensive literature search in PubMed, PsycInfo and additional 
databases for PETs for MDD. From these, we identified commonly used exclusion criteria. 
We investigated the influence of exclusion criteria on symptom outcome by multivariate 
regression models in a sample of patients suffering from MDD according to the MINIplus 
from a routine clinical practice setting (n=598). Data on routine clinical practice patients 
were gathered through Routine Outcome Monitoring.
Results: We selected 20 PETs and identified the following commonly used exclusion criteria: 
‘a baseline severity threshold of HAMD≤14’, ‘current or past abuse or dependence of alcohol 
and/or drugs’ and “Previous use of medication or ECT”. In our routine clinical practice sample 
of patients suffering from MDD (n=598), presence of ‘current or past abuse of or dependence 
on alcohol and/or drugs’ had no significant influence on outcome. ‘Meeting a baseline 
severity threshold of HAMD≤14’ and “Previous use of medication or ECT” were associated 
with better outcome, but the explained variance of the models was very small (R²=2-11%).
conclusions: the most consistently used exclusion criteria are not a major threat to the 
generalizability of results found in PETs. However, PETs do somewhat improve their results 
by exclusion of patients with minor depression and patients who used antidepressants prior 
to psychotherapy. 
Key words: major depressive disorder; psychotherapy efficacy trials; exclusion criteria; 
generalizability; treatment outcome; symptom outcome; routine clinical practice; routine 
outcome monitoring 
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intRoDuction
In the development of guidelines, randomized controlled trials (RCTs) and meta-analyses 
thereof are considered the most reliable source of evidence. However, it is unknown to what 
extent the results of these RCTs are generalizable to routine clinical practice. In RCTs, much 
effort is put in optimising the internal validity, i.e. the possibility to determine to what extent 
the observed efficacy is reproducible and attributable to the investigated treatment. The 
internal validity of trials is improved by the use of strict criteria for patient selection. While 
this is very important for methodological and ethical reasons, it has been demonstrated 
that the use of eligibility criteria may well hamper the generalizability (external validity) of 
the results [1-6]. In trials of antidepressant treatment of major depression (MDD), a fairly 
consistent set of exclusion criteria is used [2]. Based on this set of criteria, we and others found 
that only 12–34% of the patients who received treatment for MDD in routine outpatient 
psychiatric care settings and fee-for-service private practice were eligible for participation 
in an antidepressant efficacy trial (AET) [1,3,7]. Some studies showed that eligible patients 
had a better treatment outcome than non-eligible patients in routine outpatient care [8]. 
In contrast, we found that only exclusion of minor depression was associated with better 
treatment outcome [9]. Thus, the AET exclusion criteria had a limited influence on treatment 
outcome. 
 Whereas the influence of exclusion criteria on treatment outcome is a topic in research 
on AETs, this is not the case for research on psychotherapy efficacy trials (PETs). To our best 
knowledge, only one study reported on the eligibility of “real life” patients for PETs. A total of 
95% of patients with several common psychiatric disorders were eligible for at least one PET 
and 75% for two or more [10,11]. However, the authors did not investigate the comparability 
of the exclusion criteria used in the PETs. Lack of consistency in this respect may diminish 
the unequivocality of the results of PETs and thereby the generalizability of the results to 
“real life” patients. 
 In this paper, we present the effects of the most used exclusion criteria of PETs on 
eligibility of “real life” patients. First, we identified the exclusion criteria used in PETs. 
Subsequently, we examined the proportion of patients with unipolar depression eligible 
for PETs, applying the most used exclusion criteria, to a sample of “real life” patients with 
major depressive disorder (MDD) from the Leiden Routine Outcome Monitoring Study [12]. 
Finally, we investigated the influence of eligibility for PET on symptom outcome from the 
first treatment step, in this sample.
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identification of exclusion criteria in Pets
In line with previous research on the consistency in the use of exclusion criteria in AETs [2], 
we performed a search in PubMed and PsycInfo for publications in English on PETs for adult 
patients suffering from MDD. Furthermore, we checked the reference lists of the included 
publications for relevant studies. We also consulted: http://www.psychotherapyrcts.org. 
This website is composed by a group of researchers from the VU University Amsterdam, 
the Netherlands, and contains a database of RCTs and comparative studies of the effect 
of psychotherapy on adult depression. We selected PETs in which outpatient treatment 
was investigated and in which one of the comparison groups was treated with either only 
individual cognitive behavioral therapy (CBT) or individual interpersonal therapy (IPT) as 
these two treatments are usually incorporated in treatment guidelines. For all the studies 
that met our inclusion criteria, we retrieved eligibility criteria from their Methods sections.
the Dutch mental health care system and treatment steps for mDD
The Dutch mental health care system is organized in a stepped-care-manner and uses 
treatment guidelines which are based on evidence from AETs and PETs. Patients with mood 
complaints visit their general practitioner (GP) first. GPs will refer patients with a first episode 
of a mild depression either to counseling sessions or prescribe antidepressants. The Dutch 
and many other guidelines recommend that patients with moderate depression should be 
treated with CBT or IPT or pharmacotherapy, based on the patient’s preferences [13-15]. 
Reasons to refer patients to a regional mental health provider (RMHP) are a preference of 
patients for psychotherapy (only provided by psychotherapists), severity or recurrence 
of depression, and non-response to the GP’s treatment. After baseline assessment and a 
clinical interview at our RMHP, patients are offered treatment steps as recommended by 
the guidelines. If patients are not too severely ill and have sufficient mastery of the Dutch 
language, they are eligible for psychotherapy when this is their preferred treatment. 
Patients
Data on “real life” patients were drawn from the Leiden Routine Outcome Monitoring 
Study [12]. In 2002, the RMHP Rivierduinen (service area with 1.1 million inhabitants), in 
collaboration with the University Medical Hospital Leiden, implemented ROM and evidence 
based, stepped care protocols. In ROM, all patients referred to the RMHP for treatment 
of a mood, anxiety or somatoform disorder have an extensive baseline assessment. 
Treatment progress is then assessed at three to four monthly intervals and before starting 
a new treatment step. The baseline assessment comprises, besides a clinical interview, a 
standardized diagnostic interview (Mini-International Neuropsychiatric Interview Plus 
[16]), the collection of sociodemographic and socioeconomic data, the administration of 
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disease specific severity-scales, and general measures of health. All ROM instruments are 
administered by independent and specially trained research nurses. For a more extensive 
description of ROM, we refer to the design paper [12]. Patients were between 18–65 years 
of age, referred for treatment between January 2002 and January 2007 to the RMHP 
Rivierduinen, and had at least one follow-up assessment. 
 Since the goal of this research was to evaluate the generalizability of the results of 
psychotherapy trials, which generally use symptom reduction or remission on an observer 
rated instrument as primary outcome, we used the data collected with equivalent 
instruments in our ROM system. In ROM, MDD was diagnosed with the Dutch version of the 
MINI-Plus and depression severity was assessed with the Montgomery Asberg Depression 
Rating Scale (MADRS, [17]). To explore putative selection bias, we performed a lost to follow 
up analysis by comparison of patients only assessed at baseline with those included in our 
study. We investigated the eligibility and the effects of eligibility on outcome in all MDD 
patients referred for treatment irrespective of the treatment they received (antidepressants 
or psychotherapy). Since the type of treatment that patients receive might influence 
outcome, we adjusted for “treatment modality” in these analyses. To examine the effects of 
eligibility to PETs on treatment results of psychotherapy specifically, we also conducted the 
analyses in patients who were actually treated with CBT or IPT.
effects of exclusion criteria on symptom outcome in daily practice 
In line with previous research on exclusion criteria in AETs [1-3,18,19], we explored the 
influence on outcome of exclusion criteria used in >75% of the PETs. In line with the 
methodology of PETs, we defined outcome in our daily practice population as the extent 
of improvement on the MADRS (difference between baseline and post treatment), and in 
line with the methodology of both AETs and PETs also as proportion of responders (50% 
reduction of symptoms), and as proportion of remitters (MADRS ≤10) [20] after the first step 
treatment for MDD. 
statistical analysis
The effects of the exclusion criteria on outcome were computed by univariate and 
multivariate linear and logistic regression analyses. In the multivariate (adjusted) analyses 
on each individual exclusion criterion, the effects of the exclusion criterion on outcome 
were adjusted for age, gender and all the other exclusion criteria. In the analysis on all MDD 
patients we also adjusted for “treatment modality” (type of treatment that the patients 
received: antidepressants, psychotherapy or a combination of both). For the lost to follow-
up analyses, independent sample t-tests and Chi-square analyses were carried out. The 
statistical software package SPSS 16.0 was used.
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identification of exclusion criteria in Pets 
Our PubMed search yielded 3931 potentially relevant titles of studies. Another 203 
potentially relevant studies were retrieved from reference lists of manuscripts and from the 
database of the VU University Amsterdam. The majority of these studies were carried out 
in specific subgroups, such as elderly, ethnic minorities or patients with specific somatic co 
morbidity (n=4085). Therefore, these studies were excluded. Another 22 manuscripts were 
excluded because they were duplicates between the three databases. Of the remaining 
27 PETs, seven were excluded for the following reasons: in one PET the psychotherapeutic 
intervention appeared to include a prominent role for the spouse of the patients [21]; in 
another, the use of in- and exclusion criteria was mentioned but not made explicit [22]; 
five PETs were excluded as they used the same datasets as other studies already part of 
our review [23-27]. Finally, 20 PETs could be included [28-42]; [43-47]. In 18 studies (90%), 
individual CBT was one of the intervention arms and in 5 studies (25%) individual IPT was. 
In 12 PETs (60%), antidepressants (most frequently tricyclic antidepressants) were used as 
comparison treatment. No PETs used treatment as usual or a waiting list group as control 
group. 
 From the PETs, we identified 38 exclusion criteria, which we grouped into the following 
15 categories (+ number of studies that reported the use of this criterion): 1) bipolar disorder 
or a history of a (hypo-)manic episode (19 studies); 2) history of schizophrenia or psychosis 
or psychotic features (18 studies); 3) current or past abuse of or dependence on alcohol and/
or drugs (17 studies); 4) not meeting a minimum severity threshold (16 studies); 5) previous 
use of medication or electro convulsive therapy (ECT) (14 studies); 6) co morbid personality 
disorder (12 studies); 7) cognitive disorders (11 studies); 8) somatic concerns (11 studies); 
9) receiving other treatment at the start of the trial (10 studies); 10) anxiety disorder as a 
primary diagnosis (9 studies); 11) contra indication for the use of medication (9 studies); 12) 
suicidality (8 studies); 13) previous psychotherapy (8 studies); 14) co morbid Axis I disorders 
(5 studies) and 15) crisis situation (4 studies). In line with the model of Zimmerman and 
colleagues on commonly used exclusion criteria in AETs [2], we planned to examine the 
criteria that were used in more than 75% of all PETs, which were: 1) bipolar disorder or a 
history of a (hypo-) manic episode (95%); 2) schizophrenia, a history of psychosis or psychotic 
features ( 90%); 3) current or past abuse of or dependence on alcohol and/or drugs (85%) 
and 4) not meeting a minimum severity threshold (80%; most common: cut-off score of 14 
on the Hamilton Rating Scale for Depression [48] HAMD17). “Previous use of medication or 
ECT” was used in only 70% of the PETs, but we included this criterion in our further analyses 
as we hypothesized that it may have a large impact on eligibility of “real life” patients. Bipolar 
disorder and psychosis are considered to be different entities from MDD. Not only in PETs, 
but also in clinical practice, patients are treated differently if they have bipolar disorder or 
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a history of a (hypo-) manic episode, or a history of schizophrenia or psychosis or psychotic 
features. Therefore, these exclusion criteria are not likely to jeopardize the generalizability of 
the results of PETs for MDD to daily practice. Furthermore, we included the frequently used 
criteria “current or past abuse or dependence on alcohol and/or drugs” and “not meeting 
a minimum severity threshold” in our analyses. Co morbid substance abuse and relatively 
mild depression often occur in daily practice. Therefore, the frequently used exclusion 
criteria, “current or past abuse or dependence on alcohol and/or drugs” and “not meeting 
a minimum severity threshold” are likely to jeopardize the generalizability of the results of 
PETs to daily practice. Since in clinical practice alcohol abuse might be more common than 
drug abuse, we studied the effects of “current or past abuse or dependence on alcohol” and 
“current or past abuse or dependence on drugs” separately. Table 1 shows the exclusion 
criteria, the 15 summarized categories and their frequencies as identified in PETs. 
table 1. (Categories of ) exclusion criteria found in psychotherapy efficacy trials.
categorical exclusion criterion subtypes of exclusion criteria included in 
category*
Proportion of 
trials using the 
criteria
Bipolar disorder or history of  
(hypo-) manic episode 
95%
Schizophrenia, a history of psychosis 
or psychotic features
90%
Current or past abuse or dependence 
on alcohol and/or drugs
 − Alcohol abuse or dependence
 − Drug abuse or dependence
85%
Not meeting a minimum severity 
threshold
80%
Previous use of medication or ECT  − ECT less than 6 months before start of trial
 − History of use of a tricyclic antidepressant
 − Use of amitriptyline less than 3 months prior 
to trial
 − Use of imipramine less than 3 months prior 
to trial
 − Use of paroxetine less than 1 year prior to trial
 − Use of any antidepressant less than 2 months 
prior to trial
 − Use of any antidepressant less than 1 month 
prior to trial
 − Use of any antidepressant less than 2 weeks 
prior to trial
 − Current use of an antidepressant
70%
Co morbid personality disorder  − Borderline personality disorder
 − Antisocial personality disorder
 − Schizotypical personality disorder
60%
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categorical exclusion criterion subtypes of exclusion criteria included in 
category*
Proportion of 
trials using the 
criteria
Cognitive disorders  − Cognitive disorders in general
 − Organic brain syndrome
 − Delirium or dementia
 − Mental retardation
55%
Somatic concerns  − Somatic co morbidity in general
 − Co morbid somatisation disorder
55%
Receiving other treatment at start of 
trial
50%
Anxiety disorder as primary 
diagnosis 
 − Generalized anxiety disorder
 − Specific phobia
 − Obsessive-compulsive disorder
 − Panic disorder 
45%
Contra indication for the use of 
medication in general 
45%
Suicidal ideation 40%
Previous psychotherapy, with or 
without success
 − History of psychotherapy
 − Psychotherapy less than 5 years prior to trial
 − Psychotherapy less than 2 years prior to trial
 − Psychotherapy less than 1 year prior to trial
 − Psychotherapy less than 2 months prior to trial
 − Current psychotherapy
40%
Psychiatric co morbidity in general, 
including eating disorders
25%
Crisis  − Need for immediate intervention
 − Indication for admission
20%
*If no subtypes are mentioned, the categorical exclusion criterion was reported in the same way in all trials. 
Patients
Between January 2002 and January 2007, 1653 outpatients seeking treatment at RMHP 
Rivierduinen suffered from MDD according to the MINIplus. 774 patients (46%) had at least 
one follow-up assessment. Extensive chart review was done for those 774 patients. As we 
confined our study to patients with unipolar depression, we excluded 42 patients who were 
suspected to have a bipolar disorder or psychotic features. Furthermore, 132 patients had 
to be excluded from further follow-up analysis due to missing information on treatment, 
admission to an inpatient-clinic during follow-up, remission on the MADRS at baseline or 
a time-span between baseline and follow-up assessment which we considered either to 
be too short (less than four weeks) or too long (more than 52 weeks) to provide reliable 
information. Finally, 598 patients were selected for follow-up analysis. Of these 598 patients, 
80 patients only received individual psychotherapy (CBT or IPT) for MDD; 82 patients 
received only antidepressants; 90 patients received psychotherapy for a co morbid disorder 
other than MDD or the focus of psychotherapy could not be extracted from chart review; 
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167 patients received a combination of psychotherapy for MDD and antidepressants; 90 
patients received antidepressants and social supportive counseling; 89 patients received 
other forms of treatment, i.e. mood stabilizers, group therapy, training courses. Clinical and 
demographical characteristics of the whole sample as well as the 80 patients who received 
psychotherapy only are reported in table 2. In an earlier study on this sample we examined 
selection bias, due to loss to follow up of patients. We showed that the patients of this 
sample were very similar to the patients who were lost to follow up [7]. In table 2, we present 
the baseline features and symptom outcome in ROM patients suffering from MDD. 
table 2. Baseline features and treatment outcome in ROM patients suffering from MDD.
All mDD patients (n=598) Patients who received 
psychotherapy only (n=80)
Age (in years) 39.3 (SD 11.3) 36.2 (SD 10.8)
Gender (% female) 66.7% (n=399) 73.8% (n=59)
mADRs pre treatment 25.9 (SD 6.5) 24.1 (SD 6.0)
mADRs post treatment 18.2 (SD 9.4) 16.5 (SD 9.1)
treatment outcome
 Effectsize¹
 Proportion of responders²
























































¹ Effectsize is a definition of treatment outcome often used in PETs and defined as: the extent of improvement (Δ MADRS 
pre- and post treatment) adjusted for the standard deviation pre treatment. 
² Response is defined as a 50% reduction of symptoms on the MADRS.
³ Remission is defined as MADRS≤10.
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effects of exclusion criteria on symptom outcome
As we confined our study to unipolar depression, we excluded patients with a “bipolar 
disorder or a history of a (hypo-) manic episode” and patients with a “history of schizophrenia 
or psychosis or psychotic features” from our daily practice sample. Hence, we did not explore 
the effects of these two frequently used exclusion criteria in PETs. We did analyze the effects 
of the exclusion criteria “current or past abuse or dependence on alcohol and/or drugs”, “not 
meeting a minimum severity threshold” and “Previous use of medication or ECT” on outcome. 
In the literature, the baseline severity threshold (a cut-off score of 14 on the HAMD17 for 
PETs) is usually defined as a score on the HAMD17. In our routine clinical practice (ROM), 
depression severity is assessed with the MADRS. To enable comparison, we converted the 
scores MADRS of the ROM patients into HAMD17 scores with the equation proposed by 
Zimmerman [49] : MADRS = 1.43 X HAMD + 0.87. Recently, the Item Response Theory (IRT) 
was suggested to be a more reliable method to convert MADRS scores into HAMD17 scores. 
As a sensitivity analysis, we also used the IRT method [50] procedures yielded similar results 
for the conversion of the MADRS scores into HAMD17 scores. 
 Table 3 shows the proportions of patients meeting the exclusion criteria for all 598 
patients with MDD, as well as for the 80 patients treated with psychotherapy. In the group of 
all MDD patients, the criterion “previous use of medication or ECT” had the largest effect on 
proportion of eligible patients. In the 80 psychotherapy patients, the criterion “not meeting 
baseline severity threshold” had the strongest effect.
table 3. Exclusion criteria in ROM patients suffering from MDD.
exclusion criterion All mDD patients (n=598) Patients who received 
psychotherapy only (n=80)
current or past abuse or dependence  
of drugs
2.3% (n=14) 5.0% (n=4)
current or past abuse or dependence  
of alcohol 
5.0% (n=30) 2.5% (n=2)
not meeting Baseline severity threshold 21.9% (n=131) 30.8% (n=24)
Previous use of medication or ect 
(all patients received antidepressants,  






Table 4 shows the joint effects of the exclusion criteria on symptom outcome. In the group 
of all 598 depressed unipolar patients the criterion ‘current or past abuse of or dependence 
on alcohol and/or drugs’ had no significant influence. In the 80 psychotherapy patients, 
patients that met this criterion were too few in number for analysis of the effect. In the group 
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of all 598 depressed patients, patients with a baseline severity ≥14 on the HAMD17 had 7.23 
points (95% CI 5.31–9.14 p<0.001) more improvement on the MADRS than patients meeting 
the exclusion criterion of “not meeting minimum severity threshold”. The exclusion criterion 
“not meeting a minimum severity threshold” had no effect on the proportion of responders, 
but decreased the proportion that reached remission (OR 0.53, CI 0.33–0.84, p=0.01). For 
the subsample of psychotherapy patients, the joint analysis of exclusion criteria showed no 
associations with the exclusion criterion ‘not meeting minimum severity threshold’. 
 For all 598 patients with MDD, exclusion of patients meeting the criterion “previous use 
of medication or ECT” was associated with a more favorable proportion of responders and 
remitters in the remaining sample (OR 1.53, CI 1.00–2.34, p=0.05, unadjusted). Among the 
80 psychotherapy patients, those who met the criterion “previous use of medication or ECT” 
had 7.2 point less improvement on the MADRS than others (95% CI 1.94–13.30, p<0.01, 
unadjusted). However, in the joint analysis with the other exclusion criteria, the associations 
were no longer significant.
 The explained variance (R²) of the joint influence of the eligibility criteria 
respectively for all patients and psychotherapy patients was very small (adjusted for 
age, gender and type of treatment): 9 and 11% for the improvement on the MADRS; 
2 and 7% for the proportion of patients who responded to therapy (50% reduction of 
symptoms); 4 and 7% for proportion of patients who reached remission (MADRS ≤10). 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We evaluated the criteria for patient selection in PETs in 598 outpatients with a unipolar 
major depressive disorder in a Dutch general psychiatric outpatient setting. We tried to 
follow the model developed for the consistency of exclusion criteria used in AETs [1,18]. 
However, we found a lack of consistency in the use of exclusion criteria in PETs. Only four 
criteria were used in at least 75% of the studies: “bipolar disorder or a history of a (hypo-) 
manic episode”; “schizophrenia, a history of psychosis or psychotic features”; “current or past 
abuse of or dependence on alcohol and/or drugs” and “not meeting a minimum severity 
threshold” (most common: cut-off score 14 on the HAMD17). The criterion “previous use of 
medication or ECT”, was used in 70% of the studies and would lead to exclusion of the largest 
percentage (44.1%) of patients from our sample. For patients receiving psychotherapy only, 
the largest percentage (30.8%) would be excluded because of the criterion ‘not meeting 
minimum severity’. In addition, we examined the influence of exclusion criteria for PETs 
on symptom outcome in our sample. The influence of exclusion criteria on improvement, 
response and remission was small, suggesting that the most consistently used exclusion 
criteria are not a major threat to the generalizability of the efficacy results found in PETs.
comparison of exclusion criteria used in Pets to those used in Aets
To our knowledge there are no other studies on the effects of the exclusion criteria used in 
PETs on the generalizability to routine clinical practice. When we compared our results to 
those obtained in studies on the generalizability of AETs [2,18], there were some notable 
differences. First, PETs are less consistent in the use of exclusion criteria than AETs. The 
exclusion criteria “previous use of medication or ECT”, “cognitive disorders” and “somatic 
co morbidity” were only found in PETs. Furthermore, PETs use a lower minimum severity 
threshold than AETs (14 versus 18 on the HAMD17) and exclude cluster B personality 
pathology more often (57% versus 21%). However, they less often use psychiatric co 
morbidity and suicide risk (resp. 24% versus 59% and 43% versus 75%) as exclusion 
criteria. Differences between PETs and AETs may have to do with the conduct of many 
AETs by pharmaceutical companies, especially for drug registration purposes. These AETs 
consequently have to adhere to standard exclusion criteria formulated by the authorities. 
Furthermore, pharmaceutical companies may want to maximize the likelihood to find an 
effect by selection of patients who are more severely ill. They may also minimize the risk of 
having their drug associated with suicide by exclusion of suicidal patients. Although not 
reported in PETs, this fear may also have led to patient exclusion in PETs.
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comparison with previous research on effects of exclusion criteria on symptom 
outcome
We found that the exclusion of patients who are “not meeting the baseline severity 
threshold of HAMD ≤14” is associated with a smaller proportion of patients who reach 
remission (OR 0.53), while in our previous research in the same sample we found a positive 
association between exclusion of patients with a baseline severity of HAMD≤17 (used in 
AETs) and probability of remission (OR 2.0) [7]. This finding may be explained by the fact 
that there were many patients in our sample who had a baseline severity between HAMD 
14 and 17 (n=107, 18% of our study sample) who did not reach remission (78% of these 107 
patients). We are currently investigating the characteristics of this specific group of patients 
with mild depressive symptomatology who seem to be at risk for a more chronic course 
of their depressive disorder. Furthermore, the treatment success in our sample was rather 
modest, yet in line with other research done in daily practice [51]. We commented on the 
differences between treatment outcome in daily practice and RCTs in previous research 
[52]. Interestingly, the within-group effect size of MDD treatment in our ROM population 
was relatively high compared to the modest remission and response percentages. An 
explanation for this discrepancy may be that we computed all symptom outcomes for ROM 
reported in table 2, including effect sizes, on the MADRS. However, in PETs, remission and 
response are often measured on the MADRS or HAMD, but effect sizes are usually computed 
on the BDI-II [53]. In our previous report, we investigated the effect sizes for MDD treatment 
on the BDI-II in our ROM population [52] and found indeed smaller effect sizes (0.85 for 
individual psychotherapy) than the ones based on the MADRS reported in the present study. 
Another explanation is that the standard deviation on the MADRS at baseline is relatively 
small in our ROM population, perhaps as a result of the assessment by specially trained 
independent research nurses.
 We found that patients who used medication prior to psychotherapeutic treatment 
seem to benefit less from psychotherapy. Probably, these patients are non-responders or 
partial responders in a first treatment step for MDD and may form a more treatment resistant 
group. Hence, it is possible that PETs efficacy results were increased by exclusion of these 
patients. However, in routine clinical practice, many patients have used or are on medication 
before they start psychotherapy. 
 In line with our research on the influence of exclusion criteria of AETs on treatment 
outcome [7], we found an explained variance that was very small. This suggests that 
although many “real life” patients are not eligible for RCTs on MDD [1,3,6,7], the use of 
eligibility criteria might not jeopardize the generalizability of the results in “real life” settings. 
In previous research was found that patients who were eligible for AETs had a favorable 
treatment outcome [8], but the explained variance was not explored. 
 Most likely many other factors, besides eligibility, contribute to differences in outcome 
between RCTs and daily practice, like the Hawthorne effect [54], sociodemographic and 
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socioeconomic differences between RCT participants and “real life” patients [9] and the 
extent of protocol adherence of both therapist and patient, in which is highly invested in 
RCTs and likely not to the same extent in daily practice. We elaborated more extensively on 
the difference between efficacy and effectiveness in a previous report [52]. Further research 
on factors that contribute to differences in outcome between trials and daily practice is 
highly recommended. 
strengths
We used a large sample of patients with MDD from routine outpatient clinical practice (the 
Leiden Routine Outcome Monitoring study [12]), for which detailed data were available, 
enabling analysis of a subsample of patients receiving only psychotherapy. The use of ROM 
data provided comprehensive data that are very representative and generalizable to “real 
life daily practice” since there are nearly no restrictions for participation. Furthermore, we 
consider the fact that the Dutch healthcare system provides unrestricted access to mental 
healthcare as a strong quality of this research. Unrestricted access diminishes the possibility 
of selection bias even further. 
Limitations
The large variability in which exclusion criteria are defined in PETs made loss of information 
unavoidable. In addition, in our patient sample, there was a considerable loss to follow-up 
of outcome measurement. However, the study sample follow-up group was similar to the 
lost-to-follow-up group for most sociodemographic and clinical features. Patients were lost 
to follow-up because they dropped out of treatment or, in 38% of the cases, remained in 
treatment without follow-up assessments. Loss to follow up is a problem in all studies with 
a more naturalistic design. For example, STAR*D reached a loss-to-follow-up of 48% in step 
II of the study [55].
 In line with psychotherapy efficacy trials, we specifically chose to define outcome as 
symptom reduction or remission on an observer rated instrument in order to evaluate the 
generalizability of results from efficacy trials. For patients, other treatment goals might also 
be important, such as improvement of social functioning or quality of life. For therapists, 
other methods of defining treatment success, might be more useful such as clinically 
significant change [56]. Future effectiveness research, incorporating more definitions of 
outcome that are relevant to patients is therefore highly recommended. ROM can be a very 
useful methodology to support effectiveness research, and will also provide data to improve 
effectiveness research itself, as it enables a comparison between different types of treatment 
in daily practice, where one daily practice treatment can be a control treatment for the one 
under investigation. It will also provide data to explore the role of co morbid disorders in 
treatment and to improve diagnostic procedures in daily practice. Since there is a growing 
awareness that there is not just one type of major depressive disorder, in the future, ROM 
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will hopefully be helpful in the step towards personalised MDD treatment instead of “one 
treatment for all”. 
 Another limitation of this study is the rather small size of the patient group receiving 
psychotherapy only. More patients received psychotherapy in combination with 
antidepressants, which in many cases were already prescribed by the referring physician. 
Unfortunately, the small number of patients with documented “current or past abuse or 
dependence of alcohol and/or drugs” in our psychotherapy sample prohibited exploration 
of this criterion. Finally, an extensive Routine Outcome Monitoring system including 
diagnostic instruments, symptom severity scales, both observer rated and self report, and 
generic instruments measuring quality of life and social functioning is a costly investment 
for psychiatric practice and criticism is often heard, especially from policy makers. However, 
besides the opportunities to improve the quality of treatments in daily practice and the 
possibilities to scientifically evaluate questions that rise from daily practice, it also might 
be cost-effective. Since ROM provides information on treatment progress, it might enable 
the clinician to move to a next treatment step in case of stagnation in an earlier stage. Since 
ROM is relatively young, research in the field of its cost-effectiveness has, to our knowledge, 
not been carried out yet. It is, however, highly recommended. 
concLusions
We found that patient selection in psychotherapy trials in MDD lacks consistency. A 
consistent set of exclusion criteria is recommended in order to facilitate comparison between 
trials and especially for daily practice to evaluate the generalizability of their results. We 
also found that the most consistently used exclusion criteria are not a major threat to the 
generalizability of results found in PETs. However, PETs do somewhat improve their results 
by exclusion of patients with minor depression and patients who used antidepressants prior 
to psychotherapy. 
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ABstRAct
Rationale, Aims and objectives: It is important for clinicians to know to what extent 
the results of randomized controlled trials (RCTs) are generalizable to their psychiatric 
practice, since RCTs are considered to be the most reliable source of evidence for treatment 
guideline development. Furthermore, it is important to know whether results from 
individual randomized controlled trials (RCTs) can be directly compared to each other. 
Sociodemographic and socioeconomic (SES) features influence treatment outcome in 
major depressive disorder (MDD). Differences in (reporting of ) SES features of participants 
in RCTs will hamper comparison and jeopardize the external validity (generalizability) of 
their results. We explored the reporting of SES features in RCTs for depression. 
methods: We selected 45 antidepressant efficacy trials (AETs) and 19 psychotherapy efficacy 
trials (PETs). We listed the reported sociodemographic and -economic features.
Results: Reporting on SES features was very diverse and often limited. Especially important 
SES features like educational level, socioeconomic status and income were reported 
insufficiently. The mean age of RCT participants in MDD trials was 41 years. Participants are 
predominantly female (62%) and white (89%). Of the participants 61% were employed and 
45% of the participants were married/cohabitating. 
conclusions: Standardisation of reporting on sociodemographic and socioeconomic status 
is needed to adequately judge the generalizability of RCTs to daily practice and to facilitate 
comparisons within the body of RCTs. 
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intRoDuction
Major depression is one of the most common psychiatric disorders, affecting about 121 
million people worldwide [1]. Improvement of the quality of depression treatment would 
be beneficial to many people [2-4]. During the past decades, the selection of treatment for 
patients suffering from depression has shifted from an approach based on clinical expertise 
towards evidence based medicine. This has resulted in guidelines based on results from 
randomized controlled trials (RCTs) of antidepressants and/or psychotherapy [5,6]. There 
are long standing concerns regarding the generalizability of the results from the strictly 
controlled RCTs to the treatment of patients in “real world” clinical practice [7-12]. Patients 
in routine clinical practice have been shown to differ from patients included in RCTs on a 
number of clinical features, like the severity of symptoms or the presence of co morbidity or 
suicidality. These clinical differences between RCT participants and daily practice patients 
are mainly caused by selection bias due to the use of eligibility criteria [13-17]. However, 
beyond the use of clinical eligibility criteria, there are other forms of (probably unintended) 
selection bias which might jeopardize the external validity (i.e. generalizability) of RCTs. 
Patients may be eligible, but still not willing to participate in RCTs for several reasons, 
for instance a preference for a treatment modality. Furthermore, due to recruitment and 
inclusion procedures, participants in RCTs might also differ importantly from “real life” 
patients with respect to sociodemographic and socioeconomic background [7].
 Previous research in both general medicine and psychiatry has shown that socio-
demographic and socioeconomic features influence the outcome of treatment. Lower 
socioeconomic status and increased age were associated with poorer treatment outcome 
and mortality in several medical conditions [18,19]. In psychiatry, several studies on 
the influence of age and gender on the outcome of antidepressant treatment showed 
a negative association with increased age and the male gender [20-26]. In three studies 
increased age was not associated with poorer treatment outcome of psychotherapy for 
depression [27-29], and in one study, male gender was associated with better treatment 
outcome in psychotherapy for depression [28]. In pharmacotherapy, being married and a 
better socioeconomic or employment status predicted better outcomes. In psychotherapy, 
employment had no influence [25-28,30-33]. Remarkably, level of education was 
predictive for outcome neither in pharmacotherapy nor in psychotherapy [20,23,27,33-
37]. Furthermore, patients with different ethnic backgrounds seem to benefit equally from 
pharmacotherapy and psychotherapy, yet in certain ethnic minorities treatment adherence 
was found to be significantly worse [38-43].
 As sociodemographic and socioeconomic features (SES features) may influence 
treatment results, clinicians should be able to compare their “real life” patients with the 
participants of the trials in order to assess the generalizability of the results of the trials 
to their own population. Therefore, the quality of the reporting of SES features in RCTs is 
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Inclusion: We included peer reviewed publications of RCTs, published through 2007 in 
outpatients with a unipolar, non-psychotic depression according to DSM-III-R or DSM-IV (major 
depressive disorder MDD). Because we aimed to review the reporting of sociodemographic 
and socioeconomic features in RCTs usually selected for the development of guidelines for 
routine treatment, we excluded trials which a priori included only participants from specified 
subgroups like elderly or a specific ethnic minority. For the same reason, we also excluded 
augmentation trials, trials that focused on refractory depression, or trials limited to patients 
with a particular co morbid condition such as alcoholism, anxiety disorder, or medical 
illness. Furthermore, it was essential that the publication provided baseline information on 
sociodemographic and/or socioeconomic features. When there were several publications 
from the same trial, we included the report that provided the most detailed information 
on sociodemographic and/or socioeconomic features. When the reports on a trial provided 
the same information, we included the first report. We included trials written in English, 
since international guidelines for treatment of MDD are predominantly based on English 
literature. 
Psychotherapy: We performed a Medline search for RCTs investigating psychotherapy 
(cognitive behavioral therapy and interpersonal therapy) for adult patients suffering 
from MDD. Furthermore, we performed an additional search in PsycInfo and checked the 
reference lists of included trials for other relevant studies as well as the database http://
www.psychotherapyrcts.org. This website contains a database of RCTs and comparative 
studies examining the effect of psychotherapy on adult depression, collected by a group of 
researchers from the VU University in Amsterdam, the Netherlands, and Linköping University 
in Sweden. We selected the psychotherapy efficacy trials (PETs) in which outpatient treatment 
was investigated and in which either only individual cognitive behavioral therapy (CBT) or 
individual interpersonal therapy (IPT) was the intervention or control group, as these two 
treatments are usually incorporated in treatment guidelines. 
Pharmacotherapy: Because of the large number of published antidepressant efficacy trials 
(AETs), we restricted our search to AETs published in journals from the top ten Impact Ranking 
psychiatric journals of 2005. By including only high impact factor journals, we expected to 
have a sample of trials with the most systematic manner of reporting SES features. The journals 
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were Archives of General Psychiatry; Molecular Psychiatry; American Journal of Psychiatry, 
Biological Psychiatry; Neuropsychopharmacology; Journal of Psychopharmacology; Journal 
of Clinical Psychiatry; Psychotherapy/Psychosomatics; the British Journal of Psychiatry and 
Sleep. We added Psychopharmacology Bulletin to our selection of journals, since AETs from 
this journal are frequently cited in literature on antidepressants. We excluded trials with 
experimental medication such as dexamethason or valproate. 
sociodemographic and socioeconomic features
For the included RCTs, we explored the sociodemographic and socioeconomic features 
of the intent-to-treat samples. If intent-to-treat data were missing we used the data 
of the completers. We determined the most frequently described features and their 
operationalisation. If the operationalisation of the sociodemographic and socioeconomic 
features in a study was not well defined, we tried to contact the authors for further 
information. We converted the reported SES features into dichotomous or trichotomous 
variables. 
statistics
Descriptive summary statistics (means, frequencies, percentages) were used to describe 
the baseline sociodemographic and socioeconomic features of the RCT patients. These 
procedures were performed in SPSS 16.0. As standard deviations for continuous variables 
(age) were often missing in trials, we corrected for sample size by dividing the sum of all 
“mean age x number of patients in a trial” by the total number of patients of all trials. 
ResuLts
Review of sociodemographic and socioeconomic features used in Rcts
Based on our criteria and search strategy, we included 64 published RCTs; 45 AETs and 19 
PETs. We found no PETs published after 2007 meeting our inclusion criteria, and therefore 
also limited the inclusion of AETs to those published before 2008. Table 1 shows a list of the 
included trials. The total number of patients who participated in these trials is 9694; 8838 
patients in the AETs group and 856 patients in the PETs group. Table 2 provides an overview 
of the eight most frequently described sociodemographic and socioeconomic features that 
were used in the 64 studies. Remarkably, only three features were reported in at least half 
of the included trials: mean age (n=62, 96.9%), gender (n=63, 98.4%) and race or ethnicity 
(n=41, 64.1%). The operationalisation of sociodemographic and socioeconomic status, 
which varied greatly among the studies for some features, will be discussed below.
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table 2. Reporting of sociodemographic/socioeconomic features in RCTs.
sociodemographic/ socioeconomic characteristic number of trials reporting on the feature (%)
Age (mean) 62 (96.9%)
Gender 63 (98.4%)
Race/ethnicity 41 (64.1%)
Marital status 23 (35.9%)





Sixty-two (97%) trials reported a mean age for their study population. Of the two trials 
who did not report a mean age, one trial divided the population in age categories (<30, 
30–39, >39 years of age). The mean age of the participants in RCTs was 41 years. The AET 
participants had a mean age of 41 years, the PETs participants of 37 years. 
Gender
There were 63 trials (98%) that described the distribution of the population by gender. 
Patients were predominantly female (62% woman versus 38% man). In AETs 61% of the 
patients were women. In the PETs 72% of the participants were female.
Race and ethnicity
There were 41 trials (64%) that reported race or ethnicity of the study population. Of these 
trials, two only gave a short description of race, for example: predominantly Caucasian. The 
other 39 studies used 16 different ways to define race/ethnicity. The most frequently used 
definition of race was white/non-white. Seventeen of the 39 trials used this definition (44%). 
Furthermore, the following descriptions were used: European; (non) Caucasian; Hispanic or 
Latino; African-descent or African American or Black; Asian or Oriental; Middle Eastern; Other 
Ethnicity. We converted the reported information on race or ethnicity into the dichotomous 
variable white/non-white. We considered Hispanic as “white”, since two out of three authors 
of the RCTs, who we contacted, responded that they had considered Hispanic as “white”. 
Latino, European and Caucasian are also considered to be “white” [44-46]. For this analysis, 
we considered “non-Caucasian, African descent, African American, black, Asian, middle 
Eastern, Oriental and other” as “non-white”. Patients in AETs and PETs were predominantly 
white. The percentage of patients considered “non-white” in the AETs group was 11%. In the 
PETs this percentage was 15%. 
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marital status
Twenty-three trials (36%) reported the marital status of their patients. Fourteen different 
definitions were used to describe the marital status. The most frequently used definition, 
which was used, only four times, was: married/not-married. We dichotomised marital status 
into “married/cohabitating” – “not married”. In the RCT population 45% of the participating 
patients were married/cohabitating. Of the patients participating in AETs 46% was married/
cohabitating. In PETs, 43% of the participants were married/cohabitating.
employment
Only twelve (19%) trials reported information on employment status. Seven different types 
of definition were used to define employment status. The two most commonly used ways 
of reporting were: “employed-unemployed” (25%) and “percentage employed participants” 
(25%). We converted all reported information on employment status into: “paid work” – “non-
paid work”. We considered the subcategories “unemployed”, “homemaker”, “house person”, 
“housewife”, “student” and “retired” as “non-paid work”. One trial [47] reported categorical 
information on employment status, which could not be converted into the dichotomous 
variable “paid work”- “non-paid work.” The percentage of people with paid work in AETs was 
59% and in PETs 66%.
education
Seventeen trials (27%) reported information on educational level. Approximately half 
of these trials described the educational level by years of education (n=9). The other half 
described the educational level by means of categories (n=7). One trial used both ways to 
describe the educational level. All seven trials describing the educational level by means of 
categories used different definitions. We converted the reported information on educational 
level of all trials into a trichotomous variable: high school or less – some college education – 
college graduate or more. Two trials reported information that could not be converted into a 
trichotomous variable. This exclusion resulted in too few trials (n=5) to reliably estimate the 
educational level of the RCT population.
socioeconomic status
Only three trials (5%) reported socioeconomic status (SES). Two trials used the Hollingshead 
and Redlich’s two-factor index of social position. This index refers a person’s social class 
to that of his family and is determined with reference to the education and occupation 
of the family head plus the location of the family place of residence. Five class levels are 
distinguished, with level five being the lowest class and level one the highest [48]. One 
trial used the Blishen index [49] to describe the social economic status. This index is based 
on the Canadian Census and uses 514 occupational categories according to the Canadian 
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Classification and Dictionary of Occupations. Indicators of prevailing education and income 
levels are derived for each occupational category. A lower index indicates a lower SES. 
income
Only three trials (5%) reported information on income. Two trials reported income/year as 
a continuous variable (amount of money/year), one trial reported income as a categorical 
variable (<8.000, 8.000–16.000, >16.000 US Dollar per year). Too few selected trials reported 
on income to estimate the income of the RCT population.
 The sociodemographic and socioeconomic features of the RCT participants are described 
in table 3.
table 3. Sociodemographic/socioeconomic features of RCT participants.
Rct (n=64) Aet (n=45) Pet (n=19)
Age (years) 41 41 37 
Gender 
(% female)











Educational level Reported only in 8% of included trials - -
Socioeconomic status Reported only in 5% of included trials - -
Income Reported only in 5% of included trials - -
Discussion
To our knowledge, this is the first review on the reporting and operationalisation of 
sociodemographic and socioeconomic features of participants in antidepressant efficacy 
trials (AET) and psychotherapy efficacy trials (PET) in major depression. 
 Remarkably, we found that in RCTs the reporting and operationalisation of 
sociodemographic and socioeconomic features turned out to be very diverse and for 
socioeconomic variables often very limited, even in the high impact factor journals. Only 
age, gender and race were reported in the majority of studies. All other features were 
reported in less than 40% of the trials and often operationalised in very different ways. The 
lack of standardisation in defining sociodemographic and socioeconomic variables and their 
insufficient reporting in RCTs may be explained by the fact that interest in the relation of 
social economic status and treatment outcome is relatively young. Only recently, RCTs have 
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been carried out in specific populations like low-income women [50] and ethnic minorities 
[51,52]. RCTs in specific subgroups is one way to address the influence of socioeconomic 
features on treatment outcome in MDD, yet more interest for SES features in “general” 
trials is needed, since guidelines are based on results from these trials. Furthermore, our 
findings suggest that there are differences between AET participants and PET participants 
with respect to several sociodemographic and socioeconomic features. In meta-analyses 
results from AETs and PETs are often directly compared, without controlling for SES features 
as marital status, educational level, employment status etc., since these features are not 
reported in trials. SES features are known to influence outcome, and therefore one risks 
to introduce confounders in the comparison between AETs and PETs. Several factors may 
explain differences in the SES features between participants in AETs and PETs, for example 
patients’ preferences for certain types of treatment, or the use of specific eligibility criteria in 
AETs, like the exclusion of women who are pregnant or do not use contraceptives.
Both clinical practice and scientific research would benefit from uniform reporting of a 
standard set of SES features. In this way, estimation of the generalizability of results of RCTs 
to daily practice, comparison between RCTs and future research on the influence of SES 
features on outcome is facilitated. 
 There are some limitations to our study to consider. We performed a restricted search 
for AET’s, which may not fully represent the available literature. However, the fact that we 
found significant underreporting of SES features in the AETs from the included high impact 
factor journals suggests that that underreporting of SES features in AETs in the whole body 
literature might be even worse. On the other hand, we found no association between the 
impact factor of the journal and the reporting of sociodemographic features.
 We only included RCTs published till 2008, as we did not find PETs after 2007 that met our 
selection-criteria. It is possible that the reporting of sociodemographic and socioeconomic 
features has improved after 2007. We examined a sample of AETs published after 2007 [53-
59] that met our exclusion criteria. In these studies published after 2007 we found a similar 
variety of reporting. Finally, it is important to note that when discussing the generalizability 
of results of RCTs to daily practice, one might easily overlook the fact that RCTs are explicitly 
designed to provide relative outcomes (differences between active treatment and placebo), 
rather than absolute effects of treatment. However, as treatment guidelines are based on 
the results from RCTs and used in daily practice, where the absolute treatment effect is far 
more important than the relative effect, it is very important for clinicians to know to what 
extent RCT participants resemble their “real life” patients. 
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concLusions
Previous research has shown that SES features of patients can influence treatment outcome 
in depression. RCTs for treatments of depression do not adequately report on SES features. 
A uniform reporting of a standard set of sociodemographic and socioeconomic features 
is recommendable; especially on those features that are already known to be associated 
with treatment outcome (age, gender, marital and employment status). This would facilitate 
comparisons not only within the body of RCTs, but especially of RCT populations with ‘real-
life’ populations, which would clearly benefit daily practice and guideline development. 
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ABstRAct 
Purpose: Sociodemographic and socioeconomic characteristics of participants in anti-
depressant and psychotherapy efficacy trials (AETs and PETs) for major depressive disorder 
(MDD) may limit the generalizability of the results. We compared trial participants to 
daily practice patients. We subsequently assessed the influence of sociodemographic and 
socioeconomic status on treatment outcome in daily practice. 
methods: Data on daily practice patients were derived through Routine Outcome Monitoring 
(ROM). We included 626 patients with MDD according to the MINIplus. Distributions of age, 
gender, race, marital status and employment status were compared to participants in 63 
selected AETs and PETs. Influence of these features on treatment outcome was explored 
through multivariate regression analysis. 
Results: Trial participants were older, more often male (diff. 4%, p=0.05), white (diff 4%, 
p<0.001) and not married (diff 7%, p=0.003). Although significant, most differences were 
relatively small. However, the difference in employment status was striking: 34% of the ROM 
patients were currently working, versus 68% of the trial participants (diff. 34%, p<0.001). 
Being employed contributed to a positive treatment outcome: OR 1.8 for response (50% 
reduction of MADRS), OR 1.9 for remission (MADRS ≤10). 
conclusions: employment status should be taken into account while interpreting results 
from RCTs and as predictor of treatment success in daily practice. 
Keywords: major depressive disorder, randomized controlled trial, sociodemographic 
status, socioeconomic status, patient selection 
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intRoDuction
International guidelines on treatment of major depressive disorder are based on evidence 
retrieved from scientific research. Meta-analyses and large randomized controlled trials 
(RCTs) are considered to give the most reliable evidence on treatment outcome for most 
therapies. RCTs use very strict procedures in design, patient selection, randomization, 
and methodology to enhance internal validity, i.e. the ability to adequately determine the 
efficacy of an intervention versus a control condition. While doing so, RCTs diminish their 
external validity, i.e. the generalizability to routine daily practice. Therefore, many clinicians 
and researchers have stated that the practical value of RCTs as source of evidence for 
treatment efficacy in daily practice is limited [1-7]. 
 In previous research [1], many differences which might influence treatment outcome 
between trial methodology and daily practice have been described. One of the important 
domains that influence external validity is the selection of participants. The methodology of 
recruitment, the use of eligibility criteria, the (unintentional) use of criteria beyond eligibility 
(e.g. by recruitment only of patients with medical insurance, or in a certain area), the use 
of run-in periods and enrichment strategies, all lead to the exclusion of possible non-
responders, and may lead to selection bias in the research population. For major depressive 
disorder (MDD), most research has focused on the influence of eligibility criteria on external 
validity. Several researchers [8-11] have shown that only a minority of daily practice patients 
would be eligible for RCTs. The influence of these eligibility criteria on treatment outcome is 
not yet clear: Wisniewski and colleagues [9] found that eligible patients had better treatment 
outcome than non-eligible patients, on the other hand, in our own research [11], we found 
no differences in treatment outcome between eligible and non-eligible patients. However, 
the use of eligibility criteria is only one aspect of patient selection. Even if eligibility criteria 
are met, recruited RCT participants differ from not recruited participants in terms of age, 
sex, race, educational status, social class and place of residence [1]. In previous research, we 
found a great variety in the reporting of sociodemographic and socioeconomic (SES) features 
in major depression trials. SES factors are known to influence treatment outcome in MDD 
[12-22]. Differences in SES status of participants might be one of the explanations for the 
differences between treatment outcome in RCTs and in pragmatic trials. However, although 
much effort is put in approaching daily practice as much as possible in pragmatic trials like 
STAR*D, they still have several properties of an RCT and selection bias by recruitment is not 
completely ruled out [23]. 
 In the current project, we first compared the SES status of participants in psychotherapy 
efficacy trials (PETs) and antidepressants efficacy trials (AETs) to the SES status of a daily 
practice population of patients suffering from MDD. Subsequently, we explored the influence 
of the SES status on treatment outcome in daily practice to assess whether possible SES 
differences between RCT participants and daily practice patients contribute to differences 
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in treatment outcome between RCTs and routine practice. Comprehensive data on patients’ 
characteristics, treatment modalities and treatment outcome were available through an 
extensive Routine Outcome Monitoring system (ROM) and extensive chart review. ROM 
provides outcome data on treatments without the properties of clinical trial but with strong 
methodogical features. Therefore ROM is a qualified instrument to obtain insight in “real life 
daily practice” [24].
Aims of the study 
We investigate the differences in sociodemographic and socioeconomic features between 
“real life” patients suffering from MDD and trial participants. Furthermore we explore the 
influence of sociodemographic and socioeconomic features on treatment outcome. This 
study gives insight on the extent of generalizability of results from RCTs to daily practice as 
well as the influence of sociodemographic and socioeconomic status on treatment outcome 
in daily practice. 
metHoDs
selection of Rcts and definitions of ses features in Rcts
We included peer reviewed publications of RCTs, published through 2007 in outpatients 
with a unipolar, non-psychotic major depressive disorder according to DSM-III-R or DSM-
IV. Because we aimed to review the reporting of sociodemographic and socioeconomic 
features in RCTs usually selected for the development of guidelines for routine treatment, 
we excluded trials which a priori included only participants from specified subgroups like 
elderly or a specific ethnic minority. Furthermore, it was essential that the publication 
provided baseline information on sociodemographic and/or socioeconomic features. We 
included trials written in English, since international guidelines for treatment of MDD are 
predominantly based on English literature. Because of the large number of published AETs, 
we restricted our search to AETs published in journals from the top ten Impact Ranking 
psychiatric journals of 2005. By including only high impact factor journals, we expected to 
have a sample of trials with the most systematic manner of reporting SES features. For PETs, 
which are less frequently published, we performed a Medline search for RCTs investigating 
psychotherapy (cognitive behavior therapy and interpersonal therapy) for adult patients 
suffering from MDD. We performed an additional search in PsycInfo and checked the 
reference lists of included trials for other relevant studies as well as the database http://
www.psychotherapyrcts.org. 45 AETs and 19 PETs were selected. Detailed information 
on RCT-selection and exploration of SES features of RCT participants has been previously 
reported [25]. The selected AETs and PETs were equally distributed between Europe and the 
United States of America. Of all the different SES features mentioned in the selected RCTs, 
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we only used the SES features that were reported in at least 15% of the selected trials (n=10). 
In RCTs, SES features are described in various manners. In order to allow an estimation of the 
mean socioeconomic status of RCT participants, the reporting of the SES feature in the RCT 
had to be in such manner that the feature could be converted in a dichotomous variable. 
The following SES features were reported frequently enough (in at least 15% of the trials) 
and were suitable for comparison between RCTs and our ROM population: age, gender, 
race, marital status and employment status. Educational level was relatively often reported 
in RCTs but in so many different ways that dichotomization was not possible. Income and 
social position were reported in less than 15% of the RCTs. The selected SES features were 
defined as follows:
 • Age: age at baseline assessment calculated in years. 
 • Gender: percentage females in the population.
 • Race: percentage white patients in the population. 
 • Marital status: percentage of married/cohabitating patients. 
 • Employment status: percentage of patients who have a paid job. 
Treatment outcome in MDD trials is usually defined as percentage of responders (50% 
reduction of symptoms) or as percentage of remitters (score below a certain severity cut-
off ). 
Patient selection and definitions of ses features in the Routine outcome 
monitoring population
In the Netherlands, health insurance for all citizens is regulated by the government. 
Therefore, (mental) health care is easily accessible and not restricted by the financial means 
of individual patients. The Dutch health care system is organised in a stepped-care-manner 
and described in treatment guidelines. First, patients visit their general practitioner (GP). In 
case of depression, the treatment guidelines for GPs recommend that patients with mild 
depression are treated by their GP with lifestyle advices. If the depression is moderate 
(clinical judgment) the GP can decide to prescribe antidepressants. Reasons to refer patients 
to a regional mental health provider (RMHP) are: preference of patients for psychotherapy 
(not provided by GPs); severe depression (clinical judgment); presence of co morbid 
disorders; complex situation of the patient due to physical health problems; social problems 
etc.; duration of the depression; and lack of result of antidepressant therapy. After baseline 
assessment and a clinical interview at our RMHP, patients suffering from major depression 
are offered to choose between psychotherapy and antidepressant therapy (if the severity 
is not too high, judged by the interviewing clinician in combination with results from 
ROM). When patients are already taking antidepressants from their GP, if needed the dose 
is optimized, and subsequently patients are offered to switch to another antidepressant or 
psychotherapy is added to the antidepressant therapy. 
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In 2002, the Regional Mental Health Provider (RMHP) Rivierduinen (service area with 
1.1 million inhabitants), in collaboration with the University Medical Hospital Leiden, 
implemented a comprehensive system of routine outcome monitoring (ROM) and evidence 
based, stepped care protocols. In ROM, all patients referred to the RMHP for treatment 
of a mood, anxiety or somatoform disorder have an extensive baseline assessment. 
Treatment progress is then assessed at intervals of three to four months and before starting 
a new treatment step. The baseline assessment comprises a standardized diagnostic 
interview (Mini-International Neuropsychiatric Interview Plus [26]), the collection of 
sociodemographic and socioeconomic data, the administration of observer rated scales and 
self report questionnaires, and general measures of health and quality of life. All patients 
with sufficient mastery of the Dutch language who are able to complete computerized 
and written questionnaires are eligible for ROM. After baseline assessment and a clinical 
interview, patients suffering from major depression are offered to choose between 
psychotherapy and antidepressant therapy. When ROM data are used for research purposes, 
these are provided to researchers in an anonymous form, as dictated by the Psychiatric 
Academic Registration Leiden (PAREL) regulation. This procedure has been approved by the 
Medical Ethical Committee of the University Medical Hospital Leiden. The design of Routine 
Outcome Monitoring has been reported previously [27].
 From the ROM population who sought treatment at the RMHP Rivierduinen from January 
2002 until January 2007, we included all outpatients who met the following criteria:
 • Patients had a DSM-IV diagnosis of a current major depressive disorder as established by 
the Mini International Neuropsychiatric Interview. 
 • Patients had at least one follow-up assessment in ROM. 
 • Patients were not suspected of bipolarity/psychotic features by their clinician.
 • Patients were not admitted to an inpatient clinic during follow-up. 
 • Patients did not have a MADRS-score ≤ 10 at baseline assessment. 
 • The time-span between baseline and follow-up assessment was not too short (less than 
four weeks) or too long (more than one year) to provide reliable information.
We conducted an extensive chart review in order to obtain information on the type of offered 
treatment. We examined possible selection bias due to our inclusion criteria by comparing 
the baseline severity of the depression and the SES features of the selected patients to 
the characteristics of patients who had no follow up assessments in ROM. We compared 
the selected patients to all patients who suffered from major depression according to the 
MINIplus (including patients who dropped out of treatment after baseline assessment and 
patients of whom it was not clear if they dropped out or not). Subsequently, we compared 
the patients with follow-up to patients who did receive treatment, but had no follow-up 
assessments in ROM. Information on how many patients did receive treatment was obtained 
through an anonymized database from the medical administration of RMHP Rivierduinen. 
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Patients in our population received different types of treatment for their depression. Most of 
the treatments (84%) were in line with international treatment guidelines: antidepressants 
(19% with additional social supportive therapy/counseling), individual psychotherapy 
(mostly cognitive behavioral therapy or interpersonal therapy) or combination therapy 
of pharmacotherapy and cognitive behavioral therapy or interpersonal therapy. Sixteen 
percent of the patients received treatment other than antidepressants, individual 
psychotherapy or combination treatment. In line with RCTs we defined treatment-response 
as a 50% reduction of symptoms on the Montgomery Asberg Rating Scale for Depression 
(MADRS, [28]) and remission as MADRS≤ 10.
 In ROM extensive information on sociodemographic and socioeconomic status is 
gathered. Age and gender are recorded. Ethnicity is primarily assessed by the recording 
of patients’ and their parents’ countries of birth. Consistent with most RCTs, we considered 
patients who were born (or whose parents were born) in Suriname, Antilles, Turkey and 
Morocco as non-white. Two-third of the patients from other non-Dutch origins was non-
white. We considered patients who were single, living-apart-together, divorced or widowed 
as “not married/cohabitating”. 
 Like other member states of the European Union, the Netherlands have a social security 
system which provides sickness benefit to people who are temporarily not able to work and 
disability benefit to those who are not able to work anymore. In the USA, the provision of 
sickness or disability benefit depends upon the insurance policies. Other countries provide 
no sickness or disability benefit or use their own system. Clearly, there is an important 
difference in financial status between receiving a sickness or disability benefit or not. It is 
unknown whether in RCTs, patients who receive sickness benefit are considered as having a 
paid job or not. Therefore, to allow comparison with RCTs, we defined employment status in 
ROM with two separate variables: employment status I and II:
 For employment status I patients who reported having a paid job at baseline 
assessment are considered as having “paid work”. In this definition “paid work” means that 
patients are working at the time of baseline assessment. Patients on sickness or disability 
benefit, unemployed, student or housewife were considered as having “no paid work”. For 
employment status II patients who receive sickness or disability benefit were classified 
as having “paid work” while unemployed patients, students and housewives were still 
considered as having “no paid work”. In this definition having “paid work” means that 
patients receive an income out of a job, but that a substantial part of these patients (53% of 
the patients classified as having paid work) is not working but on sickness benefit. 
statistical Analysis
We first compared the included sample from our ROM population with the lost-to-follow-up 
in ROM patients by using Chi-square tests and independent sample t-tests. Subsequently, 
the SES features of RCT participants were compared to those of our ROM population by 
110 | Chapter 6
comparison of proportions of two independent groups [29]. The selected RCTs did not 
report enough information on the characteristic “Age” to allow a comparison between RCT 
population and our population. 
 Finally, we examined the influence of SES features on outcome in routine clinical 
practice. In our sample, there were missing values for the following variables: type of 
offered treatment (n=28), and socioeconomic characteristics (n=82). Comparison of 
complete cases and cases with missing data showed differences on several variables 
such as age, gender and treatment outcome. In such instances, complete case analysis 
may yield biased estimates [30]. Therefore, the MICE (multivariate imputation by chained 
equations [31]) method was used to estimate missing values for type of offered treatment, 
and socioeconomic characteristics. The influence of the sociodemographic (age, gender, 
race) and socioeconomic (marital status, employment status) on treatment outcome was 
computed by logistic regression after MICE. Univariate regression models (unadjusted 
analysis) were used to explore the influence of the individual SES features on treatment 
outcome. A multivariate regression model (adjusted analysis) was used to explore the joint 
influence of all SES features on treatment outcome. In this model, type of offered treatment 
and educational level were entered as possible confounders. In our previous research [11] 
on the same patient population, we showed that typical clinical features of MDD patients 
in daily practice, namely co morbid Axis I disorders, substance abuse, and suicidality, which 
are often used as exclusion criteria in RCTs, were not associated with treatment outcome 
in clinical practice. A low baseline severity, however, was associated with a less favorable 
treatment outcome. Therefore, we entered baseline severity of the depression as another 
possible confounder in our multivariate regression model.  
 Odds-ratios (OR) and their confidence-intervals were computed by using the robust 
standard error. Statistical analyses were performed with SPSS 16.0 and STATA10.0. 
ResuLts 
Daily practice (Rom) population
4157 outpatients were assessed at baseline between January 2002 and January 2007. Of 
these patients, 1653 suffered from a current major depressive disorder according to the 
MINIplus. Since in scientific literature it is not well defined when a depression should be 
considered the “primary diagnosis” or when a so called “co morbid disorder”, we included 
all patients who suffered from major depression according to the MINIplus. From the 1653 
patients suffering from major depression, 46% (n=774) had at least one follow-up assessment. 
Extensive chart-review was done for those 774 patients. 148 patients had to be excluded 
from further follow-up analysis due to suspected bipolarity/psychotic features, admission to 
an inpatient clinic during follow-up, remission on the MADRS at baseline or an insufficient 
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time-span between baseline and follow-up assessment. Finally, 626 patients were eligible 
for follow-up analysis. Of 76% of these 626 patients, the clinician stated that depressive 
disorder was the primary clinical diagnosis. 24% of the patients suffered from depression, 
but it was considered to be a co morbid disorder. Selection of the patient population is 
described in figure 1. The characteristics of the patient population are described in table 1. 
patients with major 











Psychotic features on MINIplus: n=7
Suspected (hypo) manic episodes in 
past  on MINIplus: n=12
Admission to clinic during follow-up: n=43
Clinical suspiscion bipolarity or 
psychotic features n=23
Older than 65: n=1
Time between baseline and  
follow-up assesment
 <4 weeks or >52 weeks: n=47
MADRS≤10 at baseline: n=15 
 
Figure 1. Selection of the follow-up group.
table 1. Baseline characteristics of ROM patients.
N=626








Presence of co morbid other Axis I disorder 69.9%
(majority anxiety disorder)
Mean MADRS at baseline 25.8 (6.5)
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¹ Dichotomization of variable for comparison to RCT/AET/PET, see Method section.
² AD=antidepressants, IP=individual psychotherapy, SST=social supportive therapy.
³ 95% CI= 95% confidence interval.
The selected patient group was similar to the not-selected patients in baseline severity of 
the depression and most SES features. The selected patients were slightly older (39.2 versus 
37.3 years) and more often married/cohabitating (52.6% versus 46.9%) than the patients 
who were not selected (see table 2, supplementary material). Of the patients who were lost 
to follow-up, and therefore not selected, 63% received treatment in our outpatient clinics for 
mood-, anxiety, and somatoform disorders after baseline assessment (37% was referred to 
other specialized departments or did drop out of treatment). We also compared the selected 
patients to the patients who did receive treatment in our outpatient clinics but had no 
follow-up in ROM and found them to be very similar (see table 3, supplementary material). 
Therefore we consider our selected patient sample as fairly representative for patients who 
receive outpatient treatment for depressive disorders. 
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Rct participants versus daily practice (Rom) population
We compared the RCT population and our ROM sample on age, gender, ethnicity, marital 
status, and employment status. RCT participants were less often female (62% vs. 66%), more 
often white (89% vs. 84%), less often married/cohabitating (45% vs. 52%) and more often 
employed (68% vs. 34%) than daily practice (ROM) patients. Both in antidepressant and 
psychotherapy trials, participants were more often white, less often married/cohabitating 
and more often employed than daily practice (ROM) patients. Both in antidepressant and 
psychotherapy trials, the male-female ratio was different than in daily practice (ROM): in 
antidepressant trials the ratio is in favor of males (39% vs. 34% male) compared to daily 
practice (ROM), while in psychotherapy trials the ratio is in favor of females (73% vs. 66% 
female) compared to daily practice (ROM). Although the differences were statistically 
significant, they were sometimes relatively small and significance was probably reached 
due to the large number of patients included in both groups. However, the exception is 
the difference between RCT participants and our daily practice population in employment 
status (employment status I: defined as currently having “paid work”, not on sickness or 
disability benefit); 68% of the RCT participants were currently employed, whereas only 34% 
of the daily practice patients had a paid job. Results from the comparison between RCT 
participants and our population are described in table 4.
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influence of ses features on treatment outcome in the daily practice (Rom) 
population
In the univariate analyses, having a paid job (employment status I, in which patients who 
receive sickness benefit were defined as not having a paid job) contributed positively to 
remission (MADRS≤10 [28]) and response (50% reduction of the MADRS). If patients on 
sickness benefit are also considered to have a paid job (employment status II), the influence 
of employment status on treatment outcome disappeared. None of the other SES features 
contributed significantly to treatment outcome. In the multivariate analyses, we investigated 
the influence of Age, Gender, Race, Marital status, and Employment status (Employment I) 
on treatment outcome in one model. In this model we also adjusted for baseline severity 
of the depression, so that we could analyze the influence of SES features irrespective of the 
severity of the illness. We found that having a paid job contributed positively to remission 
(OR 1.85, 95%CI 1.2–2.8; RSE 0.21; p=0.003, R-square 7%), and response (OR 1.76, 95%CI 
1.2–2.6; RSE 0.20; p=0.005, R-square 3%). Results from the unadjusted analysis of the 
influence of the individual SES features are described in table 5; Results from the analysis of 
the joint influence of all SES features adjusted for baseline severity of the depression, type 
of offered treatment and educational level are described in table 6. 






(95%CI 0.97–1.00; RSE 0.008; p=0.13)
OR 0.99 
(95%CI 1.0v1.0; RSE 0.01; p=0.10)
Gender OR 0.97 
(95%CI 0.65–1.44; RSE 0.20; p=0.87)
OR 1.09 
(95%CI 0.8–1.6; RSE 0.21; p=0.66)
Race OR 0.48 
(95%CI 0.27–1.1; RSE 0.41; p=0.08)
OR 0.51 
(95%CI 0.2–1.1; RSE 0.41; p=0.08)
Marital status OR 1.32 
(95%CI 0.9–2.0; RSE 0.02; p=0.17)
OR 1.32 
(95% CI 0.9–2.0; RSE 0.20; p=0.17)
Employment I OR 2.30
(95%CI 1.6–3.4; RSE 0.20; p<0.001)
OR 1.82
(95%CI 1.3–2.6; RSE 0.34; p=0.002)
Employment II OR 1.12 
(95%CI 0.7–1.1; RSE 0.23; p=0.61)
OR 1.18 
(95%CI 0.8–1.8; RSE 0.21; p=0.42)
OR: odds ratio
CI: confidence interval
RSE: robust standard error
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table 6. Joint influence of SES features on treatment outcome: adjusted analysis. Age, gender, race, 
marital status and employment I status entered in one model as predictors of outcome corrected for 




(50% reduction of mADRs)
Age OR 0.99
(95%CI 0.97–1.00; RSE 0.01; p=0.21)
OR 0.99
(95%CI 0.97–1.00; RSE 0.01; p=0.15)
Gender OR 1.07
(95%CI 0.69–1.67; RSE 0.23; p=0.75)
OR 1.10
(95%CI 0.73–1.59; RSE 0.20; p=0.65)
Race OR 0.67
(95%CI 0.32–1.40; RSE 0.38; p=0.29)
OR 0.63
(95%CI 0.33–1.19; RSE 0.32; p=0.15)
Marital status OR 1.33
(95%CI 0.85–2.07; RSE 0.23; p=0.21)
OR 1.10
(95%CI 0.73–1.67; RSE 0.21; p=0.64)
Employment I OR 1.89
(95%CI 1.24–2.81; RSE 0.21; p=0.003
OR 1.76
(95%CI 1.19–2.60; RSE 0.20; p=0.004)
OR: odds ratio
CI: confidence interval
RSE: robust standard error
Discussion
In the current project, we compared sociodemographic and socioeconomic features of 
participants in randomized controlled trials for depression to those of patients in daily 
practice. Participants in RCTs for major depression differed from daily practice patients with 
respect to age, male-female ratio, ethnicity and marital status, but those differences were 
relatively small (less than 7% difference on all features). One striking difference between RCT 
participants and daily practice patients is their employment status. Only 34% of the daily 
practice patients had a paid job (patients who were students, housewives, unemployed 
or on sickness or disability benefit were considered as having “no paid work”) at time of 
assessment, while 68% of the RCT participants had a paid job at time of the trial participation. 
In routine clinical practice, having a paid job contributed positively to treatment outcome, 
both on remission (OR 1.85) and response (OR 1.76) on the MADRS. Age, gender, race and 
marital status did not contribute to treatment outcome in routine clinical practice.
 Previous research found unequivocal results on the associations between 
sociodemographic and socioeconomic features and treatment outcome: in general, 
increased age seemed to be associated with worse outcome in pharmacotherapy [13-19], 
but not in psychotherapy [20-22], and one study found that men had better treatment 
outcome in psychotherapy than women [21]. Patients who were married benefitted more 
from both pharmacotherapy and psychotherapy [18-21,32-35]. 
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The difference in employment status between RCT participants and daily-practice patients 
was striking. In a recent study was found that the quality of mental health is associated with 
lesser years of unemployment [36]. In previous research, in non-routine practice settings, on 
the relation between employment and treatment success, it was found that employment 
status improved outcome for antidepressants, but not for psychotherapy [18-21,32-35]. In 
the univariate analyses we found that “currently working” (employment status I) is associated 
with better treatment outcome, while “receiving income out of a job” (employment status 
II) seemed not be associated with treatment success. It is, however, likely that other clinical 
factors, such as baseline severity, could have acted as a confounder in these univariate 
analyses, since patients with a more severe depression might drop out from work earlier. 
Therefore, in our multivariate analyses we adjusted for baseline severity of the depression. 
Still, having paid work (defined as currently working) almost doubled the probability of 
response or remission. From clinical experience, one might expect that the social status 
and the daily structure, routine and distraction provided by paid work will be factors that 
contribute to the positive response on depression treatment. Alternatively, it may be that 
patients who remain working despite the opportunity of sickness benefit have personality 
traits that increase the likelihood of positive treatment outcome, like for example optimism. 
Future research is needed to explore these different possibilities. 
Of course, besides differences in SES features, there are many other differences between 
RCT participants and daily practice patients, caused by the use of stringent exclusion criteria 
in RCTs. For instance, the presence of co morbid Axis I disorders is used as an exclusion 
criterion in more than 75% of the antidepressant efficacy trials [37] and in 25–50% of the 
psychotherapy efficacy trials [38]. In previous research, we found that only 17–24% of our 
patients would be eligible for participation in antidepressant efficacy trials [11]. Most of our 
patients would have been excluded because of the presence of co morbid Axis I disorders 
and not meeting a baseline severity threshold. However, in our previous research [11], we 
also found that in daily practice the exclusion of patients with co morbid Axis I disorders 
does not influence the treatment result for depression. One can therefore argue that it is 
unlikely that co morbidity acted as a major confounder in our analysis of the influence of SES 
features on treatment outcome for depression. It is, however, very well possible that having 
a co morbid disorder could lead to earlier withdrawing from work. Since co morbid disorders 
occur frequently in depressed patients, more specific research on the association between 
drop-out from work and co morbidity is recommended.
strengths
We consider the large sample of well-characterized, routinely monitored patients from 
routine clinical practice to be the major strength of our study. To our knowledge, no previous 
research has reported on the influence of sociodemographic and socioeconomic features 
on treatment outcome in major depression in routine daily clinical practice. 
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Limitations 
There are also some limitations to consider. In our model of sociodemographic and 
socioeconomic features of RCT participants, we converted all information on these features 
reported in the individual RCTs into dichotomous or trichotomous variables. This conversion 
lead to loss of information, but was necessary for comparability with published data [25]. 
Another limiting factor might be that in the model AETs outnumbered PETs, both in number 
of included trials and number of included patients per trial. Thus, the features of the RCT-
participants as a group were dominated by the features of AET participants [25]. There 
was a considerable loss-to-follow up in our sample. Nevertheless, we demonstrated that 
our patient selection was fairly representative for the daily practice patients who received 
treatment. It was not possible to analyze in our study which aspect of “having a paid job” 
contributed positively to a favorable treatment outcome. Furthermore, no information on 
the duration and the number of episodes of depression was available in our ROM data. 
Chronic depression is known to have al less favorable prognosis and it is possible that 
especially patients who suffer from chronic depression have to resign from work, which 
may have confounded our results. Finally, since sociodemographic and socioeconomic 
features are closely related to the culture in the country of origin in which research takes 
place, cultural aspects might have somewhat limited the generalizability of our results. It 
is unknown to what extent the Dutch health care system (and that of several other, mostly 
European, countries) may limit the generalizability of our results to other countries that do 
not have an extensive social security system. Furthermore, we have to take into account 
that we compared a western psychiatric population to an RCT population derived from 
western countries (Europe and USA). Since our aim was to compare RCT participants (who 
are most often from western countries) to our daily practice patients, the fact that all RCT 
participants were from western countries did not limit our research. However, our results 
are probably not generalizable to countries outside the western world. Future research on 
the generalizability of results from RCTs to psychiatric patients in other parts of the world is 
highly recommended. 
concLusion
In conclusion, we found that RCT participants and daily practice patients only differed 
slightly on most sociodemographic and socioeconomic features, with the exception of 
having a paid job. Having a paid job contributed significantly to treatment success in daily 
practice and should be taken into account both while interpreting results from RCTs as well 
as in depression treatment in daily practice. Further research is recommended to explore 
which specific aspects of employment status contribute to better treatment outcome. 
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summARY oF ouR FinDinGs
In today’s psychiatric practice in Western societies, most mental health care institutions 
have implemented treatment algorithms or guidelines for the treatment of major 
depressive disorder (MDD). These treatment algorithms/guidelines are all based on results 
from randomized clinical trials (RCTs), also called efficacy trials. In daily psychiatric practice, 
many clinicians have the impression that results found in trials (efficacy) are better than the 
results of the same therapies in routine care (effectiveness). In this thesis, we investigated 
whether the clinicians’ impression that efficacy is higher than effectiveness is correct and, 
if the impression is substantiated, which factors explain the difference. Criticism about 
the generalizability of results from RCTs to daily practice has often been heard. Clinicians 
believe that the possible difference in effect is explained by differences between their 
patients and participants in MDD trials. Clinicians are supported by previous research on 
the generalizability of results from MDD trials. It has been shown that only a minority of “real 
life” patients is eligible for participation in RCTs, because of the stringent criteria for patient 
selection [1-3] and perhaps also because of (un)intended selection due to the methodology 
of recruitment of participants in trials [4]. The STAR*D trial [5] found that participants who 
were eligible for “classical” MDD trials had a beneficial outcome compared to participants who 
were not [6]. The STAR*D trial, with very broad inclusion criteria, has many similarities with 
daily practice. However STAR*D also has characteristics of an RCT, like the use of a baseline 
severity threshold for inclusion, no possibilities for patient preferences in the first treatment 
step, and a large investment in treatment adherence of both therapists and participants. 
Despite the broadness of the inclusion criteria, it is possible that the RCT characteristics of 
STAR*D may still have limited its generalizability to daily practice. For this project we derived 
our data directly from daily practice through Routine Outcome Monitoring (ROM). By doing 
so, we were able to investigate whether clinicians are right when they state that treatment 
outcome in daily practice is less hopeful than in efficacy trials. Subsequently, we were 
curious to see whether the evidence from the STAR*D trial of a better treatment outcome in 
“RCT-eligible” patients could be replicated. If clinicians would, hypothetically, exclude all of 
their non-eligible patients, would their treatment results improve?
 In order to assess whether effectiveness is really lower than efficacy (chapter 2), we 
compared the within group efficacy reported in fifteen meta analyses on three types of 
MDD treatment; antidepressants, individual psychotherapy and a combination of both, 
with the effectiveness of the same treatments in daily practice, measured by ROM. A meta 
analysis provides an aggregated estimate of results found in RCTs. Meta analyses of RCTs are 
most often carried out to investigate whether the active drug/psychotherapy is superior to 
placebo (which is called the between group efficacy). However, we were not interested in this 
relative effect of active drug/psychotherapy, but in their overall or absolute effect (which is 
called the within-group efficacy). We compared this overall efficacy with the effectiveness 
in “reality”. Our overall conclusion in chapter 2 is that the impression of clinicians, that 
treatments in “reality” are not as effective as in scientific research, is true:
Effectiveness of MDD treatment in daily practice is lower than efficacy results from 
RCTs on MDD treatment. This is the case for antidepressant treatment, individual 
psychotherapy as well as combination treatment.
Above we mentioned that clinicians attribute the smaller treatment effects in “real life” to 
the fact that only a selection of patients is allowed to participate in RCTs. To investigate 
this, we first made an inventory of the exclusion criteria used in RCTs. Next we studied how 
many patients would have to be excluded if these criteria were applied in clinical practice, 
and then we compared treatment effectiveness in “real life” patients who meet the selection 
criteria versus patients who do not. 
 For inclusion in an MDD efficacy trial, in antidepressant efficacy trials (AETs) as well as 
in psychotherapy efficacy trials (PETs), participants indeed have to meet a set of eligibility 
criteria (in and exclusion criteria). These eligibility criteria are necessary to optimize the 
internal validity of the trial. In AETs, there is consistency in the use of exclusion criteria [7,8]. 
The most commonly used exclusion criteria in AETs are: not meeting a baseline severity 
threshold of 18 on HAMD17 [9]; co morbid Axis I disorders; co morbid Axis II disorders (in 
particular borderline personality disorder); suicidality and co morbid substance abuse. 
In the literature it is reported that only a minority of MDD patients from fee-for-service 
practices are eligible for AETs [1,2]. In this thesis, we investigated whether in the Netherlands 
in routine care also only a minority of patients with MDD would be eligible for AETs. We 
planned to do the same for PETs, yet studies on patient selection in PETs were absent. 
Therefore, we first had to investigate which exclusion criteria were used in a large set of PETs 
(chapter 4). We found that the following exclusion criteria were frequently used in PETs: not 
meeting a baseline severity threshold of 14 on HAMD17 [9]; co morbid substance abuse and 
antidepressant treatment prior to participation.
  The next step was to apply the exclusion criteria of AETs (chapter 3) and PETs (chapter 4) 
to a “real life” (ROM) population (in which no selection takes place besides sufficient mastery 
of the Dutch language to complete the ROM questionnaires). We used a large dataset 
of MDD patients who sought treatment in Rivierduinen, a large regional mental health 
provider (RMHP). We found that clinicians are right when they state that their patients are 
very different from RCT participants.
 • “Real life” MDD patients often do not meet the baseline severity threshold (42% for 
AET threshold and 22% for PET threshold).
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 • “Real life” MDD patients do report suicidality (15%).
 • “Real life” MDD patients do have Axis I (63%) and Axis II co morbidity (7% borderline 
personality disorder).
 • “Real life” MDD patients do have co morbid substance abuse (9%).
 • “Real life” MDD patients do have often used antidepressants prior to referral to 
psychotherapeutic treatment (44%).
Apart from selection based on explicit criteria also implicit selection may be important in 
RCTs, for instance with respect to sociodemographic and socioeconomic (SES) features. In 
chapter 5 we studied which SES features were reported in AETs and PETs. It became clear that 
educational level, socioeconomic status and income were reported insufficiently. However, 
for some features (age, gender, ethnicity, marital and employment status) enough data were 
available to enable comparison with “real life” patients (chapter 6). Our most striking finding 
was:
“Real life” MDD patients significantly less often have a paid job at time of treatment than 
RCT participants.
Having identified criteria that play a role in the selection of patients for RCTs and having 
demonstrated that application of these criteria in “real life” would indeed exclude a large 
group of patients from treatment, the next question is whether “real life” patients who 
are eligible for RCTs are doing better in treatment than “real life” patients who would be 
excluded. We found that exclusion of patients with mild depression, patients who used 
antidepressants prior to psychotherapy or patients without a paid job, improved treatment 
outcome in the remaining patient group, but only in a modest way. Besides, Axis I and Axis 
II co morbid disorders, substance abuse and suicidality were not associated with treatment 
outcome in our MDD patients. Furthermore the extent to which the difference in treatment 
outcome between RCTs and “real life” can be attributed to patient selection based on 
exclusion criteria is very small (explained variances 1–4% for the AET criteria; 4–11% for the 
PET criteria, dependent on definition of outcome). The same accounts for implicit selection 
based on the SES features age, gender, ethnicity, marital and employment status (explained 
variance 3–7%).
 Therefore, our most striking overall finding was that: 
in our “real life” patients, being eligible (meeting all criteria) for Rcts was not 
associated with a better treatment outcome.
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GeneRAL Discussion
We found that if only RCT eligible patients were treated in daily practice and non eligible 
patients would be excluded, the treatment success in daily practice would not improve. 
So….yes, clinicians àre right that their MDD treatment results are less favorable than 
those from efficacy trials, and yes, they àre right that their patients differ very much 
from RCT participants due to the use of stringent exclusion criteria and (un)intended 
sociodemographic/socioeconomic patient selection by recruitment procedures. However….
the use of exclusion criteria and the selection of patients with a different socioeconomic 
status in RCTs do not explain the difference between efficacy and effectiveness. So, it might 
be that the items from patient selection that we analyzed are not the major threat to the 
generalizability of the results from MDD trials to daily practice as has been suggested in the 
past. In the next paragraphs, we will elaborate on the implications of our findings for clinical 
practice and the scientific field. We will seek further explanations for the difference between 
efficacy and effectiveness of MDD treatment. Although the effect of the use of exclusion 
criteria was modest on treatment outcome, we will however comment on the implications 
of our findings that patients suffering from minor depression, as well as patients who used 
antidepressants prior to their psychotherapy seem to benefit less from their treatment. We 
will also discuss the implications of our finding that patients without a paid job have a less 
favorable treatment outcome. Finally, we will discuss the limitations of our project and will 
conclude with recommendations both for future research and clinical practice.
Why do efficacy and effectiveness differ?
In this thesis, we found evidence for the assumption of clinicians that treatment results in 
daily practice are disappointing compared to those in MDD trials (of the same therapies). Of 
MDD patients in antidepressant trials, 34–47% reaches remission, whereas in daily practice 
only 21% of the patients are that fortunate after the first treatment step. For individual 
psychotherapy (cognitive behavioral therapy or interpersonal therapy), 34–58% of trial 
participants reach remission, while in daily practice only 27% of the patients reach remission 
after the first treatment step. Patients who receive combination therapy in daily practice 
reach remission in 21% of the cases, while in trials 45-63% do. We have shown that (un)
intentional patient selection based on exclusion criteria or on socioeconomic grounds does 
not explain the difference between efficacy and effectiveness. Then, what does? Does Dr. X, 
introduced in the Introduction section of this thesis, turn out to be a lousy therapist? Is the faith 
of younger colleagues in his knowledge and experience misplaced? Or do we have to look for 
other explanations for the difference between efficacy and effectiveness?
 Dr. X, now getting worried, provokingly states that the disappointing outcome results that 
we found in this thesis are typical for the RMHP Rivierduinen, for the Leiden area, or for Dutch 
psychiatry. Is he right? The effectiveness that we found is in line with the results of STAR*D 
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[5,10,11], which suggests that the modest treatment results are not typically from the 
RMHP Rivierduinen or Dutch psychiatric practice. The similarity of our results to those from 
STAR*D is a notable finding. As mentioned at the start of this chapter, STAR*D is a pragmatic 
trial, with on the one hand methodological characteristics of RCTs, but on the other hand 
resemblances with routine psychiatric practice. Much effort was put in treatment adherence 
and motivation, both at the side of patients and of clinicians. This may have inflated the 
treatment success. On the other hand, following patient’s or doctor’s preferences for a 
specific drug or psychotherapy, as is usual in daily clinical practice, was not allowed in the 
first treatment step in STAR*D. As the allowance of preference is associated with better 
treatment outcome [12-15], this might have diminished treatment success in STAR*D. In 
our population, no special effort was made to improve treatment adherence besides care 
as usual. Therefore, based on treatment adherence alone, one would probably expect less 
favorable treatment outcome in the ROM population than in STAR*D. On the other hand, in 
our daily practice population patient and doctor’s preferences were of course allowed, which 
may have raised our treatment effect compared to STAR*D. These two factors together may 
have contributed to similar results in STAR*D and our ROM data. More emphasis on the 
improvement of treatment adherence, as is done in RCTs as well as in STAR*D, may improve 
the treatment results of daily practice. Furthermore, many other factors may contribute 
to the differences between efficacy and effectiveness. They may be features of patients, 
therapists, setting or RCT methodology. We will discuss them one by one in the following 
paragraph.
Patient features
Today, Dr. X’s first patient is Ms. Y. Ms. Y is a moderately severe depressed and traumatized single, 
middle-aged woman who just lost her job and whose cat just died. Counseling sessions in a 
private practice and antidepressant treatment by her general practitioner did not improve her 
mood. She is somewhat sceptical about her referral to dr. X but is determined to give it a try and 
tell dr. X about all her problems in the first session. Right before his busy clinic starts, Dr. X quickly 
opens his mailbox. In his mailbox is an enthusiastic letter from a young colleague working in an 
academic center who asks psychiatrists to send in patients for a promising trial with a specific 
drug. What are the chances that Ms. Y will be willing to participate in this trial?
Likely, there are differences between RCT participants and daily practice patients, which we 
did not explore. For instance, participants in RCTs probably are a subgroup with a special 
motivation: they are willing to take the risk to be treated with a placebo. It is yet unknown 
which other specific characteristics this subgroup has and whether these characteristics 
may contribute to treatment outcome. Recruitment procedures might introduce (un)
intentional selection bias by recruiting patients with a prognosis that differs from the “real 
life” population. Clinicians might not send patients with a poor prognosis for participation 
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to trials or these patients might not be motivated to participate. More importantly, in the 
Netherlands, and in other countries with a stepped health care system where the general 
practitioners (GPs) have the function of gatekeeper, many MDD patients with a good 
prognosis will be (successfully) treated by their GP or in private practice (so called first line 
treatment) and will not be referred to the RMHPs. Consequently, RMHPs only treat patient 
populations with a poorer prognosis. RCTs probably recruit MDD patients from both the GP 
population with a good prognosis and from the RMHP population (with a poorer prognosis) 
and in the “worst” case only from the first line population. The overall prognosis of RCT 
participants is therefore probably better than of RMHP patients. In order to optimize the 
generalizability of results from RCTs to “real life” (RMHP) psychiatric practice, it would be 
recommendable to conduct trials which include only patients who already went through 
GP or private practice treatment. 
therapist features
On a regular Friday, six a clock in the afternoon, Dr X. leaves his institution. It has been a busy 
week; at least twenty patients a day, staff meetings, resident supervision, two patients in severe 
crisis, an absent colleague who will probably be ill for a longer period, and a deadline for a report 
on a patient who had a complaint about his treatment. Dr X. cannot deny his feeling of tiredness 
and he starts to look forward to the moment that he will retire. Meanwhile, he feels a not-severe-
but-nevertheless-nasty flu coming up. In his briefcase he has a brochure of a new and promising 
trial for MDD patients. On the cover of the brochure there is a smiling physician in a crispy white 
coat, who seems to be half the age of Dr. X.
Therapists who participate in trials might differ from daily practice clinicians in terms of 
workload, motivation, extent of updating training, and many other aspects. While for trial 
therapists the proper conductance of the treatment under investigation is their main 
goal, so to speak “real life” clinicians can be distracted by many other tasks than state of 
the art treatment of MDD patients. For instance, “real life” clinicians may have very limited 
time per patient as a result of a caseload that is too large. Furthermore they often have 
to stand in for absent colleagues, perform instant assessments of so called crisis patients, 
and sometimes also have managerial tasks. And all this in between their therapies for MDD 
patients…Furthermore, clinicians are probably very dedicated to their patients, yet perhaps 
headstrong when it comes to strictly following the protocol described in the treatment 
guidelines. Therapists who participate in trials might be more motivated for the treatment 
under investigation than “real life” clinicians. Maybe it is even so that especially highly 
skilled or specialized clinicians participate in trials. All these factors contribute to differences 
between RCT therapists and “real life” clinicians. Motivation, protocol adherence, extent of 
education, time per patient, and experienced workload are all factors likely to be associated 
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with treatment outcome. So, if patient selection is not the (only) answer to the difference 
between efficacy and effectiveness, therapist selection may well be one of them.
Differences between trial setting and daily practice setting
As a response to a shimmering trial brochure that calls for participants, Dr X. sends in Mr. Z. 
for participation. Mr. Z. is a 45 year old patient who suffers from MDD. He is a little bit sceptical 
about the results of antidepressant therapy, since his cousin and his neighbor did not improve on 
this medication. The trial therapist convinces Mr. Z. that the trial antidepressant is very new and 
promising. He explains the procedure of the trial to Mr. Z. and tells him that he will have a chance 
to either receive this new drug or a placebo. Mr. Z. is persuaded to participate. Without knowing 
(a double blind procedure) Mr. Z receives a placebo. The inspired trial therapist sees Mr. Z. every 
week during the follow-up time of the trial, which is 8-12 weeks. After 3 months, treatment results 
are assessed and the trial therapist says goodbye to Mr. Z. He thanks Mr. Z. for his willingness to 
participate and for his contribution to the development of treatment of MDD.
Every treatment has a placebo effect: the mere fact that the patient is receiving treatment 
has a beneficial effect. The aim of RCTs is to prove that the active drug under consideration 
has a significantly larger effect than a placebo (the between group efficacy, see above). 
In clinical practice the placebo effect also contributes to the overall treatment effect. It is 
likely, that the placebo effect in trials is larger than in daily practice. We will provide some 
arguments why this might be the case:
 A proportion of participants in RCTs will spontaneously recover (like in daily practice) 
during participation. Spontaneous recovery will augment the proportion of patients 
who reach remission in a trial, while this effect cannot be attributed to the investigated 
treatment. In one meta analysis, spontaneous recovery was estimated to constitute one 
third of the placebo effect [16]. In daily practice, patients who recover spontaneously will 
probably not enter treatment or will drop out prematurely. They will not enter a ROM follow 
up assessment and therefore do not contribute to treatment outcome in ROM. Furthermore, 
participants in trials (and clinicians as well) have the feeling that they are treated in a 
special, new and promising way. This belief might contribute to improvement in RCTs and 
is called the Hawthorne effect [17,18]. Finally, as discussed above, in trials much effort is 
put in optimizing both patient’s and clinician’s protocol adherence. Protocol (or guideline) 
adherence seems to be positively associated with treatment success [19-25]. One specific 
aspect of protocol adherence is the frequency of follow up visits. In RCTs, frequency of 
appointments is closely monitored, while in daily practice appointments are sometimes 
cancelled by the clinician or patients for reasons of illness or otherwise. As a result of that, 
patients in RCTs have more regular and more frequent follow up visits. In a meta analysis 
on the therapeutic effect of follow up assessments in AETs, it was found that extra follow 
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up visits were associated with better treatment outcome and that the therapeutic effect of 
follow up assessments represents about 40% of the placebo response in AETs [26].
study features
Therapist A conducted a trial with a new type of psychotherapy. She was very enthusiastic 
about this type of treatment, but unfortunately after a lot of effort it turns out that the results 
are disappointing. The effect of the new psychotherapy was comparable to that of treatment as 
usual. What are the chances that this therapist will lose her motivation and the results will end 
up in her top drawer? And if not, what are the chances that her negative results will be published 
in a prominent psychotherapy journal?
Negative findings are reported a lot less often than positive findings. This is the so called 
publication bias [27]. Nowadays all medication trials have to be made available in public 
registers that are available to everyone (e.g. Nederland’s Trial Register) ahead of the start. 
However, treatment guidelines are based on articles published in scientific journals. Due to 
publication bias, efficacy may be overestimated. This may partially explain the difference 
between efficacy and effectiveness. Recently, several methodologies have been developed 
for meta-analyses in order to adjust to some extent for publication bias. It also has been 
suggested that the efficacy in MDD trials is exaggerated due to so called rater bias. The 
severity of MDD might be somewhat inflated by participating therapists at the beginning 
of the trial. At the same time, severity rating of the depression might be somewhat deflated 
at the end of the trial. If so, treatment success of trials (which can be the pre-post treatment 
difference) might be exaggerated and thus contribute to the difference between efficacy 
and effectiveness. However the extent of rater bias in MDD trials is still unknown. In one 
study rater bias was found to occur in MDD trials, yet its extent was too small to invalidate 
the results of the trials [28].
minor depression, prior antidepressant use and having a paid job: implications of 
our findings
Although modest, we found that the exclusion of patients with mild depression, patients 
who used antidepressants prior to psychotherapy and patients without a paid job, improved 
treatment outcome in the remaining patient group. Although our most striking overall 
finding was a negative (absence of association) one: “In our “real life” patients, being eligible 
(meeting all criteria) for RCTs was not associated with a better treatment outcome”, we 
didn’t want to leave our positive findings undiscussed. The influence of exclusion of patients 
who do not meet the baseline severity threshold, who use antidepressants prior to their 
psychotherapy and who do not have a paid job is described in detail in the chapters 3, 4 and 
6. Below we summarize our main findings. 
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We found that exclusion of ROM patients who suffered from minor depression (baseline 
severity of less than 18 on HAMD17) lead to a larger proportion of patients who reach 
remission (OR 2.0; 95% confidence interval 1.3–3.1). This association was found for 
psychotherapy, antidepressant treatment and a combination of both. As mentioned before, 
AETs often use a baseline severity threshold of HAMD17 ≤18 as exclusion criterion. We also 
found that exclusion of patients who have a baseline severity less than 14 on the HAMD17 
(the threshold used in PETs) lead to more improvement in the remaining patients (β=7.23; 
95% confidence interval 5.31–9.11). 
 We found that mild to moderate depression is very common in routine clinical practice 
(42% of the patients do not meet the AET severity threshold and 22% do not meet the PET 
severity threshold). Why this specific group rarely reach remission in their first treatment 
step is still unclear. Maybe these patients more often have a chronic mild depression instead 
of episodes of more severe MDD, and therefore have a different prognosis. It is also possible 
that these patients have other traits that differ from more severe MDD patients, such as lack 
of optimism as a personality trait. Future research is recommended on the characteristics 
of the large group of “real life” patients suffering from minor depression. To what extent the 
results of RCTs are generalizable to this group also needs to be further explored. 
 In addition, we found that exclusion of patients who used antidepressants prior to 
psychotherapy enlarges the extent of improvement of PETs (β=7.62; 95% confidence 
interval 1.94–13.30). These patients probably do not or only partially respond to medication, 
often prescribed by their GP or in private practice. As mentioned above in this chapter, these 
patients might have a worse treatment prognosis, than the ones who did not go through 
another treatment prior to their psychotherapy. Our finding accentuates that it would be 
recommendable to conduct trials which include only patients who already went through GP 
or private practice treatment, in order to optimize the generalizability of results from RCTs to 
“real life” (RMHP) psychiatric practice.
 We compared demographic characteristics of the groups. We found a substantial 
difference in the proportion of patients employed at time of participation. 68% of the 
RCT participants had a paid job, while only 34% of the ROM patients were working at the 
time of treatment. ROM patients who were working had better treatment outcome than 
patients who were not, irrespective of the baseline severity of their depression (OR 1.76; 
95% confidence interval 1.2–2.6 for the proportion of MDD patients who respond and OR 
1.85; 95% confidence interval 1.2–2.8 for the proportion of patients who reach remission). 
In chapter 6 we showed that having financial security is probably not the aspect of having a 
job that contributes to treatment success. We recommend further research on which aspects 
of employment contribute to treatment outcome of MDD patients. The results of this future 
research can be used in the development of new MDD treatments or improvement of the 
existing ones by increasing the attention for the role of social factors in MDD treatment.
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Limitations of our project
There were three major limitations to our research: Firstly, the lack of consistency in efficacy 
trials with respect to type of instruments, definition of outcome and use of exclusion criteria. 
Secondly, the missing data and large loss to follow up in the ROM data that is inherent to 
research in clinical practice. Lack of routinely collected treatment information and data on 
life history in the ROM data forced us to rely on data from extensive charts review. Thirdly, 
although our results seem to be representative for “real life” MDD patients, there are also 
limitations in the generalizability of our results. In the next paragraphs, we will first discuss 
the implications of the lack of consistency in RCTs, discuss the limitations of working with 
ROM data, and finally we will critically review the limits of the generalizability of our results.
Research on research: limitations in estimating efficacy
We investigated the efficacy of antidepressant treatment, individual psychotherapy 
and combination treatment. We studied the estimation of efficacy in RCTs and found an 
inconsistency in the use of instruments to assess depression severity. We also found an 
inconsistency in the definition of outcome: response is consistently defined as a 50% 
reduction of symptoms, but remission is defined by different cut off scores. Furthermore, 
we found that PETs are inconsistent in their use of exclusion criteria. These inconsistencies 
in the underlying data might compromise the validity of the aggregated efficacy estimates 
that are given in meta-analyses. 
 In addition, AETs and PETs have a different manner in evaluating treatment outcome, 
due to a different research tradition. The difference of defining outcome between AETs and 
PETs did not hinder our analysis, but it somewhat diminished the comprehensiveness of 
our results for clinicians, since we had to compute outcome in line with AETs as well as 
PETs. In table 1, we provide an overview of the instruments and definitions of outcome used 
in the meta- analyses included in our study. In the frame we describe the inconsistencies 
in instruments and outcome definition and their implications for our results in detail. The 
comparability of efficacy estimates, in meta- analyses but also in the comparison with 
“real life” cohorts would benefit greatly from more consensus on the instruments and the 
eligibility criteria for AETs and PETs. Finally, within our selection of AETs and PETs, for the 
exploration of eligibility criteria in PETs (chapter 4) and the reporting of sociodemographic/
socioeconomic features in AETs as well as PETs (chapter 5), many more AETs were available 
than PETs. For AETs we therefore limited our search to high impact journals, while we 
included all PETs within the same time frame. Although our selected AETs and PETs were 
similar with respect to countries of origin and timeframe, there is a slight possibility that our 
methodology of RCT selection has introduced some selection bias.
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inconsistencies in the use of instruments in Rcts 
In AETs, the most commonly used severity scale is the HAMD [9], especially in trials from the United 
States. The MADRS [29] is also often used in AETs, especially in European trials, sometimes as 
primary outcome measurement, often as secondary instrument. In our selection of meta analyses 
on AETs, they all used the HAMD. Yet, two different versions of the HAMD (17 and 21 items) are 
used. Both versions are validated, but how a cut off score for remission on one version relates to 
a cut off score on the other version is not clear. In ROM the MADRS is used. The fact that we had 
to convert the MADRS to HAMD scores in all our analyses, might have influenced our results on 
the efficacy-effectiveness difference. In order to give the most reliable estimate of HAMD scores, 
we used three equations [30,35,36] to convert our MADRS scores. We found that two equations 
yielded the similar results [30,36] and we performed a validity check with another method for 
conversion: the Item Response Theory [32]which also yielded similar results. We therefore expect 
little limitations to our analyses due to the fact that HAMD is not used in ROM.
inconsistencies in the use of cut offs for remission in Rcts
All meta analyses on AETs used the same definition of response and therefore we did not encounter 
difficulties in the efficacy–effectiveness comparison. However, most patients in ROM suffered from 
mild to moderate depression, which lead to very similar proportions of response and remission. 
Therefore, we did not report separately on the efficacy-effectiveness difference for response 
(chapter 2). The definition of remission varies between AETs and some meta analyses include trials 
with different definitions of remission. In our selection of meta analyses four different cut off scores 
to define remission were used. For the computation of the effectiveness of MDD treatment in “real 
life” we used a stringent (and scientifically investigated) cut off of MADRS ≤10 [30], which equals a 
score of 6.4 on the HAMD17 [31,32]. By using this stringent cut off score, it might be that we were 
too harsh in estimating the efficacy-effectiveness difference. In reality the efficacy-effectiveness 
difference might be a little smaller, especially for the efficacy-effectiveness difference in meta 
analyses that included only trials that used a less stringent cut off [33,34]. However, the most often 
used cut off score for remission (HAMD17 score of 7) in the meta analyses is, to our opinion, close 
enough to our definition of remission in “real life” (MADRS ≤10 ≈ HAMD17≤6.4)) to give a reliable 
estimate of the difference between efficacy and effectiveness. 
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inconsistencies in the use of exclusion criteria in Pets
We found that PETs are not consistent in the exclusion criteria they use. Only 4 of the 38 criteria 
were used in 75% of the papers (chapter 4). This, of course, hampers the comparability of PETs 
and thus the reliability of meta analyses of PETs (and the comparability of PETs with AETs). It also 
has consequences for the interpretation of the results described in chapter 4. Firstly, calculating 
the overall efficacy of PETs as is done in three of our selected meta analyses [37-39] while the 
comparability of PETs is low, raises questions about the reliability of the results from these meta 
analyses. Therefore, the reliability of our results on the efficacy-effectiveness difference might 
likewise be jeopardized. Secondly, it was impossible to take all exclusion criteria into account 
when we investigated which “real life” patients would have been eligible for PETs. We restricted 
ourselves to the four most consistently used criteria, making the comparison of treatment effects 
in eligible and non-eligible patients just an approximation.
Research on ROM data: limitations in estimating effectiveness
The ROM data were gathered in clinical practice, as part of the routine diagnostic and 
treatment processes. Although such data have the advantage of offering insight into the 
vicissitudes of “real life” patients, they also have limitations just because of these vicissitudes. 
First of all, data integrity is not guaranteed. By using computers with touch screens and 
software that makes it impossible to skip a question in a questionnaire and by having 
test nurses supervising the filling out of the questionnaires, we tried to make the data as 
complete as possible. However, it was clinical practice, not a research project in which double 
checking of data and data gathering are the standard procedure. Thus incompleteness was 
inevitable. Also the large number of questionnaires may have impeded completeness. We 
addressed the problem of missing data as good as possible by using elaborate statistical 
methods (MICE, multivariate imputation by chained equations, [40]). Second, in the period 
in which the data for our project were gathered, the follow up assessments in ROM were 
not organized properly. The consequence is an almost 50% loss to follow-up. In the relevant 
chapters of this thesis we discussed how we tried to handle this loss. On the other hand, a 
large loss to follow up may be inherent to studies with a naturalistic design: STAR*D had 
reached a loss-to-follow-up of 48% in step II of the study. Third, in ROM data on the history 
of the patient’s life and his illnesses are rudimentary. Unfortunately, as those data are also 
not available in a useful digital format, we had to depend on an extensive chart review. All 
these factors will have reduced the reliability of the data. However, they are more extensive 
and relate to a larger number of patients than in any other project. Therefore, we felt that 
our data are a significant contribution to this new field of research.
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Generalizability of our results: limitations
In this thesis, we explored the outcome of antidepressant and psychotherapeutic treatment 
of MDD from baseline assessment to the first follow up assessment. We have not addressed 
patient selection and its influence on outcome of RCTs on combination treatment, as 
combination treatment is a second step in the treatment algorithm of MDD. 
 As mentioned earlier, all ROM patients at the RMHP are referred by either their GP (most 
often) or by a psychiatrist working in private practice. Many patients already underwent 
treatment for their MDD prior to referral. Our results are therefore only generalizable to 
outpatient clinics that treat similar patients. The generalizability of our results to private 
practices, GP practices and mental health providers who treat only or merely patients 
that are treatment naïve (and who probably have a more favorable prognosis) or patients 
who are non responders to several therapies (so called third line institutions) is most likely 
limited. 
 The meta-analyses that we used in this project were carried out in the United States 
of America and Europe. These studies included a predominantly white patient population. 
Our ROM population also is a predominantly white patient population treated in Western 
psychiatric practice. We do not know whether our results are also valid in other cultures. 
Neither do we know to what extent they apply to non-Western immigrants in the Netherlands 
who were unable to fill out the questionnaires.
Future directions in effectiveness research and opportunities for clinical innovation
In this last section of the discussion we will present some recommendations for future 
research in line with our project and also for clinical development.
We will start with recommendations for future research. 
 • As described earlier, our loss to follow-up was considerable. From personal 
communications with other centers using ROM it is clear that this is a nearly universal 
problem. The large loss to follow up in the STAR*D trial also emphasizes the problem 
of loss to follow up in research done in clinical practice. Of course, the loss to follow up 
could be decreased by a better organization. Probably the covenant with the insurance 
companies to increase the proportion of patients with follow up data may help. 
However, the high loss to follow up should also become a focus of research. Almost one 
third of these lost to follow up patients remain in treatment, so do these patients refuse 
to participate in ROM or do clinicians forget to sign up their patients? Future research 
will have to focus on reasons why patients do not participate in follow up assessments. 
And the other two thirds of the patients? Did they recover and then disappear? Or were 
they unsatisfied with their treatment and no longer showed up? It is remarkable that 
the urge to investigate these topics is not felt widely. Perhaps patients who are lost to 
follow up have specific features such as a common social background, more co morbid 
disorders or specific personality traits. From our lost to follow up analysis, we learned 
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that although the patients who were lost to follow up were very similar to the ones who 
were not, especially single male MDD patients suffering from co morbid post traumatic 
stress disorder were at risk of dropping out and being lost to follow up. Future research 
might reveal specific subgroups that are at risk for drop out or loss to follow up and 
need a specific approach to stay in treatment and have a proper evaluation of it. Also 
more research is needed on the side of the therapists: are there specific professional 
groups that do not support ROM? And what do they need to feel the need for routinely 
systematic evaluation of their treatment?
 • Research on treatment effectiveness and benchmarking requires large databases. 
Therefore, it is important that the ROM of mental health care centers use, as far as 
possible, the same questionnaires and procedures. In the current financial crisis, many 
policy makers need/tempt to make stringent cutbacks in the budgets of mental health 
care. One way to reduce the costs of ROM is to reduce the number of instruments in 
ROM as much as possible. This, however, may seriously jeopardize the usefulness of ROM 
data as a reliable instrument for the evaluation of treatment progress in clinical practice. 
Furthermore, it certainly jeopardizes the usefulness of ROM data for scientific research. 
A discussion about what the necessary ingredients of ROM are, is necessary. The data of 
the Leiden Routine Outcome Monitoring Study may be helpful to provide this discussion 
with data, i.e. by the exploration of the validity of key items in the available instruments 
and the possibilities of answer-steered exposure to new items of questionnaires (patients 
do not fill out complete questionnaires, but will get new items based on their response 
to the former ones).
 • Further research on the influence of factors in which AETs and PETs on one hand and “real 
life” patient cohorts on the other hand differ, should be continued. More specifically, data 
not included in this study, for instance on earlier treatments and patient history, should 
be included. Also, then, replication studies on our findings can be carried out, preferably 
in real life cohorts with more complete data and less loss to follow-up.
 • We investigated MDD. It would be useful to extend this type of research to other 
disorders, for instance anxiety disorders. Such research would elaborate which problems 
are unique for MDD and which are general.
Is our finding of modest effects of the first step in evidence based MDD treatments a reason 
to discard the guidelines, throw away evidence based medicine and go back to experience 
based medicine? Back to the “good old days” where individual doctors knew best for 
individual patients and where clinicians acted on personal experience? No. Research 
indicates that there is a positive association between the introduction of evidence based 
therapies in daily practice and the improvement of MDD treatment, yet its relation is still 
not unmistakably clear. It is time to answer the question that was asked by A.J Rush in 1993: 
“Clinical Practice Guidelines: good news, bad news, or no news?”[41]. Many researchers have 
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tried to answer this significant question, and it is a difficult one to answer. Many factors are 
involved in treatment in daily practice and therefore daily practice is very complicated to 
address scientifically [19]. ROM is a very promising and valuable methodology to get insight 
in the many aspects of routine psychiatric practice. So, indeed, effectiveness in daily practice 
is not as positive as we hoped for. But go back to experience based treatment? No one 
knows what treatment results were before the introduction of evidence based medicine. 
And no one will ever find out, because experience based treatments cannot be explored 
in terms of effectiveness, since they differ between each patients and nothing is recorded 
automatically. So one of the big yet bitter advantages of the introduction of guidelines is that 
we now know that effectiveness is currently not as good as the promising results from RCTs. 
ROM may provide data to improve in an evidence based way the treatment results in clinical 
practice, e.g. by the future possibilities to identify patients who are at risk of non response or 
to define subgroups of patients that respond better to a certain type of treatment. 
 Are the modest MDD treatment results in daily practice a reason for panic or despair, 
then? A reason to become depressed? A reason to cut down the budget on mental health? 
We don’t think so. The age of evidence based medicine went hand in hand with the age 
of optimistic belief in antidepressant treatment, efficacy trials on ssri’s and an enormous 
increase in the prescription of antidepressants. Among others, pharmaceutical industries 
conducted efficacy trials on antidepressants and showed that depression is a treatable 
disorder. Those days of optimism are over. Antidepressants seem not be as effective as was 
believed [42], not even in the short term, 6-8 weeks follow-up trials in which no effort is 
spared to optimize adherence, and in which only patients with moderate to severe MDD are 
treated. From our results and from those of the STAR*D trial [10,11], it is clear that in daily 
practice even short term treatment of MDD is hard, and the results modest. In addition, it 
has become evident that depression is a chronic illness [43-45], which remits and recurs, and 
rarely disappears.
 Depression causes a lot of suffering, some patients who suffered both from very severe 
“somatic” illnesses or terrible personal losses and major depressive disorder, stated that their 
depression was the worst. The loss of hope, a continuous feeling of worthlessness and/or 
despair, the inability to participate in daily life in the broadest sense of the word together 
with all the physical complaints that may occur when one suffers from major depressive 
disorder, surely makes MDD a disease that justifies all efforts from patients, caregivers, 
clinicians, researchers, and mental health policy makers. MDD is an expensive disease 
with respect to direct costs on the health care budget (not only the mental health care 
budget) and indirect costs with respect to absenteeism. Depression is the leading cause 
of disability and the fourth leading contributor to the global burden of disease according 
to the World Health Organization (https://www.who.int/en). MDD is a very serious medical 
issue, like other chronic diseases such as diabetes or chronic obstructive pulmonary disease 
(COPD), not a temporarily suffering from worries that will go away after a good talk with 
140 | Chapter 7
your neighbour. It is of importance that the people in charge of the mental health care 
budgets, the policymakers, the government and the minister of Public Health take notice of 
the complexity, severity and chronicity of MDD.
 Having learned that we, as clinicians and researchers, have to be modest about the 
prognosis of patients suffering from MDD who seek treatment for it, we cannot just sit and 
wait... We can improve treatment adherence of patients and clinicians and we can develop 
staging and profiling of MDD. This discussion will be closed by elaborating on these three 
topics.
 Firstly, we can ameliorate our methods to improve treatment adherence of patients. 
Many new developments may improve adherence: e-health, apps with medication 
instruction, sms alerts for medication, technical devices that help patients to monitor 
changes in their mood by providing feedback several times a day, and collaborative care (an 
integrated approach of the biological, social and psychological aspects of MDD). For better 
treatment adherence, we have to invest in the education of patients suffering from MDD. It 
has been proven that informing patients about the nature of their disease and its treatment, 
the duration, the expected results and time span, the expected investment of the patients 
and possible side effects of the treatment, which accounts for both pharmacotherapy and 
psychotherapy will improve adherence [46,47]. It is hard to tell a patient who just got out of 
a period of feeling worthless and guilty, who had nights without sleep, days without energy 
or appetite and who nearly came to the edge of committing suicide, that it is likely that 
this illness will return, sooner or later. Nevertheless, education is a very important part of 
MDD treatment. Future research on the effect of improvement of treatment adherence on 
outcome in daily practice is highly recommended. Secondly, improvement of the protocol 
adherence of clinicians in daily practice might also lead to an increase of effectiveness. 
Due to a variety of reasons, clinicians in daily practice sometimes find it difficult to strictly 
follow the protocol (especially when it comes to the frequency of follow up contacts or 
taking blood levels of antidepressants). Further research on the association between 
protocol adherence and outcome is recommended [19]. In this project, we presented 
ROM as a valuable methodology to do scientific research in daily practice. Other potential 
benefits of ROM remained underexposed in this thesis so far, but need to be mentioned. In 
Rivierduinen, ROM was primarily designed to ameliorate the evaluation of the treatment of 
individual patients and patient groups. A systematic evaluation of treatment progress after 
each treatment step helps clinicians and patients to see whether they are on the right track, 
and what further steps need to be taken. If ROM is fully incorporated in daily routine, it can 
be a helpful tool for clinicians to remain adherent to their treatment protocol and to switch 
in time to a next treatment step in the protocols for MDD treatment.
 Finally, depression treatment itself can be improved by so called staging and profiling 
(a specific therapy for a specific stage or subtype of the disease). At this moment, almost all 
patients suffering from MDD are treated the same way, either with antidepressants or with 
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psychotherapy (or a combination of both). The choice for either one of treatment modalities 
is based only on severity of the depression and the preferences of the patients. Yet, there 
are many clues that not all MDDs are the same. Within the disorder, different symptoms 
or symptom dimensions may have different etiology. Different symptom dimensions [48] 
have been demonstrated to be associated with different genetic pathways [Van Veen, in 
press], with differences in the dysregulation of the HPA-axis [49,50], and different types 
of childhood trauma [51] [Van Veen, submitted] and life events [Wardenaar, submitted]. 
Currently more and more results become available indicating that different subtypes of 
depression need different treatment. For instance in the STAR*D trial was found that specific 
genotypes together with co morbid anxiety disorders (in our ROM sample 43% suffered 
from co morbid anxiety and/or somatoform disorders) are associated with non-response to 
antidepressants [52]. Similar results were found in the Genome Based Therapeutic Drugs for 
Depression (GENDEP) study [53].Therefore, patients suffering from MDD should not all be 
treated in the same way, but with treatment tailor made for their type of depression. Future 
research should focus on those tailor made treatments.
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titel: ZiJn DePRessie-tRiALs GeneRALiseeRBAAR nAAR De 
KLiniscHe PRAKtiJK?
subtitel: Wat clinici altijd al hadden willen weten over RCTs, maar niet durfden te 
vragen….
Dr. X is een 60-jarige, alom gerespecteerde, psychiater die in een grote psychiatrische polikliniek 
werkt. Hij ziet iedere dag vele patiënten met uiteenlopende psychiatrische stoornissen. Jongere 
collega’s verwijzen vaak complexe patiënten naar hem vanwege zijn lange ervaring. Dr. X 
heeft gedurende zijn carrière al veel ontwikkelingen in de psychiatrie meegemaakt: nieuwe 
psychofarmaca, de antipsychiatrie, de zelfbewustwording van patiënten, de afnemende 
populariteit van de psychoanalytische therapie, het toenemend belang van behandelprotocollen 
en de vooruitgang in inzicht in biologische aspecten van psychiatrische stoornissen. In de 
polikliniek waar dr. X werkt, zijn, zoals in vele poliklinieken, de nationale richtlijnen voor 
behandeling van psychiatrische stoornissen omarmd en geïmplementeerd. Zoals veel van zijn 
collega’s was dr. X geïnteresseerd, maar ook wat sceptisch, en hij maakte zich zorgen dat deze 
richtlijnen alle creativiteit uit het vak zouden doen verdwijnen. Toch zette dr. X zich in voor 
navolging van de behandelrichtlijnen. Hij hield zijn vakliteratuur bij over psychofarmaca en 
psychotherapie, vooral voor depressie, aangezien de meeste van zijn patiënten daaraan lijden. 
Hij las de veelbelovende resultaten uit randomized controlled trials (RCTs) voor verschillende 
antidepressiva en nieuwe methodes van psychotherapie. Ondertussen waren de resultaten 
van medicatie of psychotherapie in zijn praktijk vaak teleurstellend en bleven zijn patiënten 
worstelen met hun depressie. Dr. X kreeg de indruk dat het effect van depressie behandeling een 
stuk groter is in RCTs dan in “de echte wereld”. Hij ging zich het volgende afvragen: zijn mijn 
patiënten wel hetzelfde als die deelnemers aan depressie-trials? Hoe moet ik de resultaten uit 
RCTs interpreteren? Vertellen RCTs ons eigenlijk wel iets over de “echte wereld”? En klopt het 
eigenlijk wel dat wij onze behandelrichtlijnen baseren op resultaten uit RCTs die misschien zo ver 
van de dagelijkse praktijk staan? 
 In dit proefschrift hebben wij geprobeerd de vragen van dr. X te beantwoorden.
Dr. X behandelt veel patiënten met een depressie. Depressie is een stemmingsstoornis, 
die zich kenmerkt door aanhoudende somberheid of neerslachtigheid en/of het verlies 
van belangstelling of genoegen. Daarnaast is er bij depressie sprake van een aantal 
van de volgende symptomen: verandering in eetlust; verstoord slaappatroon; ruste-
loosheid of traagheid; vermoeidheid of energieverlies; schuldgevoel, bezorgdheid 
of angst; concentratieproblemen en gedachten aan zelfmoord. Een depressie is een 
veelvoorkomende en ernstige psychiatrische aandoening, die bij een groot aantal patiënten 
meerdere malen terugkeert in het leven. Wereldwijd staat depressie op nummer één als het 
gaat om invaliderende ziektes, zo stelt de World Health Organisation. Depressie komt zowel 
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bij mannen als vrouwen voor, in iedere leeftijdscategorie en bij iedere etnische of sociaal 
-economische achtergrond. Depressie komt meer voor bij vrouwen dan bij mannen (ruim 
één op de tien mannen maakt eens in zijn leven een depressie door, terwijl voor vrouwen 
dit één op de vijf is). Depressieve patiënten lijden erg onder hun ziekte. Daarnaast vormt 
depressie een maatschappelijk probleem: depressieve mensen maken meer gebruik van 
gezondheidszorg en uitkeringen en depressieve mensen zijn vaak niet in staat om te werken, 
waardoor er veel arbeidsproductiviteit verloren gaat. In Nederland zijn de geschatte kosten, 
in totaal, van depressie ongeveer 1.1% van de totale kosten van de gezondheidszorg. 
 Depressie is een behandelbare aandoening. Psychiaters en psychologen in Nederland 
volgen, net als Dr. X, daarvoor de multidisciplinaire richtlijnen voor behandeling 
van depressie. Bij een depressie zijn behandeling met medicatie (antidepressiva) en 
psychotherapie ongeveer even effectief gebleken. Als de patiënt de voorkeur geeft aan een 
psychotherapeutische behandeling, kan hij kiezen voor cognitieve gedragstherapie, waarbij 
de patiënt door middel van oefeningen zijn depressieve gedachten en gedragingen probeert 
te veranderen. Hij kan ook kiezen voor interpersoonlijke therapie, waarin een patiënt de 
levensfase of gebeurtenis die de aanleiding was voor het ontwikkelen van een depressie 
doorwerkt met de psychotherapeut. Beide vormen van psychotherapie zijn ongeveer even 
effectief, al is er veel meer onderzoek gedaan naar cognitieve gedragstherapie. Pas bij 
onvoldoende effect van psychotherapie of antidepressiva wordt aangeraden om te starten 
met combinatietherapie (een combinatie van medicatie en psychotherapie). Dit principe 
van enkelvoudig beginnen en pas later behandelingen combineren noemt men stepped 
care. In Nederland worden de behandelrichtlijnen samengesteld door speciale werkgroepen 
met experts uit het werkveld en uitgegeven door het Trimbos Instituut. 
 In de richtlijnen voor behandeling van depressie wordt aangegeven welke therapieën 
er bewezen effectief zijn, ook in het Nederlands meestal aangeduid met de Engelse 
term evidence based. Het bewijs voor effectiviteit wordt verkregen uit wetenschappelijk 
onderzoek. De onderzoeksmethode die beschouwd wordt als de methode die het meeste 
“harde” bewijs oplevert is de randomized controlled trial (RCT). In een RCT wordt in een van te 
voren vastgestelde groep patiënten gekeken of een behandeling effectiever is dan placebo 
behandeling (een medicament dat er net zo uitziet als het onderzochte medicament, maar 
dan zonder werkzame stoffen). In het geval van psychotherapie is een placebo niet haalbaar 
en wordt gekeken of een bepaalde psychotherapie effectiever is dan de behandeling die 
gebruikelijk is voor de ziekte, in het Engels aangeduid als Treatment As Usual (TAU) of 
op een wachtlijst staan (de zogenoemde “wachtlijst groep”). De onderzoeksopzet RCT is 
heel strikt omdat hij bedoeld is om aan te tonen dat er een heldere relatie is tussen een 
behandelinterventie en de uitkomst van deze behandeling op een specifieke stoornis zonder 
dat er sprake is van placebo effect. Men spreekt van placebo effect als patiënten “spontaan” 
opknappen als zij het idee hebben een behandeling te krijgen, zonder dat er sprake is van 
de werkzame component van die behandeling. Om in een RCT zo ondubbelzinnig mogelijk 
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te kunnen aantonen dat het effect echt het gevolg is van de onderzochte behandeling is er 
niet alleen een controlegroep nodig; de deelnemende patiënten mogen bijvoorbeeld ook 
geen andere ziekten hebben dan die waarop de behandeling gericht is. 
 In de dagelijkse praktijk, zoals die van dr. X is dat anders. Vaak hebben patiënten naast hun 
depressie nog andere psychiatrische stoornissen. De combinatie van een angststoornis en 
een depressie komt erg vaak voor. Ook drinken depressieve patiënten vaker dan gemiddeld 
alcohol en soms gebruiken zij drugs. Al deze problemen zijn een reden om niet mee te 
mogen doen aan een depressie trial. De vraag is dan natuurlijk: als de meeste depressieve 
patiënten uit de dagelijkse praktijk anders zijn dan deelnemers aan zo’n depressie trial, 
zijn de resultaten van zulke trials dan wel van toepassing op (generaliseerbaar naar) de 
dagelijkse praktijk? Die vraag hebben wij geprobeerd te beantwoorden in dit proefschrift. 
 Tot tien jaar geleden was het onduidelijk hoe effectief behandelingen voor depressie in 
de dagelijkse praktijk waren. Het effect van behandeling werd weinig gemeten door clinici 
en als ze het al deden werd het niet op een systematische manier gedaan. Daardoor waren 
er geen gegevens over de behandelresultaten bij depressieve patiënten in de dagelijkse 
praktijk. Onderzoekers hebben toen een nieuwe onderzoeksopzet ontworpen die de 
dagelijkse praktijk veel meer benadert dan de RCTs dat deden. Patiënten hoefden niet aan 
een veelheid aan strikte criteria te voldoen voor deelname en de behandeling vond plaats in 
de dagelijkse praktijk. Deze onderzoeksopzet wordt ook wel de pragmatische trial genoemd. 
Een bekend voorbeeld hiervan is de STAR*D trial, een heel grote pragmatische trial uit 
2004 naar behandeling van depressie in de Verenigde Staten. Er deden 4000 patiënten 
aan mee. Een nadeel van pragmatische trials is, dat hoewel zij de dagelijkse praktijk zoveel 
mogelijk benaderen, ze toch altijd eigenschappen van een RCT houden. Een andere 
manier om behandeleffect te kunnen meten in de dagelijkse praktijk is Routine Outcome 
Monitoring (ROM). Bij Routine Outcome Monitoring wordt de psychiatrische stoornis van 
patiënten in dagelijkse praktijk bij binnenkomst en daarna steeds na een vaste periode 
gemeten met gevalideerde meetinstrumenten (vragenlijsten). In 2002 heeft Rivierduinen, 
in samenwerking met de afdeling Psychiatrie van het LUMC ROM ingevoerd in de dagelijkse 
praktijk van poliklinische behandeling van patiënten met een stemmings-, angst-, of 
somatoforme stoornissen. Na enkele jaren is ROM in Rivierduinen uitgebreid naar andere 
psychiatrische stoornissen. Rivierduinen, een grote GGZ instelling met meerdere vestigingen 
in Zuid-Holland, heeft een verzorgingsgebied van ongeveer een miljoen Nederlanders. 
ROM heeft als enige criterium voor deelname dat patiënten het Nederlands voldoende 
moeten beheersen en dat zij niet te ernstig ziek zijn voor het invullen van vragenlijsten. 
Bij binnenkomst krijgen patiënten allemaal, naast het gebruikelijke intakegesprek met 
een behandelaar, een serie vragenlijsten waarmee systematisch wordt nagegaan welke 
klachten zij hebben en hoe ernstig deze zijn. Daarnaast wordt bij alle patiënten gekeken 
hoe ze hun kwaliteit van leven ervaren, en hoe ze sociaal en maatschappelijk functioneren. 
Bij de vervolgmetingen wordt steeds gekeken hoe de ernst van de klachten op dat moment 
is en in hoeverre de patiënten tevreden zijn over hun functioneren. De patiënten vullen 
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een deel van de vragenlijsten zelf in op een computer d.m.v. een touch screen. De overige 
vragenlijsten worden ingevuld door een testverpleegkundige die de patiënt de vragen stelt. 
Het eerste doel van ROM is om behandelaar en patiënt bij de intake te informeren over de 
aard en ernst van de klachten en later over de voortgang van behandeling. Daarnaast is 
door de uitgebreide opzet van ROM van LUMC/Rivierduinen het goed mogelijk om allerlei 
vragen uit de dagelijkse praktijk wetenschappelijk te onderzoeken. Voor dit proefschrift 
maakten wij gebruik van gegevens die met ROM verzameld zijn. 
BeLAnGRiJKste BevinDinGen
In het eerste hoofdstuk, de inleiding van dit proefschrift, hebben wij een overzicht gegeven 
van de opbouw van de Nederlandse, Engelse en Amerikaanse richtlijnen voor de behandeling 
van depressie. We hebben laten zien hoe het bewijs voor effectiviteit van verschillende 
behandelingen voor depressie gewogen wordt en hoe zwaar de resultaten van RCTs wegen 
voor de verschillende richtlijnen. Vervolgens hebben we uiteen gezet welke behandelingen 
worden aanbevolen in de richtlijnen als eerste stap in de behandeling van depressie. 
Daarna zijn we ingegaan op de methodologie van RCTs en de beperkingen die deze strenge 
methodologie met zich meebrengt voor de generaliseerbaarheid van resultaten uit RCTs 
naar de dagelijkse psychiatrische praktijk. We hebben het verschil uitgelegd tussen efficacy 
(de effectiviteit van een behandeling gemeten in RCTs) en effectiveness (de werkzaamheid 
van deze behandeling in de dagelijkse praktijk). In dit hoofdstuk hebben we aangegeven 
wat de meest gebruikte meetinstrumenten zijn om de effectiviteit van behandeling van 
depressie te meten: de Hamilton Rating Scale for Depression (HAMD), de Montgomery 
Asberg Depression Rating Scale (MADRS) en de Beck Depression Inventory (BDI-II). 
De meest gebruikte manieren om effectiviteit weer te geven zijn: responspercentage, 
remissiepercentage en effectsize. Men spreekt van respons als de patiënt 50% minder 
symptomen op een vragenlijst scoort dan bij het begin van de behandeling. Men spreekt 
van remissie als patiënten beneden een bepaalde cut-off scoren (MADRS≤10). Effectsize 
is het verschil in de score van symptomen na en vóór behandeling, gecorrigeerd voor de 
standaarddeviatie (spreiding in scores) vóór behandeling. We hebben uitgelegd hoe ROM 
gebruikt kan worden om de werkzaamheid (effectiveness) van behandeling van depressie 
in de dagelijkse praktijk te meten. Tot slot hebben we in dit eerste hoofdstuk uiteengezet 
hoe de selectie van depressieve patiënten in RCTs, de generaliseerbaarheid van resultaten 
naar de dagelijkse praktijk negatief zou kunnen beïnvloeden. 
In het tweede hoofdstuk, de eerste studie in dit proefschrift, hebben we de effectiviteit van 
behandeling van depressie gemeten in 15 meta-analyses en die in onze dagelijkse praktijk 
gemeten met ROM vergeleken. Iedere meta-analyse geeft een geaggregeerde maat (het 
gemiddeld effect van een grote verzameling RCTs, gecorrigeerd voor het aantal deelnemers 
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aan de RCTs) voor het behandeleffect. Ook hebben we een vergelijking gemaakt tussen 
het effect van behandeling in de dagelijkse (ROM) praktijk en die van de STAR*D trial. 
Hiervoor hebben we 598 depressieve patiënten geïncludeerd die tussen 2002 en 2006 
behandeling zochten bij Rivierduinen. Deze 598 patiënten hadden een ROM meting 
ondergaan bij binnenkomst en hadden tenminste 1 vervolgmeting. We hebben gevonden 
dat de remissiepercentages voor alle behandelingen: antidepressiva, psychotherapie en 
combinatietherapie lager waren in de dagelijkse praktijk dan in RCTs (32% vs.40–74%). Dit 
verschil was het meest duidelijk voor psychotherapie en combinatietherapie. Er bleek geen 
verschil te zijn tussen de behandelresultaten in onze dagelijkse praktijk en die van STAR*D. 
 In het derde hoofdstuk hebben wij onderzocht hoeveel depressieve patiënten uit 
dagelijkse praktijk in aanmerking zouden komen voor een antidepressivatrial. Hiervoor 
hebben we 1653 depressieve patiënten geïncludeerd die tussen 2002 en 2006 behandeling 
zochten bij Rivierduinen en die een ROM meting hadden ondergaan bij binnenkomst. We 
hebben berekend welk percentage van deze patiënten in aanmerking zou komen volgens 
de meest gebruikte exclusiecriteria in RCTs voor antidepressiva. Dat was slechts bij 17–25% 
van onze patiënten het geval. De belangrijkste redenen voor exclusie waren: niet voldoen 
aan de minimum ernst van de depressie (HAMD ≤17) en de aanwezigheid van comorbide 
psychiatrische stoornissen. Andere veelvoorkomende redenen voor exclusie waren: 
suïcidaliteit en misbruik of afhankelijkheid van alcohol en/of drugs. Vervolgens hebben wij 
bij 626 patiënten van de 1653 patiënten onderzocht wat de invloed van de veelgebruikte 
exclusiecriteria was op het behandeleffect. Deze 626 patiënten werden geselecteerd omdat 
zij tenminste 1 vervolgmeting hadden. Onze belangrijkste bevinding in deze studie was 
dat “in aanmerking komen voor deelname (voldoen aan alle criteria)” niet van invloed is op 
het behandelresultaat in de dagelijkse praktijk. Onze interpretatie is dat het gebruik van 
exclusiecriteria waarschijnlijk niet een zodanige bedreiging is voor de generaliseerbaarheid 
van resultaten uit antidepressiva-trials als in eerder onderzoek werd gesuggereerd. 
Waarschijnlijk zijn er andere factoren die het verschil in behandeleffect in antidepressiva 
trials en de dagelijkse praktijk kan verklaren. Mogelijke verklaringen zijn de veel grotere 
inspanning die in trials wordt geleverd om therapietrouw te bevorderen, waarschijnlijk is 
de frequentie van behandelcontacten in trials hoger dan in de praktijk en speelt in trials het 
zogenaamde Hawthorne effect mee (een gunstiger uitkomst doordat patiënten hoopvoller 
zijn omdat zij meedoen aan een bijzondere behandeling in een bijzondere setting). 
 In het vierde hoofdstuk hebben wij dezelfde vraagstelling onderzocht, maar dan voor 
psychotherapie-trials. Van psychotherapie-trials was niet bekend welke exclusiecriteria het 
meest gebruikt worden. Dit hebben wij onderzocht in 20 psychotherapie-trials voor depressie. 
We hebben gevonden dat psychotherapie-trials minder consistent waren in het gebruik van 
exclusiecriteria dan antidepressiva-trials. De volgende criteria worden veel gebruikt en zijn 
mogelijk van invloed op de generaliseerbaarheid van de resultaten van psychotherapie-trials 
voor depressie: ‘niet voldoen aan de minimum ernst (HAMD≤14)’, ‘misbruik of afhankelijkheid 
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van drugs en/of alcohol’ en ‘gebruik van medicatie of electroconvulsie therapie voorafgaand 
aan de psychotherapie’. Aangezien de exclusiecriteria in psychotherapie-trials niet 
consistent worden gebruikt, was het niet mogelijk om een percentage ROM patiënten te 
berekenen dat in aanmerking zouden komen voor deelname. Wel hebben we gevonden 
dat de invloed van het gebruik van de afzonderlijke exclusiecriteria op behandelresultaat in 
de dagelijkse praktijk laag was: ‘misbruik van alcohol en/of drugs’ had geen invloed en de 
invloed van de andere twee exclusiecriteria was gering. Ook bij de psychotherapietrials is 
onze interpretatie van de gevonden resultaten de generaliseerbaarheid van de resultaten 
waarschijnlijk minder ernstig wordt bedreigd door het gebruik van exclusiecriteria dan 
eerder werd gedacht. Waarschijnlijk geldt ook voor psychotherapie dat andere factoren, 
zoals genoemd in hoofdstuk 3, het verschil in behandeleffect tussen de dagelijkse praktijk 
en trials kunnen verklaren. 
 In het vijfde hoofdstuk hebben wij de socio-demografische en socio-economische 
kenmerken (SES kenmerken) van deelnemers aan depressie-trials in kaart gebracht. Hiervoor 
hebben wij 45 antidepressiva-trials en 19 psychotherapie-trials geïncludeerd. We hebben 
gevonden dat de rapportage van SES kenmerken niet eenduidig is en dat er vaak beperkte 
informatie gegeven wordt. Vooral vermelding van opleidingsniveau, sociaaleconomische 
status en inkomen wordt vaak achterwege gelaten, terwijl die wel van invloed kunnen zijn 
op de behandeluitkomst. Uit dit onderzoek is gebleken dat deelnemers aan depressie-
trials gemiddeld 41 jaar zijn, voornamelijk vrouw (62%) en voornamelijk blank (89%) zijn. 
Onze conclusie is dat standaardisatie van de rapportage van SES kenmerken in RCTs de 
vergelijking tussen trials en met de dagelijkse praktijk ten goede zou komen. 
 In het zesde hoofdstuk hebben wij de SES kenmerken van deelnemers aan depressie-
trials (zoals gevonden in hoofdstuk 5) met die van patiënten uit de dagelijkse praktijk 
vergeleken. Wij hebben hiervoor weer de 626 depressieve patiënten die hierboven genoemd 
werden geïncludeerd. Deze patiënten ondergingen een ROM meting bij binnenkomst 
en hadden tenminste 1 vervolgmeting. Wij hebben gevonden dat trialdeelnemers ouder, 
vaker van het mannelijk geslacht, vaker blank en vaker ongetrouwd waren dan patiënten 
uit de dagelijkse praktijk. Deze verschillen bleken echter klein te zijn. Opvallend was dat 
veel meer trialdeelnemers betaald werk hadden gedurende hun behandeling dan patiënten 
uit de dagelijkse praktijk (verschil 34%). Het doen van betaald werk voorspelde een betere 
behandeluitkomst bij depressie in de dagelijkse praktijk. 
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ALGemene Discussie
Onze studies geven inzicht in het verschil in behandelresultaat voor depressie tussen 
trialsettings en de dagelijkse praktijk. We kunnen concluderen dat clinici, zoals dr. X, gelijk 
hebben, als zij stellen dat de resultaten in de dagelijkse praktijk vaak minder hoopvol zijn 
dan RCTs suggereren. Ook kunnen we concluderen dat clinici gelijk hebben als zij stellen dat 
hun patiënten uit de “echte wereld” verschillen van deelnemers aan trials; patiënten uit de 
dagelijkse praktijk zijn vaak minder ernstig ziek dan die in trials, maar ze zijn wel vaak suïcidaal 
en hebben in meerderheid andere psychiatrische stoornissen of verslavingen, allemaal 
verschijnselen die bij trials juist redenen zijn om mensen uit te sluiten voor deelname. Ook 
hebben patiënten uit de dagelijkse praktijk vaak wél antidepressiva gebruikt voordat ze aan 
psychotherapie beginnen. Daarnaast hebben depressieve patiënten in de dagelijkse praktijk 
veel minder vaak betaald werk tijdens hun behandeling dan deelnemers aan depressietrials. 
Onze belangrijkste bevinding is echter, in tegenstelling tot het vermoeden van veel clinici 
zoals dr. X: “in aanmerking komen voor een depressie trial (voldoen aan alle criteria) is niet 
van invloed op het behandeleffect in de dagelijkse praktijk”. Met andere woorden: als in 
de dagelijkse praktijk alleen nog de “schone” depressieve patiënten die in aanmerking 
komen voor deelname aan RCTs zouden worden behandeld, dan zal het behandelresultaat 
niet sterk verbeteren. De verschillen tussen trial deelnemers en patiënten uit de dagelijkse 
praktijk verklaren het verschil in behandelresultaat tussen RCTs voor depressie en de 
dagelijkse praktijk dus niet. 
 In de algemene discussie zijn we uitgebreider ingegaan op een aantal andere mogelijke 
verklaringen voor het verschil tussen efficacy en effectiveness bij depressiebehandeling. 
Waarschijnlijk zijn er andere verschillen tussen trialdeelnemers en patiënten uit de 
dagelijkse praktijk die van invloed zijn op het behandeleffect: verschillen in motivatie 
en therapietrouw en in de prognostische kenmerken van de depressie. Daarnaast zijn er 
verschillen tussen behandelaars die meedoen aan een trial en behandelaars in de dagelijkse 
praktijk: verschillen in werkdruk, motivatie en protocolgetrouwheid. De polikliniek waar een 
trial wordt uitgevoerd verschilt van de dagelijkse praktijk: trials worden vaak uitgevoerd 
in gespecialiseerde centra en er wordt voor een trial veel geïnvesteerd in therapietrouw 
en het voorkomen van uitval van behandelafspraken. Waarschijnlijk is het placebo effect in 
RCTs groter dan in de dagelijkse praktijk, wat bijdraagt aan het verschil in behandelresultaat 
tussen trials en de dagelijkse praktijk. Tot slot is er meestal sprake van publicatiebias bij 
RCTs: trials die een positief resultaat laten zien worden vaker gepubliceerd dan trials die een 
negatief effect of geen effect hebben gevonden. Het feit dat deze laatste trials niet worden 
gepubliceerd, vergroot de verschillen tussen in meta-analyses gerapporteerde efficacy en 
effectiveness. 
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Er zijn drie belangrijke beperkingen in dit onderzoeksproject: beperkingen aan de kant van 
de RCT resultaten, beperkingen in de ROM data en beperkingen in de generaliseerbaarheid 
van onze bevindingen. Ten eerste was er in RCTs voor depressie gebrekkige consistentie 
in het gebruik van meetinstrumenten, definitie van behandeleffect en het gebruik van 
exclusie criteria. Door inconsistentie in gebruik van meetinstrumenten en definities van 
behandeluitkomst in RCTs is het mogelijk dat de efficacy uitkomsten in meta-analyses 
minder valide zijn dan ze lijken. In ons onderzoek hebben we een “strenge” cut-off gebruikt 
voor onze definitie van remissie. Het is daardoor mogelijk dat in werkelijkheid het verschil 
tussen efficacy en effectiveness bij depressiebehandeling minder groot is dan wij gevonden 
hebben. Ten tweede worden behandelgegevens niet meegenomen in ROM. Informatie 
over de behandeling hebben wij verzameld door middel van uitgebreid status onderzoek. 
Naast de grote tijdsinvestering die dit status onderzoek vergde, was het soms lastig om 
de benodigde informatie uit de statussen te halen. Het is erg aanbevelenswaardig als 
in de toekomst behandelgegevens onderdeel zijn van ROM. Daarnaast was er bij ROM 
sprake van een hoge loss-to-follow- up: slechts 50% van de patiënten die een eerste ROM 
meting hadden kregen een vervolgmeting. De hoge loss-to-follow-up in onze ROM data, 
lijkt inherent aan onderzoek in de dagelijkse praktijk: bij STAR*D worden vergelijkbare 
percentages gevonden. We hebben geprobeerd om selectiebias door loss-to-follow 
up (patiënten die uitvallen zouden kunnen verschillen van patiënten die niet uitvallen, 
waardoor het behandeleffect niet meer generaliseerbaar is naar de hele patiëntengroep) 
zoveel mogelijk te ondervangen. Wij hebben de verschillen tussen de patiënten met alleen 
een ROM meting bij binnenkomst en die met tenminste één vervolgmeting onderzocht: de 
verschillen waren minimaal. Ook hebben wij met een statistische methode gecorrigeerd 
voor ontbrekende data. Tot slot zijn er, ondanks de hoge mate van representativiteit van onze 
ROM populatie, toch enige beperkingen in de generaliseerbaarheid van onze resultaten. 
Onze bevindingen zijn waarschijnlijk alleen van toepassing op poliklinisch behandelde 
depressieve patiënten uit de tweede lijn (verwezen door hun huisarts voor behandeling 
bij een GGZ instelling) en niet op patiënten met een depressie in de huisartsenpraktijk, in 
vrijgevestigde praktijken (de eerste lijn) of in academische centra (de derde lijn). Aangezien 
patiënten alleen gemeten kunnen worden in ROM als zij het Nederlands voldoende machtig 
zijn, hebben we niet kunnen onderzoeken in hoeverre onze resultaten generaliseerbaar zijn 
naar alle niet-westerse immigranten. 
mogelijkheden voor toekomstig onderzoek
Aangezien zoveel depressieve patiënten geen ROM vervolgmeting blijken te krijgen, zou dit 
een belangrijk onderwerp kunnen (en moeten?) zijn voor toekomstig onderzoek. Wellicht 
bestaan er bepaalde groepen depressieve patiënten die een hoog risico lopen om hun 
behandeling vroegtijdig af te breken? Indien er door middel van onderzoek achterhaald 
kan worden om welke patiënten dit gaat, zouden deze patiënten in een zeer vroeg stadium 
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kunnen worden opgespoord. Zij hebben misschien een specifieke benadering nodig om 
in behandeling te blijven en een goede evaluatie te krijgen van die behandeling. Dit is 
belangrijk, aangezien het afronden van een (succesvolle) behandeling voorspellend is voor 
de prognose van deze patiënten. Ook is het van belang om te weten welke behandelaars 
patiënten niet doorsturen voor een ROM meting. Het is mogelijk dat er specifieke 
beroepsgroepen (artsen, psychologen, of sociaal-psychiatrisch verpleegkundigen) zijn 
die het belang van ROM niet direct onderschrijven. Ook is het mogelijk dat clinici die hun 
patiënten niet doorsturen bepaalde andere gemeenschappelijke kenmerken hebben 
zoals leeftijd, mate van ervaring, werkdruk etc. Onderzoek onder clinici zou aan het licht 
kunnen brengen wat zij nodig hebben om de noodzaak te voelen hun behandelingen 
systematisch te (laten) evalueren. ROM zou kunnen worden verbeterd met de kennis die 
opgedaan wordt uit dergelijk onderzoek. Daarnaast is verder onderzoek naar de opzet van 
ROM zeer aan te bevelen. In tijden van financiële malaise en bezuinigingen wordt de roep 
om minder vragenlijsten per ROM-meting groter. Dit zou echter de bruikbaarheid van ROM 
als behandelevaluatie en als wetenschappelijke instrument in gevaar kunnen brengen. 
Toekomstig onderzoek naar de noodzakelijke ingrediënten van ROM is daarom hard nodig. 
 In dit proefschrift hebben wij een aantal verschillen tussen deelnemers aan depressie-
trials en patiënten uit de dagelijkse praktijk uit Rivierduinen onderzocht. Om na te gaan of 
onze resultaten inderdaad generaliseerbaar zijn naar depressieve patiënten die ambulante 
behandeling zoeken bij GGZ instellingen zou het waardevol zijn om na te gaan of in andere 
GGZ instellingen dezelfde verschillen worden gevonden (replicatie van ons onderzoek). 
Uiteraard zijn er meer verschillen te vinden tussen trial deelnemers en patiënten uit de 
dagelijkse praktijk dan wij hebben onderzocht. Verder onderzoek naar deze verschillen zou 
waardevol zijn, zeker naar kenmerken die wij in dit onderzoek niet konden bekijken wegens 
onvoldoende beschikbare informatie, zoals de voorgeschiedenis van de patiënt. Tot slot zou 
het heel interessant zijn om het huidige onderzoek uit te breiden naar andere psychiatrische 
stoornissen, zoals angststoornissen. 
 In dit proefschrift hebben wij gevonden dat het behandeleffect uit de dagelijkse 
praktijk achter blijft bij RCTs naar depressie behandeling. We hebben ook gevonden dat 
er weliswaar veel verschillen zijn tussen deelnemers aan depressietrials en depressieve 
patiënten uit de dagelijkse praktijk, maar dat die het verschil in behandeleffect niet kunnen 
verklaren. Wij hopen dat de resultaten die wij hebben gepresenteerd in dit proefschrift geen 
aanleiding zijn tot somberheid, maar juist een stimulans zal zijn voor verder onderzoek 
naar behandeluitkomsten voor depressie in de praktijk en alle aspecten die daarmee 
samenhangen. Met de resultaten van dit toekomstig onderzoek zal men waarschijnlijk in 
staat zijn om therapietrouw bij patiënten en behandelaars te verbeteren en in de toekomst 
wellicht zelfs “behandeling op maat” voor de individuele patiënt die aan een depressie lijdt 
te leveren. 
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